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Summary
RGMs (repulsive guidance molecules) are a group of recently identified GPI 
(glycosylphosphatidylinositol)-linked cell-membrane-associated proteins, comprising 
three family members, which have been implicated in BMPs (Bone morphogenetic 
proteins) signalling. BMPs have been shown to play profound roles in bone 
metastases from breast cancer and prostate cancer. This study aims to investigate the 
implication of RGMs in prostate cancer and breast cancer and their role in 
coordinating signal transduction by BMPs during disease progression o f cancer.
The aberrant expression o f RGMs was found in breast cancer which was 
associated with prognosis o f breast cancer patients. RGMA, B and C were detected in 
prostate cancer cell lines and only RGMB was expressed in breast cancer cell lines 
which allowed for the knockdown study o f RGMs in PC-3 and RGMB in MDA-MB- 
231 using ribozyme transgenes. The knockdown of RGMB in breast cancer cells 
resulted in an increase o f cellular proliferation, adhesion, motility and migration in 
vitro, which contributed to a tumour’s growth and metastasis. Furthermore, an 
inhibition o f caspase-3 was seen in cells after knockdown of RGMB which indicated 
RGMB as a regulator o f cell survival. Up-regulation of FAK and Paxillin were also 
seen in the cancer cells after loss o f RGMB expression, together with an evident 
induction o f EMT (epithelial-mesenchymal transition) which may contribute to the 
promoted cell-matrix adhesion and cell mobility. The knockdown o f RGMs in 
prostate cancer cells also lead to an increase o f cell ability to grow, adhere and move, 
in which differentiated response o f ID-1, a BMPs target gene was seen.
As RGMs were reported to be involved in BMP signalling, knockdown of 
RGMB was found to induce promotion on Smad-dependent pathways (especially 
Smad-1/5/8 pathway) and inhibition on BMP Smad-independent pathways (MAPK 
JNK pathway). It suggests that RGMs are important partners to fine-tune responses 
o f cells to BMPs stimuli, particularly during the progression and dissemination of 
cancer cells, and are potential targets for developing a novel cancer therapy.
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Chapter 1 
General Introduction
1.1 Prostate Cancer and Breast Cancer
1.1.1 Epidem iology and risk factors
Prostate cancer and breast cancer have been the most common forms of 
malignant disease in the Western world since 1975, now accounting for one third o f 
cancers in males and females.
Incidence
The recorded incidence o f breast cancer has been sharply increased since the 
1980s, reaching a peak in 1987 and remaining at a high level until now, as in some 
countries the number o f cases is gradually diminishing. (Fig. 1.1 source: cancer 
statistics 2009). In North America, breast cancer is the most common malignancy 
among women, accounting for 27 percent o f all female cancers. Fifteen percent o f all 
cancer deaths are currently due to cancer o f the breast, although since the mid-1980s 
the mortality from lung cancer has equalled and subsequently exceeded that o f breast 
cancer as a cause of death in women. In the United States of America, 192,370 new 
cases o f breast cancer were diagnosed in 2009 and there were about 40,170 deaths 
from the disease. The equivalent figures for prostate cancer are 192,280 and 27,360, 
respectively. (Jemal et al., 2009) The incidence o f prostate cancer appeared to peak 
in 1992, approximately 5 years after introduction o f prostate-specific antigen (PSA) 
as a screening test. It fell precipitously until 1995 which is attributed to the “cull 
effect” of identifying previously unknown cancers in the population by the use o f 
PSA. The slow rise since then has been at a gradient similar to that observed before 
the PSA era.
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Figure 1.1 Annual Age-adjusted Cancer Incidence Rates among Males and Females 
for Selected Cancers, United States, 1975-2005. Source: Cancer Statistics, 2009
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The estimated lifetime risk of prostate cancer in the US is 15.39% for 
Caucasians and 18.32% for African Americans, with a lifetime risk of death being 
2.63% and 4.42%, respectively.
The Caucasians have 7.21% lifetime risk of breast cancer and 2.82% risk of 
death, but for African Americans, the risks are 9.29% and 3.2% respectively. (Table 
1.1)
Table 1.1 Association of breast and prostate cancer with human races
Caucasians
130.6
African
Americans
117.5
AH Type of 
races Cancer
502.8 Breast cacner
Incidence* 156.7 248.5 710.3 Prostate cancer
Mortality*
24.4 33.5 20.9% Breast cancer
24.6 59.4 14.2% Prostate cancer
Lifetime risk 
of disease
7.21% 9.29% 9.36% Breast cancer
(2004-2006) 15.39% 18.32% 15.9% Prostate cancer
Lifetime risk 
of death
2.82% 3.2% 2.84o/„ Breast cancer
(2004-2006) 2.63% 4.42% 2.8% Prostate cancer
* Per 100,000 population, age adjusted to the 2000 US standard population.
Source: Cancer stat 2009 and DevCan: Probability o f  Developing or Dying o f  Cancer Software, 
Version 6.4.0. Statistical Research and Applications Branch, National Cancer Institute, 2009. 
www.srab.cancer.gov/devcan
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Figure 1.2. Distribution and five-year Relative Survival Rates among patients 
diagnosed with breast and prostate cancer by race and stage at diagnosis, US, 1996- 
2004.
* The rate for localized stage represents localized and regional stages combined. Staging is according 
to surveillance, epidemiology, and end results historic stage categories rather than according to the 
American Joint Committee on Cancer staging system. Source: Ries LAG, Melbert D, and Krapcho M, 
et al.
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Compared with whites, African American men and women have poorer 
survival once cancer is diagnosed. Five-year relative survival among patients 
diagnosed with both breast cancer and prostate cancer is lower in African Americans 
than in whites within every stratum of stage (localized, regional and distant).(Fig 1.2)
Gender plays a doubtless role in the aepidemiological analysis and is 
particularly important in breast cancer and prostate cancer. Overall, the lifetime 
probability of being diagnosed with an invasive cancer is higher for men (44%) than 
for women (37%). Doubtlessly, female gender is a major risk factor for breast cancer, 
although it is often forgotten, as breast cancer is 100 times more common in women 
than in men.
In the UK in 2007 almost 277 men and 45,700 women were diagnosed with 
breast cancer, that’s around 125 women a day (CancerStats, Cancer Reasearch UK 
2009). Female breast cancer incidence rates have increased by around 50% over the 
last twenty-five years and have increased by 5% in the last ten years. However, 
Breast cancer survival rates have been consistently improving for the past forty years. 
More women are surviving breast cancer than ever before. Now more than 8 out of 
10 women with breast cancer will survive the disease beyond five years, compared to 
around 5 out of 10 in the 1970s. In 2008 around 12,000 women and around 70 men 
died from breast cancer. Death rates for breast cancer have fallen by almost a fifth in 
the last ten years, but it is still the second most common cause of death from cancer 
in women after lung in the UK.
In 2007 in the UK about 36,100 men were diagnosed with prostate cancer and 
around 338,000 men were diagnosed in Europe in 2008 (CancerStats, Cancer
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Reasearch UK 2009). More than three-quarters of men diagnosed with prostate 
cancer now survive their disease beyond five years; compared to less than a third in 
the 1970s.. Whereas prostate cancer is still the second most common cause of cancer 
death in UK men, after lung cancer. In 2008 in the UK about 10,170 men died from 
prostate cancer.
Risk factors 
Risk factors for breast cancer
The incidence of breast cancer increases with age, as other epithelial cancers. It 
is only occasionally seen in the late teens. The age-specific rate increases sharply up 
to the age of 40 years. The increase thereafter slows down dramatically, although the 
overall breast cancer rate keeps rising until old age. However, the cumulative risk of 
developing breast cancer shows the majority of patients with breast cancer are over 
the age of 50 years.
A family history o f breast cancer can be associated with an increased risk o f the 
disease and susceptibility to breast cancer can be inherited. Up to 20 percent of 
women diagnosed with breast cancer have at least one affected family member and 
about 5 per cent of breast cancers appear attributable to inherited gene mutations that 
are dominant and highly penetrative.
Some other factors such as dietary fat or cholesterol intake, alcohol 
consumption, endocrine factors, nulliparity may also need to be factored in.
The cause of breast cancer remains unknown. However, epidemiological data 
normally suggests risk factors that show an increased possibility o f developing the
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disease. Such factors for breast cancer are divided into three main groups: genetic, 
endocrine, and environmental; each may be of major, intermediate, or minor 
importance. Although many minor factors have become the source of continued 
debate, some of these factors were thought to play a more important role in the 
aetiology of breast cancer, as evidence accumulates. Recently, this has been 
particularly proved by links with oral contraceptive and hormone replacement 
therapie (Benshushan and Brzezinski, 2002; Buchholz et al., 2008)
Risk factors for prostate cancer
The particular causes o f prostate cancer initiation and progression are not yet 
known, but substantial evidence indicates that both genetics and environment play a 
role in this disease. A number o f potential risk factors have been identified by classic 
epidemiology and molecular epidemiology associated with the development of 
prostate cancer.
Sporadic cancers account for about 85% of all prostate cancers, and about 15% 
are familial or hereditary. Hereditary prostate cancer accounts for 43% of early-onset 
disease (55 years old or younger) but only 9% of all cancers occurring by the age of 
85 years (Carter et al., 1992). At least eight candidate prostate cancer susceptibility 
genes have been reported which accounts for only a small fraction o f the observed 
genetic predisposition to prostate cancer. HPC1 is the best characterized among the 
known susceptibility genes. (Cooney et al., 1997; Eeles et al., 1998; Smith et al., 
1996)
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An accumulation o f aepidemiological, histological and genetic evidence 
suggest that chronic inflammation leading to cellular hype-proliferation to replace 
damaged tissue contributes to the development of prostate cancer (Coussens and 
Werb, 2002; De Marzo et a l., 2004).
An analysis of the known prostate cancer susceptibility genes and other genetic 
defects in prostate cancer suggests that inherited and acquired defects in cellular 
defence mechanisms against inflammatory oxidants may initiate and perpetuate 
prostatic carcinogenesis (Coussens and Werb, 2002; De Marzo et al., 2004).
Androgens have effects on the development, maturation and maintenance of the 
prostate, particularly by regulating both proliferation and differentiation of the 
luminal epithelium. Doubtlessly, a lifetime of variable exposure of the prostate to 
androgens plays an important role in prostate carcinogenesis. Oestrogens have been 
postulated to protect against prostate cancer by inhibiting growth of prostate 
epithelial cell but alternatively they have also been shown to increase risk by eliciting 
inflammation in concert with androgens (Naslund et al., 1988) or by the production 
of mutagenic metabolites (Yager, 2000). Insulin-like Growth Factor Axis, Leptin, 
Vitamin D, Vitamin D Receptor, and Calcium might also be involved in 
tumourigenesis and subsequent disease progression
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1.1.2 Diagnosis and Tumour Markers
Diagnosis of breast cancer and prostate cancer
There are many different types o f breast cancer according to their histological 
types, at different stages, with different aggressiveness, and genetic makeups; 
survival varies greatly depending on these factors. The two most common types are; 
ductal carcinomas which present at ducts of mammary gland, lobular carcinomas 
occurring at lobules.
Women who are diagnosed with early stage breast carcinomas almost always 
appear to have no breast problems. Mammography is recommended for screening 
women at higher risks. Screening mammograms usually take 2 views (x-ray pictures 
taken from different angles) o f each breast. For some patients, such as women with 
breast implants, more pictures may be needed to include as much breast tissue as 
possible. Women who are breast-feeding can still have mammograms, although these 
are probably not quite as accurate because the breast tissue tends to be dense. For 
diagnosing a breast cancer, "triple test" is routinely performed, including a breast 
examination by a trained medical practitioner, mammography and fine needle 
aspiration cytology.
The first noticeable symptom of breast cancer is typically a lump that feels 
different from the rest o f the breast tissue. However, by the time a breast lump is 
noticeable, it has probably been growing for years. Lumps found in lymph nodes 
located in the armpits can also indicate breast cancer. Pain is not the main symptom, 
as other symptoms accompanying a lump may include changes in breast size or shape,
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skin dimpling, nipple inversion, or spontaneous single-nipple discharge. Some 
patients would present with breast pain, swelling, warmth and redness throughout the 
breast, as well as an orange-peel texture to the skin referred to as peau d'orange. This 
is termed inflammatory breast cancer (1BC) which is caused by breast cancer cells 
invading the dermal small lymph vessels resulting in symptoms similar to 
inflammation. Paget's disease o f the breast is used to describe another symptom 
complex of breast cancer with symbolic eczematoid skin changes. Patients diagnosed 
with Paget’s experience tingling, itching, increased sensitivity, burning, pain, and 
probably a lump as well. Some metastatic breast cancers may cause severe 
symptoms due to the impact that the metastatic lesions have on tissues and organs 
being involved.
Similar to breast cancer, prostate cancer rarely causes symptoms in the early 
phase because the majority o f adenocarcinomas arise in the periphery o f the gland 
distant from the urethra. The presence o f systemic symptoms (like bone pain, renal 
failure, anaemia) caused by prostate cancer suggests an advanced disease with local 
invasion or distant metastases. Growth o f prostate cancer into the urethra or bladder 
neck can result in obstructive (e.g., hesitancy, decreased force of stream, 
intermittency) and irritative (e.g., frequency, nocturia, urgency, urge incontinence) 
symptoms.
If local invasion of prostate cancer affects the trigone of the bladder, it will lead 
to ureteral obstruction and can cause renal failure if the obstructions are bilateral. 
Local progression of disease and obstruction of the ejaculatory ducts will result in 
hemaetospermia and the presence o f decreased ejaculate volume. Although rare in
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the PSA era, impotence can be a sign o f prostate cancer that has spread outside the 
prostatic capsule to involve the branches of the pelvic plexus (neurovascular bundle) 
responsible for innervation of the corpora cavernosa.
Axial or appendicular skeleton affected by metastatic disease can cause bone 
pain or microfractures or anaemia from replacement of the bone marrow. Cancerous 
involvement of the pelvic lymph nodes and compression o f the iliac veins or 
lymphatics can result in lower extremity oedema. The early detection by PSA testing 
has reduced the proportion o f patients with prostate cancer diagnosed by symptoms 
suggestive o f advanced disease. Although the patients with prostate cancer might 
have voiding symptoms which suggest prostate disease, the majority (over 80%) of 
men diagnosed today with prostate cancer are initially suspected of disease on the 
basis o f DRE (digital rectal examination) abnormalities or serum PSA (prostate- 
specific antigen) elevations. The combination of DRE and serum PSA is the most 
important first-line test for assessing the risk o f prostate cancer being present in an 
individual. Associated with DRE and PSA findings, Transrectal ultrasound (TRUS)- 
guided, systematic needle biopsy is the most reliable method, at present, to ensure 
accurate sampling o f prostatic tissue in men considered at high risk o f harboring 
prostatic cancer.
PSA
PSA, which is located on chromosome 19, is a member of the human kallikrein 
gene family of serine proteases. It is the most important biological marker to date for 
the diagnosis, staging, and monitoring of prostate cancer (Polascik et al., 1999). 
Serum PSA has been shown to associate directly with pathologic stage and tumour
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volume (Noldus et al., 1998; Stamey and Kabalin, 1989; Stamey et al., 1989a; 
Stamey et al., 1989b; Stamey et al., 1989c). However, because PSA is not specific to 
prostate cancer cells and can be influenced by BPH and tumour grade and PSA levels 
overlap between stages, it cannot be used alone to predict accurately the extent of 
disease for an individual patient. Men with more advanced prostate cancer have 
higher grade and higher volume tumours that produce less PSA per gram of tumour 
(Partin et al., 1990).
Staging of breast cancer and prostate cancer
The goals of cancer staging are to allow the assessment of prognosis and 
facilitate educated decision-making regarding available treatment options. The TNM  
classification for breast cancer is based on the size of the tumour (T), whether or not 
the tumour has spread to the lymph nodes (N) in the armpits, and whether the tumour 
has metastasised (M) or spread to a more distant part of the body. Larger size, nodal 
spread, and metastasis have a higher stage number and a worse prognosis.
The main stages are:
Stage 0 is a pre-malignant disease or marker. For example, DCIS (Ductal Carcinoma 
in Situ) is one type o f Stage 0 tumours seen in breast cancer.
Stages 1-3 are defined as 'early' cancer and potentially curable (Table 1.2).
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Table 1.2 Breast cancer stage 1-3
Stage IA T1 NO M0
Stage IB TO
NI mi M0
T1 N lm i M0
Stage IIA
TO N 1 M0
T1 N 1 M0
T2 NO M0
Stage I IB
T2 N1 M0
T3 NO M0
Stage III A
TO N2 M0
T1 N2 M0
T2 N2 M0
T3 N1 M0
T3 N2 M0
Stage 11 IB
T4 NO M0
T4 N 1 M0
T4 N2 M0
Stage IIIC Any T N3 M0
TO No evidence o f  primary tumour; T1 Tumour < 20 mm in greatest dimension; T2 Tumour > 20 mm 
but < 50 mm in greatest dimension; T3 Tumour > 50 mm in greatest dimension; T4 Tumour o f  any 
size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules)
NO No regional lymph node metastases; N1 Metastases to movable ipsilateral level I, II axillary lymph 
node(s) (mi: Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 
2.0 mm)); N2 Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or 
matted; or in clinically detected* ipsilateral internal mammary nodes in the absence o f  clinically 
evident axillary lymph node metastases; N3 Metastases in ipsilateral infraclavicular (level III axillary) 
lymph node(s) with or without level I, II axillary lymph node involvement; or in clinically detected* 
ipsilateral internal mammary lymph node(s) with clinically evident level I, 11 axillary lymph node 
metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or 
internal mammary lymph node involvement 
M0 No clinical or radiographic evidence o f  distant metastases
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Stage 4 is defined as 'advanced' and/or 'metastatic' cancer and incurable (any T 
or any N with distant detectable metastasis).
Clinical staging of prostate cancer usually employs a variety o f parameters such 
as DRE, PSA, needle biopsy findings, and radiologic imaging, to predict the true 
extent of disease. There are two main classification systems for prostate cancer 
clinical staging: the Whitmore-Jewett and the tumour, node, metastases (TNM) 
classification systems. The Whitmore-Jewett system was created in 1956 and was 
used until 1975 when the TNM system was adopted by the American Joint 
Committee for Cancer Staging and End Results Reporting (AJCC) (Wallace et al., 
1975). The disease can be staged in accordance with extent of tumours, lymph node 
involvement and distant metastasis. According to the UICC (Union for International 
Cancer Control) 6th edition (2002) and UICC 7th edition (2010), the tumour, lymph 
node, metastasis can be combined into four stages of worsening severity. As Fig.1.3 
shown, Stage I has been expanded from T la  to T1 and T2a this year and Stage II has 
been revised from including T1 la, lb, lc  and T2 to including T2b~T2c.
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T1 Not palpable or visible 
T1a <5% or less 
T1b >5%
T1c Detected by needle biopsy
T2 Confined within prostate 
T2a < half of one lobe
T2b > half of one lobe
T2c Both lobes
T3 Through prostate capsule 
T3a Extracapsular 
T3b Seminal vesicle(s)
T4 Fixed or invades adjacent 
structures
No change from 6th
STAGE GROUPING (ANATOMIC)
(U1CCJ
Stage 1 T1, T2a NO
Stage II T2fc>-2c NO
Stage III T3 NO
Stage IVT4 NO
Any T N1
Any T Any N
Change from 6th 
Grade was in 6th
Figure 1.3 Classification o f Prostate cancer
UICC TNM Classification of Malignant Tumours,2010, (7th edition)
Source: (http://www.uicc.org/node/7735)
NO: there has been no spread to the regional lymph nodes; Nl: there has been spread to the 
regional lymph nodes
MO: there is no distant metastasis; M l: there is distant metastasis
1 6
The Whitmore-Jewett system is similar to the TNM system, with 
approximately equivalent stages.
A: tumour is present, but not detectable clinically; found incidentally
A l: tissue resembles normal cells; found in a few chips from one lobe
A2: more extensive involvement
B: tumour can be felt on physical examination but has not spread outside the 
prostatic capsule
BIN: tumour can be felt, it does not occupy a whole lobe, and is 
surrounded by normal tissue
B l: tumour can be felt and it does not occupy a whole lobe
B2: tumour can be felt and it occupies a whole lobe or both lobes
C: tumour has extended through capsule
C l: tumour has extended through the capsule but does not involve 
seminal vesicles
C2: tumour involves seminal vesicles 
D: tumour has spread to other organs
The Gleason grading system is used to help evaluate the prognosis o f men 
with prostate cancer from a biopsy o f prostate tissue or from the prostate removed
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after surgery. Cancers with a higher Gleason score are more aggressive and have a 
worse prognosis. The Gleason score ranges from 2 to 10, with 10 having the worst 
prognosis, based on the 5 Gleason patterns. The score is the sum of the first majority 
tumour pattern and the second majority pattern. Increasingly, pathologists provide 
details o f the "tertiary" component. This is why there is a small component of a third 
(generally more aggressive) pattern. So there could be a Gleason 3+4 with a tertiary 
component of pattern 5.
The patterns are classified by the features:
• Pattern 1 - The cancerous prostate closely resembles normal prostate 
tissue. The glands are small, well-formed, and closely packed.
• Pattern 2 - The tissue still has well-formed glands, but they are larger 
and have more tissue between them.
• Pattern 3 - The tissue still has recognizable glands, but the cells are 
darker. At high magnification, some of these cells have left the glands and are 
beginning to invade the surrounding tissue.
• Pattern 4 - The tissue has few recognizable glands. Many cells are 
invading the surrounding tissue
• Pattern 5 - The tissue does not have recognizable glands. There are 
often just sheets of cells throughout the surrounding tissue.
Pathological stage o f prostate cancer is determined after prostate removal and 
involves careful histological analysis o f the prostate, seminal vesicles, and pelvic 
lymph nodes if a lymphadenectomy has been performed. The pathological staging for
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breast cancer depends on the cancer cells’ original derivation and the differentiation 
ability: well differentiated (low grade), moderately differentiated (intermediate grade), 
and poorly differentiated (high grade).
With the exception of prostate-specific antigen (PSA), tumour markers do not 
have sufficient sensitivity or specificity for screening. Cancer antigen 15-3 (CA 15-3) 
is perhaps the most thoroughly investigated serum tumour markers in breast cancer. 
Being a normal product of breast cells, CA 15-3 does not cause cancer rather it 
reflects the increase of breast cancer cells. Ovarian, lung and prostate cancers may 
also produce CA 15-3. CA 15-3 may be requested along with other tests, such as 
oestrogen and progesterone receptors, Her2/neu, and BRCA-1 and BRCA-2 genetic 
testing, when advanced breast cancer is first diagnosed to help determine cancer 
characteristics and treatment options.
Breast cancer cells with oestrogen receptor (ER) and/or progesterone receptor 
(PR) depend on oestrogen and/or progesterone to grow. Testing for ER and PR is 
done to find out if a cancer is likely to be successfully treated with hormone therapy, 
such as tamoxifen (Nolvadex). Human epidermal growth factor receptor 2 (HER2) is 
present in 20% to 25% of breast cancers. Anti-HER2 treatments block HER2 to stop 
the growth of cancer cells induced by EGF. Testing for HER2 helps doctors to assess 
if a cancer can be treated with anti-HER2 treatments, such as Trastuzumab 
(Herceptin), and in some cases, may suggest whether additional treatment with 
chemotherapy may be helpful. Cancer antigen (CA) 27.29 is used most frequently to 
follow response to therapy in patients with metastatic breast cancer. (Chan et al.,
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1997; Gion et al., 1999).The CA 27.29 level is elevated in approximately one third of 
women with early-stage breast cancer (stage I or II) and in two thirds o f women with 
late-stage disease (stage 111 or IV). Because o f superior sensitivity and specificity, 
CA 27.29 has supplanted CA 15-3 as the preferred tumour marker in breast cancer. 
The metastatic breast cancer patients will have elevated levels o f associated tumour 
markers because of the metastasis site. Carcinoembryonic antigen (CEA), an 
oncofetal glycoprotein, is expressed in normal mucosal cells and overexpressed in 
adenocarcinoma, especially colorectal cancer. Cancer antigen 15-3 (CA 15-3), cancer 
antigen 27.29 (CA 27.29), and carcinoembryonic antigen (CEA) are found in 50% to 
90% of patients with metastatic breast cancer. However, these tumour markers are 
not sensitive in the early stage of cancer and are not specific to breast cancer. They 
can only be used as indicators o f metastasis, prognosis and treatment.
1.1.3 M etastasis
Metastasis is a key-defining feature o f malignancy and most problematic to 
cure. Up to 90% of deaths from cancer are due to metastasis (Hanahan and Weinberg, 
2000). It is difficult to identify the aggressive tumour definitively during the early 
stage so it is still controversial as to whether patients should undergo conservative 
treatment at this stage. All the uncertainty and questions finally attribute to the 
understanding of the mechanism of metastasis. Cancer derives from a collection of 
multiple genetic aberrations and the same can be said regarding the development of 
metastasis. A number of metastasis-related genes have been revealed. Therein some
20
key genes have been shown to be responsible for the steps and biologic mechanisms 
leading to metastasis.
1.1.3.1 Immune escape of cancer cells
Tumour cells wisely employ some mechanisms to escape from the attack of 
immune cells, thus disrupt and suppress the host immune system. These mechanisms 
include loss of tumour antigen, alteration o f HLA class I antigen, defective death 
receptor signalling, lack o f co-stimulation, immunosuppressive cytokines and T cells. 
Fas and FasL might be involved in this (Gutierrez et al., 1999). The FasL expression 
by breast tumours may induce the apoptosis o f activated infiltrating Fas-lymphocytes. 
The expression o f FasL is upregulated by oestrogen in breast cancer cells and the 
upregulation can be blocked by tamoxifen, thus allowing the killing of cancer cells 
by activated lymphocytes (Mor et al., 2000). Fas exists in transmembrane and soluble 
forms. The circulating soluble form o f Fas presents at higher levels in breast cancer 
patients (Ueno et al., 1999), induces host lymphocyte apoptosis and impairs 
expression of NKG2D and T-cell activation (Bewick et al., 2001). Therefore, the 
soluble form of Fas is considered to have potential value in clinical prognosis.
1.1.3.2 Cell adhesion molecules:
Metastasis occurs through a series o f sequential steps, all o f which a metastatic 
cell must successfully complete in order to establish growth at the secondary site. 
During the tumour progression, the profile o f the cell surface adhesion molecules 
changes and the metastatic cells acquire the profile allowing them to detach from the
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primary site and attach at the secondary site. The main morphological change of the 
tumour transition from benign to malignant and metastatic is that tumour cells change 
from a highly differentiated, epithelial morphology to a migratory and invasive 
mesenchymal phenotype, a biological process referred to as epithelial-mesenchymal 
transition (EMT). During the process o f epithelial-mesenchymal transition (EMT), 
cells progressively redistribute or down-regulate their apical and basolateral 
epithelial-specific tight and adherens junction proteins (such as E-cadherin and 
cytokeratins) and re-express mesenchymal molecules (including vimentin and N- 
cadherin).
Selectins, integrins, immunoglobulin-cell adhesion molecules and cadherins are 
four major groups o f adhesion molecules that are possibly correlated with metastasis. 
Cadherins are located in adherens junctions and desmosomes. O f the three major 
types of cadherins, type-I and desmosomal cadherein have been shown to inversely 
correlate with the metastatic properties o f cancer cells. Intercellular adhesion 
mediated by cadherins depends on the interaction of the cadherins with the 
cytoskeleton. Distruption o f the cadherin-cadherin interactions and cadherin- 
cytoskeleton linkages have a strong biological impact on the aggressiveness o f cancer 
cells. Apart from the functional influence o f cadherins on the aggressiveness o f 
cancer cells, the transcription regulation o f the cadherins also plays a key part in 
cancer spreading. The specific transcriptional repressors (including Snail, Slug, SIP1, 
Twist, and E12/E47), RTKs (EGFR, c-Met, IGF-1R, FGF receptors), non-RTK c-Src, 
secreted proteases as MMPs (matrix metalloproteinases), even the oestrogen receptor
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status and growth factors (ErbB2 and TGF-J3) can lead to the loss o f E-cadherin. Loss 
of E-cadherin disrupts adhesion junctions between neighbouring cells and thereby 
supports detachment o f malignant cells from the epithelial cell layer. This has direct 
effects on signalling pathways which promote tumour cell migration and proliferation. 
The loss of E-cadherin is frequently associated with the gain of N-cadherin, which 
has been shown to replace E-cadherin at cell-cell contacts during invasion, migration 
and metastatic dissemination o f cancer cells. The loss o f E-cadherin and gain o f N- 
cadherin is an important and interesting biological pattern during the EMT process.
The immunoglobulin super family o f cell adhesion molecules (ALCAM, 
VCAM-1, ICAM, CEACAM1, NCAM, Mel-CAM, HepaCAM, PEC AM) have 1-7 
extracellular immunoglobulin-like domains. They are attached to the plasma 
membrane by a single, hydrophobic transmembrane sequence and have a cytoplasmic 
tail. They are shown to be involved in both homotypic and heterotypic adhesion 
(Epstein, 2003).
The Selectins consist o f three family members: E-selectin, L-selectin and P- 
selectin, which are expressed by both platelets and vascular endothelium. They are a 
group o f cell surface lectins that mediate the adhesion between leukocytes, platelets 
and endothelial cells. Selectin mediated adhesion to ensure the recruitment of 
leukocytes roll to the area o f injury and inflammation. Selectins have also been 
implicated as one of the key mechanisms during the ‘docking’ process of the 
circulating tumours cells, in which tumour cells use selectin mediated adhesion,
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which occurs fast, to quickly lodge over the endothelial layer, before the subsequent 
‘docking’ process to take place.
Integrins are transmembrane glycoproteins expressed as heterodimeric cell- 
surface receptors that consist o f a  and |3 subunits. Intergrins are pivotal in controlling 
cell attachment, cell migration, cell cycle progression and apoptosis.
1.1.3.3 Invasion and motility:
The ability of invasion and motility is important for dissemination o f cancer 
cells and is required in the process o f cancer metastasis. Metastasis consists of 
distinct steps: (a) migration o f tumour cells from the primary tumour. A key event 
happened prior to or during the dissociation from primary tumour is epithelial- 
mesenchymal transition (EMT) which confers cancer cells the crucial phenotype and 
capacities for detaching and migrating away from the primary tumour; (b) invading to 
neighboring tissue and penetrating through the basement membrane and entering 
blood or lymphatic vessels, the latter o f which is referred to as intravasation. After the 
progressive growth o f primary tumour cells and extensive vascularisation, some key 
genes are involved in the initial local invasion o f the host stroma, detachment and 
embolization o f small tumour cell in circulation and the survival tumour cells 
arrested in the capillary beds o f organs and extravasation by invasion again.
1.1.3.4 Urokinases-type plasminogen activator:
Several gene families o f extracellular proteinases have a role in the control of 
the invasion ability o f breast cancer cells through the degradation o f the extracellular
2 4
matrix. The serine proteinases such as urokinases-type plasminogen activator (uPA) 
are essential for tumour cell invasion, metastasis and proliferation. The uPA protein 
converts plasminogen to plasmin by specific cleavage o f an Arg-Val bond in 
plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two- 
chain derivative in which a single disulfide bond connects the amino-terminal A- 
chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative 
is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further 
processed into LMW-uPA (low molecular weight uPA) by cleavage o f chain A into a 
short chain A (A l) and an amino-terminal fragment. LMW-uPA is proteolytically 
active but does not bind to the uPA receptor. Alternatively spliced transcript variants 
encoding different isoforms have been found for this gene. MDA-MB-231 cells are 
highly invasive and express high levels o f uPA. The silence o f uPA in MDA-MB- 
231 cells suppressed their invasion and proliferation (Arens et al., 2005). A similar 
observation was made with prostate cancer cells (Pulukuri and Rao, 2007). The uPA 
expression correlates with the progression o f prostate cancer, and the level o f uPA 
was proposed as a useful biochemical predictor of recurrence in patients undergoing 
radical prostatectomy (Kumano et al., 2009). Bikunin, a Kunitz-type protease 
inhibitor, markedly suppresses the cell motility possibly through a coordinated down- 
regulation of uPA which is likely to contribute to the cell invasion processes 
(Kobayashi, 2001) while the p38 MAPK pathway participates in endothelial cell 
migration by regulating uPA expression.(Yu et al., 2004)
The zinc-dependent matrix metalloproteinases (MMPs) is another important 
protease family whose primary function is degradation of proteins in the extracellular
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matrix. There are overwhelming amount o f experimental data to suggest that MMPs 
(19 family members) are involved in primary and metastatic tumour initiation, 
invasion and metastasis (Chambers and Matrisian, 1997; Duffy and McCarthy, 1998). 
Activation of MMP-9 directly mediated by uPA promotes cell invasion (Zhao et al., 
2008). High levels of at least two MMPs (MMP-2 and stromelysin-3) have been 
found to correlate with poor prognosis in patients with breast cancer (Duffy et al., 
2000).
The leukocyte elastases and the cysteine proteinases such as cathepsin D and L 
are reported to be involved in this step o f cancer metastasis.
1.1.3.5 Hepatocyte growth factor/scatter factor (HGF/SF)
Hepatocyte growth factor/scatter factor (HGF/SF) is a paracrine cellular growth, 
motility and morphogenic factor. Hepatocyte growth factor is mostly secreted by 
stromal cells in the body and acts as a multi-functional cytokine on cells o f mainly 
epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix 
invasion makes it a key player in angiogenesis, tumourigenesis and tissue 
regeneration. Hepatocyte growth factor regulates cell growth, cell motility and 
morphogenesis by activating a tyrosine kinase signalling cascade after binding to the 
proto-oncogenic c-Met receptor. PAK proteins, a family of serine/threonine p 2 1 - 
activating kinases, link RhoGTPases to cytoskeleton reorganization and nuclear 
signaling. Knockdown of PAK1 inhibits HGF-stimulated migration and loss o f cell­
cell junctions in DU 145 prostate carcinoma cells. This can be seen in PC-3 prostate 
carcinoma cells with knockdown of both PAK1 or PAK2, which lack cell-cell
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junctions (Bright et al., 2009). In breast cancer, HGF stimulates tumour growth and 
angiogenesis in vivo (Lamszus et al., 1996) and invasiveness in vitro (Matteucci et al., 
2005; Meiners et al., 1998). HGF was found to disrupt tight junctions in breast cancer 
cells (Martin et al., 2004) and enhance its adhesion to endothelial cells through up- 
regulation of CD44, a well characterised homing receptor for cancer cells (Mine et al., 
2003). HGF activator inhibitors (HAI-1 and HAI-2) (Parr and Jiang, 2006) and c- 
MET silencing (Jiang et al., 2001) reduce migration and invasiveness o f breast 
cancer cells induced by HGF. NK-4 is a specific antagonist to HGF and suppresses in 
vivo tumour growth and angiogenesis (Martin et al., 2003b), cell motility and 
invasion in vitro (Hiscox et al., 2000). This antagonist also affects changes in the 
transendothelial (TER) and paracellular permeability of human vascular endothelial 
cells induced by HGF (Martin et al., 2002).
HGF also can be used as predictor o f recurrence and survival. Breast cancer 
patients with more advanced TNM staging (Sheen-Chen et al., 2005) and 82.9% with 
recurrence (Taniguchi et al., 1995) were shown to have higher serum soluble HGF.
1.1.3.6 Tumour metastasis suppressor genes
There are at least 13 genes characterized as metastasis suppressors to date, 
including: Nm23, KAI-1, KISS-1, TXNIP (VDUP1), CRSP3, MKK4, Src-suppressed 
C kinase substrate (SSeCKS), RhoGDI2, E-cadherin, Drg-1, Tissue inhibitor of 
metalloproteases (TIMPs), RKIP, and BRMS1. Tumour suppressor genes function by 
loss-of-function mutations. The mutation or deletion of these genes might disrupt 
signal transduction pathways to induce cancer.
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Traditionally, it is regarded that tumour cells acquire the metastatic genotype 
and phenotype late during tumour development. Recently, it has been shown that 
tumour cells acquire die genetic changes relevant to their metastatic capacity early in 
tumourigenesis by analysing the disseminating breast cancer cells during primary and 
early stages (Demou and Hendrix, 2008; Kong et al., 2001; Smith et al., 1993).
1.1.4 Management Therapy for prostate cancer
Treatment for prostate cancer may involve active surveillance (monitoring for 
tumour progress or symptoms), surgery (i.e. radical prostatectomy), radiation therapy 
including brachytherapy (prostate brachytherapy) and external beam radiation 
therapy, High-intensity focused ultrasound (HIFU), chemotherapy, oral 
chemotherapeutic drugs (Docetaxel), cryosurgery, hormonal therapy, or some 
combination.
Traditionally, conservative management (active monitoring) has been reserved 
for older patients with a life expectancy of less than 10 years and a low-grade 
(Gleason score 2 to 5) prostate cancer. Deferred therapy for patients with prostate 
cancer is usually based on close observation with semiannual PSA tests and DRE 
and annual biopsies (Carter et al., 2002; Choo et al., 2002; el-Geneidy et al., 2004; 
Klotz et al., 2004; Patel et al., 2004; Zietman et al., 2001). However, active 
monitoring is now being studied in younger patients with low-volume, low- or 
intermediate-grade tumours to avoid or to delay treatment that might not be 
immediately necessary.
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A report of a randomized clinical trial from Scandinavia showed that patients 
with clinically localized prostate cancer managed with watchful waiting have 
significantly higher rates of local cancer progression, metastases, and death from 
prostate cancer and a shorter cancer-specific overall survival than those treated 
initially with radical prostatectomy (Bill-Axelson et al., 2005).
Hormone therapy and chemotherapy are never curative, and not all cancer cells 
can be eradicated consistently by radiation or other physical forms of energy, even if 
the tumour is contained within die prostate gland. Preoperative clinical and 
pathological parameters are often recruited to predict the pathologic stage and as 
additional information for operation. The operation can be performed by a number of 
methods including through perineal, retropubic, laparoscopic, and even robotic 
approach (Figure 1.4). The post-operation serum PSA level test has be used to 
monitor the tumour recurrence. The most common late complications of radical 
prostatectomy are erectile dysfunction, urinary incontinence, inguinal hernia, and 
urethral stricture but always associated with the patient's age. The patients with high 
risk (clinical stage: T2b and upwards; PSA level: >10; Gleason score: >7) whose life 
expectancy is at least 10 years are recommended to have the operation in conjunction 
with radiation therapy. Radiation therapy is another important treatment approach but 
with the main adverse side effects of injury to the microvasculature of the bladder, 
rectum, striated sphincter muscle, and urethra.
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Figure 1.4 Schematic view of the prostate, bladder and lymph nodes.
It’s the view the surgeon has after the abdominal incision has been made. Inside the shaded 
area are the lymph nodes removed during a staging lymphadenectomy. Source from Dr. 
Patrick Walsh's Guide to Surviving Prostate Cancer by Patrick C. Walsh, M.D., and Janet 
Farrar Worthington http://www.Dhoenix5.org/books/Walsh2/WalshRRP01.html
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Treatment for breast cancer
For the local breast tumour, the traditional surgical treatment involves total 
removal of the breast (mastectomy). The most commonly performed operation was 
the Halsted radical mastectomy (including the removal of the breast, underlying chest 
muscle (pectoralis major and pectoralis minor), and lymph nodes o f the axilla) 
(Figure 1.5). Breast conservation treatment can be considered according to patient 
choice, tumour size, the position o f the cancer in the breast, and the nature of the 
breast cancers themselves. Most authorities recommend total mastectomy if the 
tumour is more than 3 or 4 cm in diameter, multicentricity, mulifocality, centrally 
located or poorly differentiated. The overall incidence of local recurrence after breast 
conservation is higher than total mastectomy.(Newman et al., 1999) Salvage 
mastectomy can be used to treat the local recurrence after breast conservation therapy. 
Systemic treatment with tamoxifen or chemotherapy may alleviate symptoms but 
responses are often quite short lived when recurrence is widespread (Biglia et al., 
2003).
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Local recurrence after total mastectomy is difficult to treat. Radiotherapy may 
be attempted if this has not already been used; adjuvant drug treatment with either 
chemotherapy or endocrine therapy may help reduce the risk o f further recurrence. 
The management of the axillary nodes is a controversial topic to date. There are three 
main types of axillary surgery: sentinel node biopsy, axillary node sampling and 
axillary node clearance. Recent instruction o f sentinel node biopsy has, to a great 
degree, transformed the procedure and has substantially reduced the scale and 
unnecessary axillary dissections. If cancer cells are found in the lymph nodes 
following sentinel node biopsy or axillary sampling, the patient should normally 
proceed to an axillaty clearance with the possible side effect o f pain, limit o f arm 
movement and lymphoedema. For people who have large breast tumours where 
mastectomy would be necessary, chemotherapy or hormone therapy is sometimes 
prescribed before surgery to shrink the tumour to improve the surgery successful rate, 
which called neoadjuvant therapies. Women who have a mastectomy may also have 
breast reconstruction, either at the same time (immediate reconstruction) or at some 
time in the future (delayed reconstruction). Adjuvant treatment given after surgery 
includes one or more o f radiotherapy, chemotherapy, hormone therapy, and targeted 
(biological) therapy and depends on the risk of the cancer recurring or spreading.
Generally speaking, the management once metastasis has occurred must be 
delicate. Radio- and chemotherapy could be an option. Endocrine therapy has been 
an important pillar in the treatment o f breast cancer metastasis recently. The use o f 
biphosphonates and radiotherapy could be the emphasis in the management o f 
prostate cancer bone metastasis.
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1.2 Bone metastasis in prostate cancer and breast cancer
Bone is the most common site o f metastasis for certain tumour types. Breast 
cancer and prostate cancer are the two tumour types that most commonly metastasise 
to bone (Mundy, 2002).
Most circulating tumour cells pass through the bone marrow, as a consequence 
o f its vascularity. This may be the reason why cancers have such high avidity for 
bone. The bone environment also provides a particularly fertile ground for the growth 
and aggressive behaviour o f the tumour cells that reach it. There are different patterns 
o f bone effects in patients with cancer, ranging from mostly destructive or osteolytic 
(breast cancer, myeloma), to mostly bone-forming or osteoblastic (prostate cancer). 
In breast cancer, osteolysis is caused by osteoclast stimulation -  not by the direct 
effects of cancer cells on bone (Boyde et al., 1985), while the predominant osteolysis 
effect is coupled with local bone formation response (Stewart et al., 1982). In 
prostate cancer, there is a profound local stimulation of osteoblasts adjacent to the 
metastatic tumour cells. However, some patients also have osteolytic lesions which 
are similar to those with metastatic breast cancer. These two processes (bone 
resorption and bone formation) seem to be linked and both activated in bone 
metastases.
Parathyroid-hormone-related peptide (PTH-rP) is one of the main and specific 
mediators of osteolysis in metastastic breast cancer and the mediator o f bone 
destruction in most other osteolytic cancers (Bryden et al., 2002; Miki et al., 2000). 
When breast cancer cells are present in the bone microenvironment, PTHrP is
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overproduced (Guise and Mundy, 1996; Guise et al., 1996), an increase in production 
far greater than that seen in other metastatic sites (Powell et al., 1991; Southby et al., 
1990). Production of the PTHrP by tumour cells activates osteoblasts to produce 
RANKL (receptor activator o f nuclear factor-icB ligand) and downregulate 
osteoprotegrin (OPG). This activates osteoclast precursor cells, leading to osteolysis. 
Resorbed bone releases bone-derived growth factors, including TGF-p and IGF1 
(insulin-like growth factorl) and raises extracellular calcium (Ca2+) concentrations. 
The growth factors bind to receptors on the tumour cell surface and activate 
phosphorylation and signalling through pathways that involve Smad and MAPK 
(mitogen activated protein kinase). Extracellular Ca2+ binds and activates a Ca2+ 
pump. These growth factors promote breast cancer cell proliferation and further 
release o f PTHrP, to cause more bone resorption, thus forms a cycle o f regulations 
(Guise et al., 1996; Rasmussen and Cullen, 1998; Yin et al., 1999; Yu and Rohan, 
2000).
The mechanisms by which osteoblastic lesion is regulated are far from clear. 
There are several mechanisms o f osteoblastic bone metastasis caused by prostate 
cancer. TGF-p2, which is expressed at high levels by prostate cancer cell line PC-3, 
promotes the proliferation o f osteoblasts in vitro, as well as bone formation in vivo 
(Marquardt et al., 1987). Overexpression of uPA (serine protease urokinase ) by rat 
prostate cancer cells has been shown to induce bone metastasis in vivo (Achbarou et 
al., 1994), and an amino-terminal fragment o f uPA has been shown to have 
mitogenic activity for osteoblasts (Rabbani et al., 1992). uPA is also activated by
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PSA (prostate-specific antigen), a serine protease which can activate other growth 
factors, such as IGF1 (insulin-like growth factor 1) and TGF-p and cleave PTHrP 
into inactive fragments.
1.3 Bone morphogenetic proteins and their signalling pathway in 
cancer
1.3.1 BMPs
The Transforming Growth Factor-P (TGF-p) superfamily is one o f the biggest 
and important families of proteins, which participates in the development and 
homeostasis o f diverse tissues and organs through regulating cellular differentiation, 
proliferation, apoptosis and motility. Up to date, more than 30 structurally related 
growth factors have been identified in the TGF-p superfamily including TGF-ps, 
Activins, Inhibins, Bone Morphogenic Proteins (BMPs), Growth and Differentiation 
Factors (GDFs), and Mullerian Inhibiting Substance (MIS) (Heldin et a l., 1997). 
BMPs may also be alternatively named as GDFs.
The TGF-p family members play crucial roles in bone metastases. The bone 
formation involves a cascade o f  events, which triggers cellular events including 
osteoblast proliferation and differentiation as well as osteoclast apoptosis. Osteoblast 
proliferation is induced by mitogenic factors, such as transforming growth factor-P 
(TGF-p), insulin-like growth factors (IGFs), fibroblast growth factors (FGFs) and 
platelet- derived growth factor (PDGF). TGF-P might be released as a consequence 
o f resorption to induce osteoclast apoptosis and impair continued resorption. The 
osteoblast differentiation involves expression o f the structural proteins o f the bone
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matrix. BMPs are predominantly responsible for osteoblast differentiation and bone 
matrix production and mineralization
BMPs are highly related molecules which compose a subgroup of the 
transforming growth factor-P (TGF-P) super family. So far, more than 20 molecules 
have been discovered to be BMP family members, o f which the first was identified 
by Urist et al. in 1965.
Bone Morphogenic Proteins (BMPs) are osteogenic factors abundant in bone 
matrix and have been indicated to be crucial to bone metastasis o f cancer. BMP2, 
BMP4 and BMP7 are expressed in a spatially and temporally dynamic pattern, prior 
to the formation of cartilage elements (Francis-West et al., 1995; Francis et al., 1994) 
and expressed in the perichondrium within the developing limb cartilage elements 
(Jones et al., 1991; Lyons et al., 1990; Macias et al., 1997; Tabas et al., 1993). BMP6 
is expressed in prehypertrophic and hypertrophic chondrocytes (Zou et al., 1997). 
BMP8B is found in mice but not in humans. Another BMP family member, 
GDF5(Growth/differentiation factor 5) is isolated as cartilage-derived morphogenetic 
protein-1 (CDMP-1) (Chang et al., 1994; Storm et al., 1994) and expressed in the 
developing joints and perichondrium (Chang et al., 1994; Storm et al., 1994), while 
GDF9 was found only abundantly in oocytes in ovaries (Dong et al., 1996).
The BMP family proteins comprise an amino-terminal pro-region and a 
carboxy-terminal ligand o f 110-140 amino acids in length. BMPs are first 
synthesised as large precursor proteins, processed into mature proteins, and secreted 
as homo- or heterodimers (Ozkaynak et al., 1990; Wozney et al., 1990; Wozney et al., 
1988). Once they have been processed and activated, BMP proteins are biologically
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active both as homodimer, and as heterodimer molecules connected by disulfide 
bonds. The active domain o f BMPs contains a conserved motif o f seven cysteines 
and six of them form a cysteine knot, which is involved in dimerisation (Massague et 
al., 1994). However, the heterodimers o f BMP4/7, BMP2/6, BMP2/7 and 
BMP7/GDF7 are more effective than their homodimers (Aono et al., 1995; Butler 
and Dodd, 2003; Israel et al., 1996; Suzuki et al., 1997).
After activation, BMPs regulate transcription of their target genes mainly by 
signalling through specific serine-threonine receptors and intracellular Smad proteins 
(Itoh et al., 2000). Six o f the seven Type-I receptors (ALK1, ALK2/ACTR-I, 
ALK3/BMPR-IA, ALK4/ACTR-IB, ALK5/TpR-I, ALK6/BMPR-IB, ALK7 ) and 
three of the five Type-II receptors (TpR-II, ACTRIIA, ACTRIIB, BMPRII, AMHRII) 
have been implicated in BMP signalling, o f which BMPR-IA, BMPR-IB (Type-I) 
and BMPR-II (Type-II) are specific for BMPs (Shi and Massague, 2003).
BMP and bone metastasis
Osteoblast differentiation induced by BMPs is mediated mainly via the Smad- 
signalling pathway, whereas chondrogenic differentiation may be transmitted by 
Smad-dependent and independent pathways (Fujii et al., 1999). Active forms o f bone 
morphogenetic protein (BMP) type I receptors and those of activin receptor-like 
kinase (ALK)-l and ALK-2 (ALK-1 group), R-Smads (Smadl, 5) induced alkaline 
phosphatase activity in C2C12 cells. BMP6 dramatically enhanced alkaline 
phosphatase activity induced by Smadl or Smad5 which can be repressed by Smad6 
and Smad7. More interestingly, ALK-2 and ALK-3 (or ALK-6) were found to
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sy nergi Stic al ly induce higher transcriptional activity and osteoblast differentiation of 
C2C12 cells than any receptor alone (Aoki et al., 2001).
The investigation o f BMPs into their role in bone formation and bone 
metastasis are becoming increasingly interesting. It is embodied in that, apart from 
bone development and bone metastasis, BMPs also participate in various 
physiological and pathophysiological processes, such as embryonic development, 
organogenesis, and adult tissue homeostasis. BMP2 and BMP4 have potent bone and 
cartilage-inducing activity in vivo (Winnier et al., 1995; Zhang and Bradley, 1996). 
Osteogenic protein-1 (OP-1; also named BMP7), OP-2 (BMP8), OP-3 (BMP8B), 
BMP5 and BMP6 (also named Vgr-1) form another subfamily. OP-1 (BMP7) 
potentially has bone- and cartilage inducing activity in vivo and the null mice appear 
to be associated with defects in eye, kidney and skeletal morphogenesis (Dudley et 
al., 1995; Luo et al., 1995). BMP8B null mice were shown to have defects in 
spermatogenesis (Zhao et al., 1996). GDF5 acts in a relatively specific fashion for 
chondrogenesis when assayed using rat limb bud cells (Hotten et al., 1996). This, 
together with GDF6 and GDF7 were shown to induce tendon and ligament formation 
when implanted at ectopic sites in vivo (Wolfman et al., 1997). The members in the 
GDF5 subgroup act specifically in the morphogenesis of the limb skeleton. GDF8 
(also termed myostatin) and GDF9 are structurally distantly related to the other 
BMPs. GDF8 (myostatin) negatively regulates the growth o f skeletal muscle cells in 
vivo (McPherron et al., 1997). GDF9 is important to ovarian folliculogenesis (Dong 
et al., 1996).
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1.3.2 BMP signalling in cancer
There are two signalling pathways via which BMPs act to activate intracellular 
signalling molecules: the Smad dependent or Smad independent pathways.
The two different types o f serine-threonine kinase transmembrane BMP 
receptors, Type I and type II are recruited by both pathways upon activation by 
BMPs. If the dimeric ligand o f BMPs bound to the two receptors simultaneously, the 
Type-II receptors would transphosphorylate the GS domain of the Type-I receptors 
(Moustakas and Heldin, 2002). The type I receptor then transduces the signal by 
phosphorylating intracellular targets, including members o f the Smad family 
(Hoodless et al., 1996; Liu et al., 1996). This is known as the Smad dependent 
pathway.
Intracellular signals are transduced by Smad proteins. After phosphorylation, 
the R-Smads (Smadl, 5 and 8) are released from the receptor and recruit the Co- 
Smad (Smad4) to form heteromeric complexes, and translocate into the nucleus 
where they may activate transcription o f various genes (Figure 1.6). BMP4 and 
growth/differentiation factor 5 (GDF5) induce osteoblast differentiation through the 
activation of three receptor-regulated Smads (i.e. Smadl, Smad5 and Smad8). In 
contrast, BMP6 and BMP7 induce alkaline phosphatase activity through Smadl and 
Smad5, but not through Smad8 (Aoki et al., 2001). Another report also determined 
BMP7 binds predominantly to Sm adl, Smad5, and Smad8, but not Smad2 and 
Smad3 and stably interacts with BMPR-IB (BMP type IB receptors) which is 
phosphorylated by BMPR-II (Type II receptor for BMPs) in the rat osteoprogenitor- 
like cell line, ROB- C26 (Tamaki et al., 1998). Consistent with these findings, BMP4
has been shown to induce phosphorylation and nuclear translocation o f Sm adl, 
Smad5 and Smad8, but BMP-6 activated only Smadl and Smad5. BMP4 and GDF5 
are known to bind to activin receptor-like kinase 3 (ALK-3) and/or ALK-6 (also 
termed BMP type IA and type IB receptors, respectively), whereas BMP6 and BMP7 
preferentially bind to ALK-2 (Aoki et al., 2001). Smad6 and Smad7 are inhibitory 
Smads, and inhibit TGF-p family signalling by preventing the activation o f R-Smads 
and Co-Smads (Itoh et al., 2001).
If BMP ligands bound to ALK3 or ALK6 first, and then recruited BMPRII into 
a hetero-oligomeric complex (BMP-induced signalling complexes, BISC), this would 
lead to the activation of the Smad independent pathway (Nohe et al., 2004). During 
intracellular signal transduction, the X-linked inhibitor of apoptosis protein (XIAP) 
functions as an adaptor protein bridging between the Type I receptor and TGF-6 
activated binding protein (TAB 1/2/3), which is an activator of the MAPKKK TGF-6 
activated tyrosine kinase 1 (TAK1) (Shibuya et al., 1996; Yamaguchi, 1995; 
Yamaguchi et al., 1999). The activation o f TAK1 can lead to activation o f p38, a 
mitogen-activated protein kinase (MAPK) (Kimura et al., 2000; Moriguchi et al., 
1996a; Nohe et al., 2002). TAK1 can also activate Jun N-terminal kinases (JNKs), 
NF-kappaB (NF-kB) and Nemo-like kinase (NLK) (Ishitani et al., 1999; Lee et al., 
2002; Shirakabe et al., 1997).
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Figure 1.6. BMP signalling pathway through Smads and non-Smads
When BMP ligands bind to BMPR-I and BMPR-II simultaneously, the Smad 1/5/8 pathway 
was activated. Upon phosphorylation by type I receptors, ligand-specific Smads formed 
complex with Smad 4 and translocated into nucleus to activate the transcription of target 
genes. On the other hand, when BMPs bind to BMPR-I first and then recruit BMPR-II, 
intracellular signal transduction will be relayed by Smad-independent pathways.
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1.3.2.1 BMP receptors and their implication in cancer
Two different type I receptors specific for BMPs, namely BMP type IA 
(BMPR-IA or ALK-3) and BMP type IB receptors (BMPR-IB or ALK-6) and the 
Type II receptor for BMP (BMPRII) genes, are located at 10q23, 4q22-24, and 2q33- 
34, respectively. A processed BMPR-IA pseudogene was mapped to 6q23 (Astrom et 
al., 1999). Both types of BMP receptors are transmembrane serine/threonine kinases, 
composed of an amino terminal extracellular ligand binding domain, a single 
transmembrane domain, and a large serine/threonine kinase domain at their carboxyl- 
terminal. The extracellular domains of both types of receptors have three finger toxin 
folds as seen in several snake venom neurotoxins. The intracellular cytoplasmic 
region consists of an enzymatic serine/ threonine kinase domain critical in 
transducing signals of BMPs.
The long form variant o f BMPRII is composed of 1038 amino acid residues, 
which has a long C-terminal tail and occurs by alternative splicing o f mRNA (Beppu 
et al., 1997). The short form is rarely seen in most cell types and its function is 
identical with the long form when assayed in Xenopus embryos (Ishikawa et al., 
1995). The two type I BMP receptors share 85% amino acids sequence identity and 
have very similar protein structures. Upon binding to ligands, BMPR-II may interact 
with multiple type I receptors, including BMPR-IA/Brkl, BMPR-IB, and ActR-I, 
which is also an activin type I receptor. The co-operation of BMPRII and ActR-I 
required by BMPs signalling reveals the crosstalk with the activin receptor system 
(Liu et al., 1995). Up to date, functional differences between the intracellular 
domains of the two type I BMP receptors are not fully characterised.
Aberrant expression and functions o f BMP receptors have been implicated in 
the tumourigenesis and disease progression o f malignant tumours. BMPR-IB and 
BMPRII have been indicated in the prostate cancer, in which they mediate inhibitory 
effect on both in vitro and in vivo growth o f prostate cancer cells (Miyazaki et al., 
2004; Ye et al., 2008). For example, over-expression of BMPR-IB (ALK-6) in PC-3 
cells resulted in an inhibition of both in vitro proliferation and in vivo tumour growth 
(Miyazaki et al., 2004). Similarly, loss of BMP signalling molecules (including 
BMPR-IA, BMPR-IB, BMPRII, Smad4, and phosphorylated Smad 1,5,8) have been 
shown to be correlated tightly with progression of human colon adenomas to 
colorectal cancer and occurs relatively early during cancer progression (Kodach et al., 
2008). In addition, decreased expression o f BMPR-IB correlates with poor prognosis 
in breast cancer patients and leads to increased cell proliferation o f breast cancer cells 
in vitro (Bokobza et al., 2009). BMPR-IB was also demonstrated to be a major 
hallmark of the progression and dedifferentiation o f oestrogen receptor-positive 
breast cancer (Helms et al., 2005). The impact o f BMPR-IB on tumour progression, 
proliferation, and cytogenetic instability was mainly mediated via phosphorylation o f 
Smadl. The pro-proliferative effect was indicated by XIAP and IAP-2 expression in 
BMPR-IB-positive carcinomas. The aberrant expression o f BMP receptors in cancer 
may be due to regulation by hormones, growth factors and methylation status of the 
particular genes. In oestrogen-treated MCF-7 cells, estradiol decreased the expression 
levels of BMPR-IA, BMPR-IB, ACVR2A, and ACVR2B but did not affect ACVR1 
and BMPRII (Takahashi et al., 2008).
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1.3.2.2 Smad
Smad proteins can be divided into three distinct classes: the receptor-activated 
Smads (R-Smads), the common-mediator Smads (Co-Smads) and the inhibitory 
Smads (I-Smads). R- and Co-Smads have two highly conserved domains, Mad- 
homology domains 1 and 2 (MH1 and MH2) at N- and C-terminal parts o f the 
proteins, respectively. The MH1 domain o f R- and Co-Smad can bind to specific 
DNA sequences (Dennler et al., 2002; Dennler et al., 1999; Jonk et al., 1998; Shi et 
al., 1998; Yagi et al., 2002; Yingling et al., 1997; Zawel et al., 1998). The MH2 
domains are used in homo- and hetero-meric complex formation (Lagna et al., 1996; 
Wu et al., 1997). R-Smads are the only Smads that have an SSXS (Ser-Ser-X-Ser) 
motif in their C-terminal region which can be phosphorylated by type I 
serine/threonine receptors during signal transduction (Macias-Silva et al., 1998; 
Zhang et al., 1996). Among the R-Smads, Smads2/3 are described as TGF-(3/activin 
activated Smads, whereas Smad 1/5/8 are activated by BMPs (Miyazawa et al., 2002). 
However, some recent studies have shown that Smad2/3 can also be mediated by 
BMPs (Buijs et al., 2007b; Izumi et al., 2006). Co-Smad (Smad4) forms a 
heteromeric complex with R-Smads and translocates to the nucleus with them.
1-Smads interfere with the phosphorylation o f R-Smads by Type-I receptors 
through interacting with activated Type-I receptors. Smad6 has been reported to 
occur in two forms, a short form mainly consisting o f the MH2 domain and a long 
form containing an N-terminal sequence with weak similarity to the MH1 domains o f 
R- and Co-Smads. The shorter form is a stronger inhibitor o f BMP signalling than the
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long form of Smad6. Smad7 is responsible for inhibiting TGF-p/activin and BMP 
signalling, whereas Smad6 is specific for BMP signalling (Ishida et al., 2000; 
Nagarajan et al., 1999).
Smad4 and Smad7 were observed in the majority o f colorectal cancer 
specimens. Autocrine activation o f Smad signalling may affect tumour environment 
via suppression of tumour-infiltrating immune cells and probably contributes to 
tumour cell aggressiveness (Gulubova et al., 2010). The changes in inhibitory Smads 
also contribute to disease progression as demonstrated in non-small cell lung cancer 
(Jeon and Jen, 2010). A hyperactive R-Smad2 signalling pathway is critical for EMT 
and consequent disease progression o f breast cancer. Disrupting Smad signalling in 
mesenchymal breast cancer cells resulted in DNA demethylation and re-expression of 
the genes, which was accompanied by an acquisition of epithelial morphology and a 
suppression o f invasive properties (Papageorgis et al., 2010).
Smad target genes include Id 1-3, type-I collagen, Jun B and Mix.2. Id-1 
(Inhibitor of differentiation-1) is an important regulator covering a variety o f 
functions. Id-1 negatively regulates cell differentiation and promotes proliferation, 
survival and invasion of both cancer cells and vascular endothelial cells, particularly 
during angiogenesis and metastasis in various cancers (Ling et al., 2006).
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1.3.2.3 Impact of BMPs on cancer
BMP proteins have diverse effects on cancer cells. The diversity o f the 
biological influence can be seen by: 1. the difference in the signalling pathways that 
they utilised namely Smad dependent vs Smad independent pathways, 2. different 
BMPs have contrast effect on the same cells, and 3. the same BMP may have an 
opposite effect on different cancer cells. Autocrine bone morphogenetic protein-9 
signals through activin receptor-like kinase-2/Smadl/Smad4 to promote ovarian 
cancer cell proliferation (Herrera et al., 2009). However, BMP9 inhibits the growth 
o f prostate cancer cells due to induced apoptosis, which is related to an up-regulation 
o f prostate apoptosis response-4 through BMPRII and Smadl (Ye et al., 2008). 
BMP7 induces ageing and death o f breast cancer cells, by a mechanism involving 
inhibition of telomerase activity and telomere maintenance via BMPRII receptor- and 
Smad3-mediated repression of the hTERT gene (Cassar et al., 2009). Meanwhile, 
BMP7 inhibits the proliferation o f androgen-insensitive PC-3 and DU-145 prostate 
cancer cells in a medium containing 1% fetal bovine serum through CDK1, observed 
as decreased incorporation o f [(3)H] thymidine and decreased cell number (Miyazaki 
et al., 2004). BMP6 regulates the proliferation and gene expression profile of 
macrophages, in which BMPRII, ALK-2 and ALK-3 function as its receptors (Hong 
et al., 2009). BMP2 acts as a tumour suppressor promoting apoptosis in mature 
colonic epithelial cells and BMPR-IA, BMPRII and Smadl, Smad4 might be 
involved in this (Hardwick et al., 2004).
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In the Smad-independent pathway, TAK1 is a Map kinase kinase activated by 
BMP4 and BMP2 stimulation, through which BMP4 or BMP2 subsequently activates 
the p38 pathway (Kimura et al., 2000; Moriguchi et al., 1996b; Shibuya et al., 1998). 
BMP2 and BMP4 are known to play a role in the regulation o f apoptosis (Fujita et al., 
1999; Macias et al., 1997; Omi et al., 2000; Piscione et al., 2001). BMP2, in the 
presence of IL6, mediates apoptosis in MH60 cells through the TAK1 p38 pathway. 
The apoptosis induced by BMP2 can be prevented completely by the expression o f a 
kinase negactive form of TAK1. The activation of TAK1 can be blocked by Smad6 
and Smad7. BMP6 and BMP7 inhibit oestrogen-induced proliferation of breast 
cancer cells by suppressing p38 mitogen-activated protein kinase activation through 
the Smad-independent pathway (Takahashi et al., 2008). However, TAK1 pathway is 
known to be able to induce or suppress apoptosis. TAK1-MKK4-JNK pathway has 
been reported to induce apoptosis in 293T cells (Yang et al., 2004). INK plays an 
essential role through its ability to interact and modulate the activities o f diverse pro- 
and antiapoptotic proteins (induce BAX, inhibit Bcl2 and so on) (Dhanasekaran and 
Reddy, 2008).
Taken together, BMPs and their signalling pathways have been implicated in 
development and progression o f cancer, particularly in the bone metastasis. BMP 
signalling has been extensively involved in the regulation of proliferation, apoptosis, 
motility and invasion o f both cancer cells and vascular endothelial cells, conferring 
favourable phenotypic features and environment during the disease progression and 
dissemination.
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1.4 Repulsive guidance molecules (RGMs)
Apart from BMP receptors which are transmembrane kinase receptors, on the 
surface of cells, there exist other molecules which have influence on the action of 
BMPs. RGMs are the first identified BMP co-receptors on cell surface which are 
assumed to enhance the BMP signal pathway and will be the emphasis of the present 
study. This is in addition to BMP-binding proteins, Noggin and Chordin that 
extracellularly regulate BMP functions by acting as their antagonists.
1.4.1 RGM
In 2001, Wiemann et al. isolated a cDNA corresponding to human RGM 
(GenBank AL 136826). RGMA was first cloned from mRNA of chick embryonic 
optic tectum (Monnier et al., 2002). RGMA, RGMB and RGMC were subsequently 
identified in mouse in 2004 (Niederkofler et al., 2004; Oldekamp et al., 2004; 
Schmidtmer and Engelkamp, 2004). RGMA was initially found to mediate repulsive 
axonal guidance and neural tube closure, while RGMB (Dragon) contributes to 
neuronal cell adhesion through homophilic interactions. The RGMC gene may play 
role in the inherited condiction juvenile hemochromatosis a disorder o f iron overload 
in which RGMC gene is muated.
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1.4.1.1 RGMA
RGMA has been found highly conserved in vertebrates including humans 
(accession number: AK074910), mice (BC059072), chickens (AY 128507), frog 
(BC061329), zebrafish (BC091800), and salmon (BT045779) etc.
RGMA Gene characteristic:
The human RGMA gene was located at Chromosome 15q26.1. In human, 
mouse and chicken, RGMA is positioned in the opposite transcriptional orientation 
from the other nearby genes. Mctp2 (multiple C2 domains, transmembrane 2) is 
found near the 5’ end to RGMA, and Chd2 (chromodomain helicase DNA-binding 
protein 2), St8sia2 (ST8a-N-acetyl-neuraminide a-2,8-sialytransferase), and Slco3al 
(solute carrier organic anion transporter family member 3A1) are located near the 3’ 
end. The RGM genes are located on the same chromosome that encodes transducers 
o f regulated cAMP response element-binding protein, bloom syndrome protein, Furin 
precursor, Isocitrate dehydrogenase, Mesoderm Posterior protein, Neurite outgrowth 
associated protein, Mesenchymal stem cell protein, Synaptic vesicle glycoprotein, 
Tubulin polyglutamylase.
Human RGMA gene is ~46 kb and composed of four exons, which is similar to 
mouse (~44 kb). After transcription, human RGMA is assembled as an mRNA of 3.2 
kb (Figure. 1.6). The 5’ end exon is non-coding, which mostly comprises the 5’ un­
translated region (UTR) o f RGMA mRNA. The remaining 5’ UTR is included in part
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of the second exon. The second exon encodes 26 condons of the RGMA protein, 
while 72 amino acids (aa) encoded by the 3rd exon and 328 aa by the 4th exon, 
respectively. The 4th exon contains another -1800 nucleotides and a single 
polyadenylation signal of 3’ end. The 3 introns in human RGMA are o f similar 
lengths as in mouse, but are not as conserved as the exons (up to 99%). Slight 
differences in the 5' UTR bring about six gene variants. These gene variants 
consequently derived 3 protein isoforms with different lengths and N-terminals.
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Figure 1.7 Comparison o f human RGMs genomic loci and gene structures.
The relative position of the RGM genes (red line) is indicated on each chromosome (left). Neighbouring genes in the chromosome are presented 
with their transcriptional direction (arrow). Lixl -like (grey) is a putative pseudo-gene (Lixl 1). Right is the anatomy of human RGMs gene. Exons 
are indicated by boxes, with coding regions in blue and non-coding regions in yellow. The polyadenylation site is represented by a vertical arrow. 
Modified from Severyn et al., 2009.
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RGMA Gene expression
RGMA transcripts were shown to be expressed at higher levels in the central 
nervous system and lower levels in other tissues, including heart, liver, lung, skin, 
kidney and testis (Babitt et al., 2005; Metzger et al., 2005; Monnier et al., 2002; 
Niederkofler et al., 2004; Samad et al., 2004; Schmidtmer and Engelkamp, 2004). 
RGMA is also expressed in the developing mouse cochlea, lung, limb primordia 
(Oldekamp et al., 2004) and gut (Metzger et al., 2005). To date, the mechanism of 
RGMA gene expression regulation remains unknown. The expression pattern of 
RGMA transcripts in the central nervous extends to hippocampus, midbrain, the 
ventricular zone o f the cortex, part o f the brainstem and the spinal cord during the 
embryo development. In the embryonic tectum of chicken, its mRNA distributes in a 
gradient with increasing concentration from the anterior to posterior pole (Monnier et 
al., 2002).
RGM A Protein structu re  and expression
The chick RGMA protein was first identified by Monnier, Sierra et al. in 2002. 
Chick RGM contains a signal peptide, an RGD site, a von Willebrand factor (vWF) 
domain, a hydrophobic region, and a GPI (glycosylphosphatidylinositol) anchor 
(Fig.1.8). RGMA was revealed to be a two-chain protein bound to the cell membrane 
through a GPI-anchor.
The human and mouse RGMA proteins were subsequently identified
(Niederkofler et al., 2004), and are 450aa and 454aa in size, respectively. At present,
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it is estimated that human RGMA (accession number: B2RTW1) has two isoforms, 
one with the length o f 450aa and the other 485aa. The human and mouse RGMA 
protein also share very high homology with chick RGMA protein. Although the first 
amino acid o f mature protein has not been characterised experimentally, the RGMA 
precursor was estimated to contain a ~ 30 residue signal peptide at the N-terminus 
and a conserved GPI attachment signal peptide at the C-terminus, around 45 amino 
acids. Two more interesting elements, namely an RGD motif and a partial vWD 
domain have been found in the remaining protein sequence. RGD m otif (arginie- 
glycine-aspartic acid) is a tripeptide characterized as an integrin-binding site 
(Ruoslahti and Obrink, 1996). Von Willebrand factor is a glycoprotein composed o f 
five distinct structural domains (vWA, B, C, D and CK). This was reported to help 
mediate platelet adhesion at damaged blood vessels through interactions with blood 
clotting Factor VIII. (Jorieux et a l., 2000; Sadler, 1998). The type D domain (partial 
vWD region) has been conserved in all RGMs, which contains a site of 
intramolecular proteolytic cleavage. The mature RGMA is a disulfide-bonded two- 
chain protein composed o f an N-terminal fragment of -123 residues and a C- 
terminal segment o f -238, which is linked to the outside of the plasma membrane 
through its GPI anchor. It appears that mature RGMA protein is generated by 
intramolecular cleavage during the biosynthesis, although the mechanism has not 
been confirmed by experiments (Hata et al., 2006; Matsunaga and Chedotal, 2004; 
Monnier et al., 2002; Stahl et al., 1990).
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Figure 1.8 Main domain model o f RGM protein.
RGMs are composed of a N-terminal signal peptide, an RGD site (except for RGMB), von Willebrand factor (vWF) domain, a hydrophobic region, 
and a C-terminal GPI (glycosylphosphatidylinositol) anchor. The arrow marks the proteolytic cleavage site. The arrow (purple) indicates the PPC 
cleaving site (RGMC only). RGMA, RGMB and RGMC proteins are 434, 437 and 426 aas respectively.
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RGMA exhibits a wide range o f tissue expression, in different species, both 
during development and in the adult, suggesting that the potential functions of 
RGMA are not confined to axonal guidance. During mouse development, RGMA is 
widely expressed in the central nervous system, mostly non-overlapping with RGMB. 
These separate expression patterns o f RGMs in the central nervous system persist 
after birth in several brain areas (Schmidtmer and Engelkamp, 2004). RGMA 
expression is increased around the lesion sites in rats with spinal cord injury (Hata et 
al., 2006; Schwab et al., 2005a) and in humans with focal cerebral ischaemia or 
traumatic brain injury (Schwab et al., 2005b). Intrathecal administration o f anti- 
RGMA antibody is able to promote the regeneration of corticospinal tract axons after 
thoracic spinal cord injury in rats (Schwab et al., 2005a). This suggests that RGMs 
are involved in the injury repair at the central nerve system.
The role of RGMA and association with Neogenin
Recombinant RGM at nanomolar concentrations induced collapse o f temporal 
but not o f nasal growth cones and guided temporal retinal axons in vitro, 
demonstrating its repulsive and axon-specific guiding activity (Monnier et al., 2002). 
RGMA also has shown a role in mediating axonal guidance in Xenopus embryo 
forebrain supraoptic tract (Wilson and Key, 2006) and in the developing mouse 
hippocampus (Brinks et al., 2004), although interestingly RGMA does not appear to 
play a role in retinal axonal patterning in developing mice (Niederkofler et al., 2004). 
Genetic knock out o f RGMA in mice did not alter retinal axonal patterning, but 
caused defects in neural tube closure (Niederkofler et al., 2004).
RGMA functiones to suppress cell proliferation and induce neuronal apoptosis 
signalling through its receptor, Neogenin, in early vertebrate development (Shin and 
Wilson 2008) and CRC cells (Li, Yuen et al. 2009). However, Matsunaga et al. 2004 
and Matsunaga et al. 2006 showed RGMA acts as a cell survival factor which 
inhibits the pro-apoptotic activity o f Neogenin (Matsunaga et al., 2004).
RGMA also functions as a myelin-derived neurite outgrowth inhibitor in vitro 
and in vivo, and inhibits axon regeneration and functional recovery in the injured 
central nerve system (CNS) (Hata et al., 2006). The study by Hata was the first report 
to demonstrate that RGMA as an axon growth inhibitor in adult mammals. The 
authors used a function-blocking antibody to inhibit the RGMA signal. Rats that 
undergo spinal cord hemisection show better locomotor recovery and axon growth o f 
the CST (corticospinal tract) after treatment with the function-blocking antibody than 
after treatment with the control antibody.
1.4.1.2 RGMB
RGMB, also known as Dragon, is a myelin-derived inhibitor o f axon growth in 
the CNS.
RGMB Gene sequence and expression
RGMB is a single-copy gene identified in eight mammalian species. Similar to 
RGMA, RGMB was located in a conserved chromosomal locus (5ql5), and was one 
of the five linked genes which were found according to the same orientation in 
human, mouse and chicken genomes. Upstream of RGMB are Riok2 (right open
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reading frame kinase 2), Lixl (Limb expression 1) and Lnpep (leucyl/cystinyl 
aminopeptidase). Downstream is C hdl, but with a tail to tail transcriptional 
orientation to RGMB.
The RGMB gene is -25  kb in length, and contains 5 exons (Figure 1.7). The 
two 5’ non-coding exons include -406  nucleotides of a -524 nucleotides 5’ UTR of 
RGMB mRNA. The 5’ end o f exon 1 has not been mapped. There are 45 codons 
being located in the third exon, 170 codons in the forth, and 222 codons in the fifth 
plus a 3’ end UTR of 308 nucleotides.
The gene encoding RGMB/DRAGON was identified by using a genomic 
DNA-binding strategy to identify genes regulated by DRG11, a homeobox 
transcription factor expressed in embryonic dorsal root ganglion (DRG) and dorsal 
horn neurons (Samad et al., 2004). The gene was named RGMB (DRG-‘ON’ or 
Dragon), reflecting that it was turned “on” in the “DRG”. It was regulated by and co­
localized with DRG 11 in dorsal root ganglia and spinal cord. As well as these two 
regions, RGMB mRNA was also found to be expressed in the retina, optic nerve, and 
in brain regions including the developing mouse midbrain, hindbrain and forebrain 
shown by the results o f in situ  hybridization experiments. (Niederkofler et al., 2004; 
Oldekamp et al., 2004; Samad et al., 2004; Schnichels et al., 2007)
RGMB Protein and its association with neogenin
The human RGMB protein is predicted to comprise 437 amino acids. The 
primary RGMB translation product contains an N-terminal signal peptide o f -50  
residues (this has not been verified experimentally) and a C-terminal 
glycosylphosphatidylinositol (GPI) attachment signal of -35 amino acids (supplied
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by OMIM). The vWD element was included in the identifiable motifs in RGMB. 
(Samad et al., 2005; Samad et al., 2004) RGMB contains a putative internal 
proteolytic cleavage site similar to that in RGMA, but only a single-chain RGMB 
form being attached to the outer face o f the cell membrane. The mature RGMB 
contains 14 cysteines but the structure is unclear.
RGMB is expressed by oligodendrocytes and neurons in the adult rat CNS, and 
the expression of RGMB is up-regulated especially around the site o f spinal cord 
injury (Liu et al., 2009). It has also been found in myelin isolated from an adult rat 
brain (Liu et al., 2009). RGMB is co-expressed with neogenin in CGNs (cerebellar 
granule neurons) and entorhinal cortex neurons (Liu et al., 2009) and upregulated in 
the retinas o f glaucoma-affected mice, together with RGMA and neogenin 
(Schnichels et al., 2007).
Moreover, DRG axons do not express endogenous neogenin and are 
unresponsive to RGMA. DRG axons become responsive to RGMA after neogenin 
expression (Rajagopalan et al., 2004). Neogenin-RGMB interaction might be 
involved in neuronal migration in the dentate gyrus (Conrad et al.). The evidence 
showed that Neogenin and RGMB were expressed in non-overlapping compartments 
of the developing dentate gyrus.
The binding with neogenin may be a common property o f all the RGMs, as 
both RGMA and RGMC have shown the direct binding to neogenin. Some of the 
known and predicted functions o f RGMB are manifected in the context o f RGMB- 
neogenin association. In vitro and in vivo migration of dentate neuroepithelial cells 
was abolished by RGMB, and cell adhesion was reduced when cells expressing
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neogenin came into contact with cells expressing RGMB. RGMB was shown to 
suppress BMP signalling in C2C12 myoblasts and over-expression o f neogenin did 
not alter the inhibitory capacity o f RGMB (Kanomata et al., 2009a).
However, the function o f RGMB may be independent upon the association with 
neogenin. RGMB is a myelin-derived inhibitor o f axon growth in the CNS and 
inhibits neurite outgrowth in vitro (Liu et al., 2009). RGMB might be involved in 
cell-cell adhesion due to homophilic interactions (Samad et al., 2004). Elevated 
expression in the retinas o f glaucoma-affected mice and around the lesion site of 
spinal cord injury in rats suggest that RGMB may have a role in the response to 
injury o f the nervous system.
Although no other biological functions o f RGMB have been reported except for 
its possible role as a BMP co-receptor, as other RGMs, the molecules related to 
RGMs could be predicted by the gene location, gene fusion, co-occurrence, co­
expression, homology and so on based on RGM sequences. Fig. 1.9 shows the 
potential interactions of RGMs with other molecules searched by STRING, including 
the information already proved by experiments. Besides sharing high identity with 
RGMA and C, RGMB might bind to BMPR-IA, BMPR-IB, BMPRII, BMP2, BMP4, 
and interact with Smad-1, Smad-9, Noggin with more than 90% score. Additionally, 
neogenin might also interact with RGMA and RGMC as a putative receptor, and 
RGMC may also interact with Hepcidin and transferring receptor protein.
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Figure 1.9 Predicted interactions o f RGM and other proteins.
Human RGMB was searched and modified from STRING 8.3 as representation. RGMB 
might bind to BMPRIA, BMPRIB, BMPRII, BMP2, BMP4, and interact with Smadl, Smad9, 
Noggin with more than 90% score. RGMA, B and C share more than 90% identity. RGMA 
and RGMC might additionally have interaction with neogenin and RGMC have interaction 
with hepcidin and transferrin receptor protein, compared to RGMB. Left displayed all the 
potential interactions of RGMB. Right shows the modes of actions. (Sources from: 
http://string-db.org/)
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1.4.1.3 RGMC
RGMC has synonyms as Hemojuvelin (HJV), Hemochromatosis type 2 protein 
(HFE2).
RGMC Gene characteristic
The RGMC gene was identified in humans as a gene within a locus linked to 
juvenile haemochromatosis in 2003. The RGMC gene and was designated as HFE2 
and its protein product was named as hemojuvelin (Papanikolaou et al., 2004). The 
name HFE2 was given because HFE  is the name of the gene that is most commonly 
mutated in adult forms o f hereditary hemochromatosis. It was later proposed that the 
hemojuvelin gene should be given a new designation of HJV  because the designation 
of this gene as HFE2 being contrary to established convention as it was not a member 
of the HFE family. Later, the same gene has been characterized as a homologue of 
RGMA and Dragon/RGMB, and finally named RGMC.
Human RGMC  gene was located chromosome lq21.2. RGMC is one o f 10 
linked genes in a syntenic locus that includes, Txnip (thioredoxin interacting protein) 
( lq l l ) ,  Polr3gl (DNA-directed RNA polymerase III subunit RPC7-like) (lq21.1), 
Ankrd34 (ankyrin repeat domain 34) (lq21.1), L ixll (related to L ixl, which maps 
near RGMB) (lq21.1), and C hdll (related to Chdl and Chd2, which are located near 
RGMB and RGMA respectively).
Moreover, the transcriptional orientation o f RGMC and C hdll is tail to head, 
which is different from that o f RGMA-Chd2 and RGMB-Chdl (tail to tail). The
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RGMC chromosome environment is similar in mouse and human but differs from 
zebrafish. There is no Chd homologue present at the zebrafish RGMC locus.
Human and mouse RGMC  genes are around 4.3 kb and 4.0 kb respectively and 
composed o f four exons separated by three introns. The exon at the 5’ end contains 
most of the 5’ UTR o f RGMC mRNA, which is approximately 160 nucleotides. The 
second exon contains the remaining 90 nucleotides o f 5’ UTR and the first 31 codons 
o f the RGMC protein. The following 173 codons are found in the third exon and the 
remaining 222 condons in the forth exon plus a 3’ UTR of aroundl 150 nucleotides 
with a single polyadenylation signal. The four RGMC exons are well-conserved 
between human and mouse. The nucleotide sequence identities in the exons range 
from 73% to 83%, but the three introns are less conserved, although of similar length 
(Fowler, 2008).
However, as RGMA differs from RGMB, RGMC has 4 variants due to the 
differences in the 5' UTR and 5’ coding region, resulting in 3 protein isoforms 
(isoform a, b and c).
RGMC gene expression
RGMC is detected in the heart and liver (Kuninger et al., 2004; Niederkofler et 
al., 2004; Oldekamp et al., 2004) and is also highly expressed during skeletal muscle 
differentiation (Kuninger et al., 2004; Niederkofler et al., 2004; Oldekamp et al., 
2004). During embryonic development o f mouse, RGMC is detected at E l 1.5 in the 
precursors o f skeletal muscle, which is similar to Zebrafish, and at El 3.5 in the heart 
and liver (Kuninger et al., 2004; Niederkofler et al., 2005; Samad et al., 2004;
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Sprague et al., 2006). As with RGMA and RGMB, the knowledge o f RGMC gene 
regulation remains largely unknown. RGMC has been shown to be down-regulated 
by LPS (lipopolysaccharide) through tumour necrosis factor-alpha (Constante et al., 
2007). However, mechanisms o f gene transcription have not been reported, nor the 
structure and the function o f RGMC gene reporter.
RGMC Protein structure
The initial cloning o f cDNA indicated the mouse and human RGMC protein are 
426 aa and 420 aa respectively. Human RGMC has three isoforms, with the length of 
426aa (isoform a), 3 B aa  (isoform b) and 200aa (isoform c). Similar to its paralogues 
RGMA and RGMB, RGMC is composed o f a predicted N-terminal signal peptide o f 
approximately 31 residues and a C-terminal GPI-attachment signal o f approximately 
45 aas. RGMC also contains up to three asparagine-linked glycosylation sites and 
several motifs including an RGD sequence and a partial vWD domain with a 
conserved proteolytic cleavage site. Furthermore, RGMC encodes a sequence near 
the C-terminus for recognition and cleavage by a furin-like PPC (pro-protein 
convertase) (Kuninger et al., 2008; Lin et al., 2008; Silvestri et al., 2008a). As a 
result, RGMC is processed to be the three distinct isoforms in skeletal muscle after a 
series of biosynthetic steps. According to their reports, the myoblast has two forms of 
RGMC associated with the cell membrane through GPI-links. One is a disulfide- 
linked heterodimer o f N- and C- terminal fragments (20/35 kDa) from the 
intracellular proteolytic processing o f endogenous RGMC. The cleavage o f RGMC 
occurs within a Gly-Asp-Pro-His sequence that is conserved in RGMA and RGMB.
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The other is full-length RGMC (50 kDa), which can be released from the cell surface 
and accumulates in the extracellular fluid o f cultured cells as two isoforms, each 
containing an intact N-terminus, and potentially varying in the number o f asparagine- 
linked glycosylation sites, 50 and 40 kDa respectively. It is interesting to note that 
RGMB and RGMA do not have the similar isoforms and structures to RGMC.
Functions of RGMC
A role played by RGMC in systemic iron metabolism was first reported by 
(Papanikolaou et al., 2004). The defects in RGMC (HFE2) are the cause of 
hemochromatosis type 2A (HFE2A) [MIM:602390]; also known as juvenile 
hemochromatosis (JH), whereas Type 2B HH is caused by mutations in the secreted 
hepatic peptide hepcidin. HFE2A is an early-onset autosomal recessive disorder due 
to severe iron overload resulting in hypogonadotrophic hypogonadism, hepatic 
fibrosis or cirrhosis and cardiomyopathy, occurring typically before the age o f 30. It 
is the consequence o f intestinal iron hyperabsorption associated with macrophages 
that do not load iron. Deleterious mutations o f HFE2 reduced HAMP (hepcidin) 
levels despite iron overload, which normally induces HAMP expression (Barton et al., 
2008; Barton et al., 2007; Murugan et al., 2008).
RGMC induces expression o f hepcidin, which is a negative regulator o f both 
the uptake o f dietary iron from the duodenum and the release of stored iron from 
macrophages. The most possible mechanism for the action o f RGMC in iron 
metabolism is that cell-membrane associated RGMC facilitates signalling via a 
selective subset o f BMP ligands and receptors, independent of neogenin, to promote
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hepcidin gene expression (Andriopoulos et al., 2009; Babitt et al., 2006; Babitt et al., 
2007; Xia et al., 2008). However, a soluble form of hemojuvelin (s-hemojuvelin) 
exists in blood and acts as an antagonist of GPI-hemojuvelin to downregulate 
hepcidin expression, sequestering BMPs away from cell-surface receptors. Iron 
overload has been shown to reduce soluble HJV production in vitro (Silvestri et al.,
2007), while iron deficiency increases soluble HJV levels both in vitro and in vivo 
(Zhang et al., 2007). These data indicated that s-hemojuvelin could be one o f the 
mediators o f hepcidin regulation by iron (Lin et al., 2005; Lin et al., 2008). Hypoxia 
may also upregulate production o f the soluble HJV in vitro (Kuninger et al., 2008).
RGMC expression was not suppressed by interleukin-6 but by tumour necrosis 
factor-alpha, whereas hepcidin levels are directly regulated by interleukin-6 but not 
by tumour necrosis factor-alpha (Constante et al., 2007). Regulation o f iron-related 
genes by different cytokines may allow for time-dependent control o f iron 
metabolism in accordance with iron load and different circumstances.
Matriptase-2 can interact with HJV by cleaving hemojuvelin (HJV) at the 
plasma membrane. Through HJV, deficiency of TMPRSS-6 (also known as 
matriptase-2) was found to cause a decrease in BMP6 mRNA and an increase in 
hepcidin levels and Idl thereby contribute to iron deficiency anaemia (Finberg et al., 
2010). This suggests that Matriptase-2 is a suppressor of the HJV-hepcidin pathway 
by cleaving HJV. Matriptase, is a type II membrane serine protease widely expressed 
in normal epithelial cells and human carcinoma cells, being involved in cancer 
progression (Jin et al., 2006). Matriptase-2 itself was found to inhibit breast tumour 
growth and invasion which correlates with favourable prognosis for breast cancer
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patients (Parr et al., 2007) and reduces the aggressiveness of prostate cancer cells in 
vitro and in vivo (Sanders et al., 2008).
Although the direct impact on cancer o f RGMC has not been elucidated, the 
interactions between RGMC and other molecules such as BMPs, matriptase-2 and 
neogenin suggest a potential implication o f this molecule in cancer.
RGMC and its association with neogenin
Similar to RGMA, RGMC binds to the extracellular part o f neogenin (Kuns- 
Hashimoto et al., 2008; Zhang et al., 2005). Recently, it was shown that HJV- 
induced BMP signalling and hepcidin expression were not altered by neogenin 
overexpression or by inhibition o f endogenous neogenin expression, indicating that 
HJV is able to mediate the BMP signalling independently o f nogenin (Xia et al.,
2008). However, a contradictory report suggests that neogenin is required for HJV 
enhanced BMP-4 signalling (Zhang et al., 2009).
1.4.2 Receptor of RGM
Neogenin is a multifunctional transmembrane receptor belonging to the 
immunoglobulin superfamily, which was originally isolated from embryonic chicken 
cerebellum (Vielmetter et al., 1994). Its secondary structure is identifical to DCC 
deleted in colorectal cancer, a netrin receptor that is involved in axon guidance and 
cell survival. As DCC, Neogenin transduces signals induced by netrin. The
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neogenin-netrin interaction has been implicated in tissue morphogenesis, 
angiogenesis, myoblast differentiation and most recently in axon guidance.
As already discussed in early sections, Neogenin is also a receptor for repulsive 
guidance molecules (RGM). Rajagopalan et al. 2004 presented evidence that 
neogenin functions as a receptor for RGM (Rajagopalan et al., 2004). Like RGM, 
neogenin was expressed in a gradient across the embryonic chicken retina. The 
avoidance (a kind o f guidance) o f RGM by chicken temporal retinal axons was 
blocked by anti-neogenin antibody and the soluble neogenin ectodomain (Wilson and 
Key, 2006). Dorsal root ganglion axons were unresponsive to RGM, but were 
converted to a responsive state by neogenin expression (Rajagopalan et al., 2004).
The extracellular domain o f human neogenin protein contains four V-shaped 
immunoglobulin-like domains and six fibronectin type III (FNIII)-like domains. 
RGM interacts with the fibronectin domain o f neogenin (Rajagopalan et al., 2004) 
(Figure 1.10). Netrin-1 also binds to the FNIII-like domain, but the binding affinity 
of RGM for neogenin (Kd = 230 pM) is much higher than that of netrin-1 (Kd = 2nM) 
(Geisbrecht et al., 2003).
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Figure 1.10 Structure of RGM and Neogenin.
RGMs attached to the cytoplasm ic membrane through GPl-anchor. The specific domain o f  
RGM which interacts w ith the extracellular fibronectin domain o f  neogenin remains 
unknown.
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The interaction with RGMA and involvement in tumour proliferation
RGMA regulates repulsive guidance o f retinal axons through binding to 
neogenin (Cirulli and Yebra, 2007; Matsunaga and Chedotal, 2004; Rajagopalan et 
al., 2004). After RGMA binds to neogenin, some signal pathways are triggered and 
the protein kinase C, the small GTPase RhoA, RhoA kinase, the putative 
transcriptional co-activator, LIM-only protein 4 have been indicated to be involved in 
these early events (Conrad et al., 2007; Hata et al., 2006; Hata et al., 2009; Schaffar 
et al., 2008). However, RGMA does not bind to proteins related to neogenin as 
netrins do. The latter binds to DCC (deleted in colorectal cancer) and members o f the 
Unc (unco-ordinated) sub-family (Rajagopalan et al., 2004). Only Unc5b has been 
shown to have an indirect association with RGMA recently (Hata et al., 2009). The 
mechanism o f how neogenin regulates the biological effects o f RGMA has not been 
fully determined, only Matsunaga et.al (Matsunaga et al., 2004) have reported that 
the interaction between RGMA and neogenin promoted neuronal survival, except for 
the regulation on retinal axonal guidance.
The mechanisms for the regulation o f cell death are diverse. There is a type of 
cell death involving the absence o f ligand induced self-activation of the receptor, by a 
mechanism still unknown, and the subsequent proteolytic processing o f the receptor 
triggers apoptotic cell death. Ligand binding blocks the proteolytic processing and 
the pro-apoptotic activity o f the receptor. The apoptosis might be caused by the 
proteolytic cleavage o f the receptor by activated caspase-3 or other proteases, to 
expose a pro-apoptotic region in the cytoplasmic domains of the receptor (DCC, Ptc, 
etc.) or to create cytoplasmic fragments inducing apoptotic signals (RET, UNC5H,
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etc.) (Porter and Dhakshinamoorthy, 2004). Consistent with this suggestion, 
Neogenin overexpression or down regulation o f RGMA by short interfering RNA at 
E l.5 in the area o f the developing dorsal metencephalon, mesencephalon and caudal 
diencephalons in chick embryos results in an decrease in the number of cells positive 
for TdT-mediated dUTP nick end labeling (TUNEL) (Matsunaga et al., 2004).
Apoptosis is caused by the proteolytic cleavage of the receptor by activated 
caspase-3, although knowledge regarding the underlying signal transduction 
mechanisms is limited. A subsequent study has indicated that RGMA might play a 
positive role in chick embryo development, in addition to rescuing cells by 
suppressing neogenin-mediated cell death. Overexpression o f RGMA in the neural 
tube promotes neuronal differentiation, whereas suppression of RGMA represses this 
(Matsunaga et al., 2006). Thus, RGMA not only suppresses neogenin-induced cell 
death but also enhances neuronal differentiation. The final cell fate decisions might 
be made on the basis o f  the relative expression levels of RGMA and neogenin. No 
alterations in cellular proliferation or neuronal differentiation have been reported in 
RGMA mutant mice suggesting redundant mechanisms exist in rodents.
However, RGMA was also reported to suppress cell proliferation and induce 
neuronal apoptosis signalling through its receptor, Neogenin, in early vertebrate 
development (Shin and Wilson, 2008) and CRC cells (Li et al., 2009b).
Hata et al. 2006 reported that RGMA inhibits axon regeneration and functional
recovery in the injured CNS (Hata et al., 2006). Neogenin is expressed widely in the
adult CNS and spinal cord, and is distributed predominantly in the grey matter
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(Manitt et al., 2004). Netrin-1 stimulates neurite growth through neogenin 
(Barallobre et al., 2005), preventing the binding of RGMA to neogenin might allow 
the axons to be navigated by netrin-1.
The interaction with RGMC and involvement in iron metabolism
The RGMC-neogenin complex is necessary for iron accumulation within cells 
and responsible for the RGMC-induced changes in iron homeostasis (Zhang et al., 
2005). Neogenin is indicated to regulate iron homeostasis via inhibiting secretion of 
RGMC (soluble HJV, an inhibitor o f BMP signalling) to enhance BMP signalling 
and hepcidin expression (Lee et al., 2010). HJV is believed to be a coreceptor of 
BMPs in the regulation o f hepcidin expression, whereas extracellular/soluble HJV 
(sHJV) may act as an antagonist in BMP2-induced Smad 1/5/8 phosphorylation, a 
major BMP activated signalling pathway that induces hepcidin expression.
The mechanisms of RGM and neogenin interaction
The signal transduction mechanisms underlying other aspects o f the RG M - 
neogenin interaction are mostly unknown. However, during axon inhibition, RGMA 
activates the Rho/Rho kinase pathway in neurons through neogenin. Myelin-derived 
neurite outgrowth inhibitors —  namely MAG, Nogo and oligodendrocyte myelin 
glycoprotein (OMgp) —  in oligodendrocytes also induce inhibitory signalling in 
neurons by activating the Rho/Rho kinase pathway through the Nogo receptor 
complex comprising p75/Troy, NgR and Lingo-1. Downstream molecules o f Rho 
kinase, such as myosin light chain (MLC), LIM kinase (LIMK) and CRMP-2, might
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also have roles in axon growth inhibition. However, the mechanism underlying the 
activation o f the RhoA/ Rho kinase pathway after RGMA binds to neogenin remains 
unknown. Both neogenin and DCC bind to focal adhesion kinase (FAK) through their 
highly homologous intracellular domain, and subsequently regulate the netrin-1- 
stimulated outgrowth o f cortical axons (Liu et al., 2004; Ren et al., 2004). Some 
RhoGEFs (full name) might associate with neogenin to induce the activation of 
RhoA specifically in response to RGM, such as PDZ-RhoGEF and LARG, which are 
phosphorylated by FAK (Chikumi et al., 2002; Swiercz et al., 2002).
Neogenin-netrin interactions have been implicated in tissue morphogenesis, 
angiogenesis, myoblast differentiation and most recently in axon guidance (Wilson 
and Key, 2007). Netrin-1 is a secreted neural guidance cue with the unique ability to 
attract both blood vessels and axons, stimulates angiogenesis in vivo and augments 
the response to vascular endothelial growth factor (Park et al., 2004). Netrin-4 acts as 
an antiangiogenic factor through binding to neogenin and recruitment o f Unc5B 
(Lejmi et al., 2008). However, neogenin is also a receptor for repulsive guidance 
molecule. Although evidence is yet forthcoming, RGMs may have direct effects on 
tumour angiogenesis, and this effect may be the results o f the RGM-neogenin 
interaction and the involvement o f BMPs in angiongenesis.
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1.4.3 The role of RGM in the BMP signalling pathway
1.4.3.1 The regulators of BMP signalling
In the extracelluar region, several secreted proteins have been described to bind 
and sequester BMPs and thus prevent their interaction with BMP receptors: Noggin, 
twisted gastrulation, Chordin family (Cordin and Criml), Follistatin, DAN family 
(Gremlin, Cerberus, dan, U sagl, Sclerostin, Coco, PRDC), Tsg, and CCN family 
(Balemans and Van Hul, 2002; Canalis et al., 2003; Ebara and Nakayama, 2002; 
Gazzerro and Canalis, 2006; Reddi, 2001). Many of the antagonists themselves are 
target genes o f BMP signalling, thus appropriate coordination of extracellular BMP is 
ensured by the feedback loop.
Inside the cell, a number o f molecules are able to finely alter BMP signals. 
Firstly, R-Smad/Co-Smad transcriptional co-activators and co-repressors (as Smurfl 
and Inhibitory SMADs) can regulate transcription by inducing acetylation and de- 
acetylation of histones respectively. I-Smads are also BMP target genes, as with 
extracellular antagonists, creating another feedback mechanism for BMP signals. 
Some Smad-partner proteins (as Shn2) can bind directly or indirectly to Smads, and 
they can be either ubiquitous or cell specific, ensuring cell-dependent transcriptional 
responses. The BMP signalling pathway is also modulated by cross-talk between the 
canonical Smad signalling pathway and other pathways such as the Mitogen 
Activated Protein Kinase (MAPK), PI3K/Akt, Notch, and STAT pathways, which 
have either synergistic or antagonistic effects, depend on their cellular context.
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CRIM1 (cysteine rich transmembrane BMP regulator 1 (chordin-like)), 
BAMBI (BMP and activin membrane-bound inhibitor) and RGMs are described as 
some of the membrane modulation mechanisms of BMP signalling. The antagonist­
like function of the transmembrane protein CRIM 1 prevents the actions o f BMP7 and 
BMP4 in the Golgi compartment by affecting ligand processing (Wilkinson et al., 
2003). BAMBI is a pseudoreceptor which interacts with type I receptors and 
interferes with the proper formation o f the hetero-tetrameric receptor complex, thus 
inhibiting the signal transduction to R-Smads (Onichtchouk et al., 1999). On the 
other hand, RGMs act as co-receptors to facilitate and enhance BMP signalling 
transduction.
1.4.3.2 The involvement of RGMs in BMP signalling
In 2005, DRAGON was the first member o f the RGM family to be identified as 
a BMP co-receptor (Samad et al., 2005). Transfection of DRAGON cDNA into cells 
enhances transcription o f a BMP-responsive luciferase reporter (BRE-Luc), but not a 
TGF-p responsive luciferase reporter (CAGA-Luc). DRAGON sensitizes cells to 
respond more robustly to low levels o f BMP2 ligand (Samad et al., 2004; Xia et al., 
2005). DRAGON expression by siRNA inhibits BMP2 signalling as measured by 
both BRE-Luc and alkaline phosphatase activity assays in C2C12 murine myoblast 
cells (Halbrooks et al., 2007). The enhancement of BMP signalling by the 
transfection of DRAGON cDNA could be blocked by administration o f Noggin, 
which sequestered the endogenously expressed BMP ligands (Samad et al., 2005).
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However, RGMB can also be described as an inhibitor of BMP signalling in C2C12 
myoblasts and this inhibition was dependent on the secretary form o f the von 
Willbrand factor type D domain (Kanomata et al., 2009b). In C2C12 cells, only 
DRAGON suppressed ALP and Idl promoter activities induced by BMP4 or by 
constitutively activated BMP type I receptors, or even by constitutively activated 
Smadl. DRAGON.Fc (purified soluble RGMB fused to the Fc portion of human 
IgG l) significantly inhibited BMP2 or BMP4 but was less effective in inhibiting 
BMP5, BMP6 or BMP7 and did not inhibit BMP9 (Andriopoulos et al., 2009). It 
suggests that the soluble DRAGON.Fc inhibits BMP signalling, presumably by 
binding to BMP ligands and preventing their access to cell surface type I and type II 
receptors in the same way as those BMP antagonists, while cell surface GPI-anchored 
RGMB enhances BMP signalling.
RGMB directly interacts and forms a complex with BMP type I (ALK-2, ALK- 
3, and ALK-6) and type II receptors (ACTRIIA, BMPRII, and ACTRIIB), and 
enhances signal transduction through the canonical intracellular SMAD1/5/8 pathway 
in transfected HEK293 cells (Samad et al., 2005).
A role for RGMA in the BMP signalling pathway was investigated after the 
homologous DRAGON/RGMB was shown to function as a BMP co-receptor in vitro 
(Samad et al., 2005). Transfection o f RGMA cDNA into BMP-responsive cells 
enhances signalling by endogenous BMP ligands in vitro as measured by BMP- 
responsive promoter luciferase reporter assays (Babitt et al., 2005). TGF-|3 signalling 
was unaffected by RGMA (Xia et al., 2007). However, compared to RGMA and C,
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RGMB seems to have the least significant effect on the involvement o f BMP 
signalling (Halbrooks et al., 2007). In a cell-free system, purified human RGMA.Fc 
(the extracellular domain o f RGMA fused to the Fc portion of human IgG) binds 
directly to 125I-BMP-2 and 125I-BMP-4 with a K& o f 2.4 and 1.4 nM respectively, and 
this binding is not competed by excess cold BMP7 or TGF-(31. The regulation of 
RGMA on BMP signalling is via an interaction with type I receptors (ALK-3 and 
ALK-6) and type II receptors (ACTRIIA and BMPRII) thereby activating the 
canonical intracellular SMAD1/5/8 cascade, which can be inhibited by the silence of 
ALK-3, ALK-6, ACTRIIA or BMPRII or Smadl(Babitt et a l , 2005; Xia et a l ,  2007). 
The interaction is in the manner that RGMA.Fc forms a complex with ALK-6 in the 
absence or presence o f BMP2 in solution.
The underlying cause o f iron overload in juvenile hemochromatosis due to HJV  
mutations is hepcidin deficiency and that HJV acts upstream of hepcidin, positively 
modulating its levels (Huang et al., 2005; Niederkofler et al., 2005; Papanikolaou et 
al., 2004). This is due to the fact that BMP signalling can positively regulate hepcidin 
transcription in vitro, while HJV/RGMC acts as a BMP co-receptor and enhancer 
(Babitt et al., 2006). As with other RGM family members, transfection of HJV was 
demonstrated to enhance BMP in hepatoma-derived cells, but not TGF-|3 signalling 
as measured by BRE-Luc and CAGA-Luc assays (Babitt et al., 2006; Halbrooks et 
al., 2007; Xia et al., 2008). Furthermore, siRNA-mediated inhibition o f endogenous 
HJV inhibits BMP2 signalling as measured by both BRE-Luc and alkaline 
phosphatase activity assays in C2C12 murine myoblast cells (Halbrooks et al., 2007).
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RGMC ligand can dependently bind to BMP2, BMP4, and BMP6 in hepatoma- 
derived cells in vitro, but not BMP7 and TGF-pl (Andriopoulos et al., 2009; Babitt 
et al., 2006; Xia et al., 2008).
The binding affinity o f HJV.Fc for BMP2 was found to be similar to RGMA.Fc 
and DRAGON.Fc by BIAcore assay (Yang et al., 2008). However, HJV seems have 
a different ligand selectivity compared to other RGM family members based on the 
bioinhibition properties of soluble HJV.Fc protein for inhibiting signalling by various 
BMP ligands in a reporter assay. DRAGON.Fc is a strong inhibitor o f BMP2 and 
BMP4, only weakly inhibits BMP5, BMP6, and BMP7, but does not inhibit BMP9 
(as discussed above); HJV.Fc is the most potent inhibitor o f BMP6 ligands, has a 
relatively weak inhibition on signalling by BMP2, BMP4, and BMP5, and little or no 
inhibition on BMP7 or BMP9 signalling (Andriopoulos et al., 2009; Babitt et al., 
2007).
Different from other RGMs, RGMC can be cleaved from the plasma membrane 
by matriptase-2 which will weaken the BMP signalling and thereby suppress 
hepcidin expression levels to inhibit iron-deficient anaemia ((Finberg et al.; Finberg 
et al., 2010; Silvestri et al., 2008b). However, the cleavage has nothing to do with the 
soluble HJV, which is secreted by an intracellular mechanism (Silvestri et al., 2008b).
As other RGM family members do, HJV affects signalling via both types of 
BMP receptors and the Smad intracellular signalling pathway (Table 1.3). It can 
interact with ALK-2, ALK-3 and ALK-6 (Xia et al., 2008) and form a complex with 
ALK-6 in the presence o f BMP2 (Babitt et al., 2006). In hepatoma-derived cells,
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HJV was found to not only signal through BMPRII and ACTRIIA, but also alter the 
preference of BMP2 and BMP4 to signal via BMPRII alone or additionally via 
ACTRIIA (Xia et al., 2008). This might be a property shared by all RGM family 
members, however, RGMC might act more frequently through ACTRIIA as a BMP 
co-receptor, which is predominantly expressed in liver. RGMC has been shown to 
interact with neogenin as discussed above (Kuns-Hashimoto et al., 2008; Zhang et al., 
2005). Neogenin can regulate iron homeostasis via inhibiting secretion o f  HJV, to 
enhance BMP signalling and hepcidin expression (Lee et al., 2010).
Table 1.3 RGMs and their interacting molecules
RGM s Receptor BM Ps BM P receptor
Dow nstream
molecule
RGMA Neogenin BMP2/4
ALK-3, ALK-6 
ACTRIIA,BMPRII
Smad 1/5/8
RGMB Neogenin ? BMP2/4
ALK-2, ALK-3, 
ALK-6, ACTRIIA, 
BMPRII, ACTRIIB
Smad 1/5/8
RGMC Neogenin BMP2/4/6
ALK-2, ALK-3, 
ALK-6 BMPRII, 
ACTRIIA
Smad 1/5/8
This table shows receptor for RGMs and their interaction with BMP signalling. (Xia et al., 2008)
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However, to date, the exact mechanism of how RGM enhances the BMP 
signalling and the structure o f RGM-BMPRs-BMP remains unknown, and its 
implication in cancer through this pathway needs to be revealed. It is highly probable 
that two combined distinct RGM co-receptors (complex) are required for more 
efficient signalling than one individually. To enhance the recruitment of BMP ligands 
to BMP receptors complex, RGMA and RGMC form the most potent co-receptor pair, 
but it is unclear whether they exist as a heterodimer or two distinct proteins 
(Halbrooks et al., 2007).
1.5 Hypothesis and aim of this study
RGMs play a profound role in axonal guidance, neuronal development and iron 
metabolism. However their implication in cancer remains unknown.
As mentioned above, The BMPs and their signalling pathways are crucial to 
bone metastasis o f cancer as BMPs played an important part in bone development by 
their effects on osteoblast differentiation and bone matrix production. BMPs have 
distint and diverse effects on tumour cells depending on the cancer type. In some 
circumstances, BMPs played a contrast role in same cancer type during different 
studies.
Given the diverse role o f BMPs played in cancer, the effects o f RGMs on 
cancer are somewhat mysterious. However, the RGMs might at least enhance the 
effects of BMPs on cancer. As the BMP-Smad dependent pathway has an effect on 
the regulation o f osteoblast differentiation where RGMs also participate, the RGM 
family might also have effects on bony metastasis. RGMs may have their own
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regulation on cancer through BMP signalling pathway. However, whether RGMs are 
involved in the development and progression o f cancer remains unknown.
Secondly, if the RGMs do have correlation with cancer progression, how they 
participate in the regulation o f cancer cells' behaviours and what’s the mechanism 
underlying it need to be revealed. Furthermore, it will be interesting to know if there 
is any difference or common place for the three RGM members in the regulation o f 
caner cells.
Thirdly, as a co-receptor o f BMPs, how RGMs participate in BMP signalling 
pathway and utilise these pathways to execute their regulation on tumour cells and 
the mechanisms responsible for this need to be revealed further. Notably, different 
RGMs might have diverse effects on cancer, due to the distinct role of each molecule 
involved in this pathway.
Together, the expression pattern o f RGMs in cancer, the regulation on tumour 
cells behaviour, the target genes responsible for these regulations, the mediation on 
the target genes through BMP signalling pathway and the potential therapeutic value 
associated with the clinical prognosis could form a network and provide us a glimpse 
on RGMs function in cancer.
Based on the questions above, the study had the following aims:
1. To determine the expression profile o f RGMs in diverse cancer cell lines and 
and tissues and to deduce a possible clinical and prognostic value for the 
RGMs;
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2. To investigate the role of RGMs in prostate cancer and breast cancer cells.
3. To investigate the mechanisms responsible for RGMs regulation in prostate 
cancer and breast cancer cell. This choice o f tumour types was based on the 
clinical observations that breast and prostate cancer are the two leading solid 
tumours that develop bone metastasis.
4. To reveal the involvement o f RGMs in BMP signalling which is associated 
with the regulation on target genes that might be the mechanism o f tumour 
cellular behaviour changes.
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Chapter 2 
Materials and methods
2.1 General Materials
2.1.1 Animals, cell lines and tissues
Cell lines used are listed below:
Breast cancer (MDA MB 157, MDA MB 231, MDA MB 436, MDA MB 453, 
BT474, BT482, BT549, ZR751, MCF 7)
Breast fibrocytic disease (MCF 10A)
Fibroblast (MRC5)
Liver (PLC-PRF-5)
Prostate cancer (DU145, PC-3, CA HPV 10, LNCAP)
Prostate epithelial (PNT1A, PZ-HPV-7)
Bladder cancer (EJ138, RT112)
Colorectal cancer (HRT18, HT115,)
Pancreatic cancer (Mia PaCa, PANC1)
Lung (SKMES1, A549, CorL677, CorL88, CorL23, CorL47)
Cervical cancer (Hela)
The cervical squamous cell carcinoma (A431)
Melanoma (G361)
Monocytic myeloma (U937)
Leukaemic cell (WBC, HL60)
Endothelial ( HUVEC, HECV)
Mink Kidney Epithelial cell (MDCK)
Keratinocyte (HaCaT)
Leukocyte (PMN)
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All the cell lines, except those primary culture cells, were purchased from the 
European Collection of Animal Cell Cultures (ECACC, Salisbury, England).
The following tissues are used:
Human placenta, ovary, prostate, normal mammary tissues, breast cancer 
tissues, skin, omentum, colon, normal mucosa colon (NM), bone, liver, and 
mesentery tissues (MS) were all collected in the department over the past years and 
stored in deep freezer (-80 °Q, under ethic approval.
A human breast tumour cohort with a 10 year follow-up was collected in the 
department and was used in the investigation o f the the clinical and prognostic link. 
The presence of tumour cells in the collected tissues was verified by a consultant 
pathologist, Dr Anthony Douglas-Jones o f Department of Pathology of Cardiff 
University School o f Medicicne using H&E staining of frozen sections. All protocols 
were reviewed and approved by the local ethical committee and all patients gave 
written informed consent.
2.1.2 Primers
All the primers used in this study were designed using the Beacon Design 
programme (Palo Alto, California, USA) and synthesised by Invitrogen (Paisley, UK). 
The forward and reverse primers used for conventional RT-PCR and Real time 
Quantitative PCR (Q-PCR) are listed in Table 2.1.2. Table 2.1.2 also shows the 
primers used for ribozyme generation.
8 5
Table 2.1.2 Primers used in this study
Gene Primer name Primer sequence (5’~ 3’) Annealing
temperature(
V )
RGMA RGMA FI 
RGMA Zrl
TCG AC A AT A ATT ACCT G A AC G
ACT GAACCT GACCGTACACCTG 
GAAGTTCTTGAAGATG
55
RGMA F9 
RGMA R9
AGAACTTCCAGGAGTGTGTG 
G AGT GG AGC AT CTTGACATC
55
RGMB RGMB F8 
RGMB R8
GGATCCAGTGCTACTGCTAC 
GT AA AGTT GGC AT C ACC AGT
55
RGMB F 
RGMB Zr
TT CAGGTT CAAGTGACAAACG
ACTGAACCTGACCGTACATCAT
CTGTCACAGCTTGGTA
55
RGMC RGMC F 
RGMC Zr
A AT G ACTT CCT CTTT GT CCA
ACT GAACCTGACCGTACACATT 
CCT GC AT GTT CTT AAA
55
RGMC F9 
RGMC R9
GGACCCTTGTGACTATGAAG 
GTCTGGC AGT AT C A AT GGTT
55
GAPDH GAPDH F8 
GAPDH R8
GGCTGCTTTTAACTCTGGTA 
GACT GT GGT CAT GAGTCCTT
55
GAPDH F 
GAPDH Zr
AAGGTCATCCATGACAACTT
ACTGAACCTGACCGTACAGCCA 
TCCAC AGT CTT CT G
55
Snail SNAF
SNAR
ACT AT GCCGCGCT CTTT CC 
TCAGCGGGGACATCCTGAGC
55
RhoC RhoC F8 
RhoC Zr
GAGAAGTGGACCCCAGAG 
ACT GAACCT GACCGTACACTT C 
ATCTTGGCCACGCTC
55
Slug Slug ZF 
Slug Zr
CTCCAAAAAGCCAAACTACA
ACTGAACCTGACCGTACAGAG
GATCTCTGGTTGTGGTA
55
86
Twist Twist ZF 
Twist ZR
AAGCTGAGCAAGATTCAGAC
ACTGAACCTGACCGTACAGAG 
GACCTGGT AGACCGAAGT
55
Neogenin N eoF l 
Neo Zrl
ATCCATGTCCCTTTCAGAC 
ACTGAACCTGACCGTACAAG 
CAT GTTTT GAGACG AAG AG
55
Neo F8 
Neo R8
C A AAA AT GGGG AT ATGGTT A 
TTGTGTTTCTACTCGCAGTG
55
FAK FAK FI 
FAK Zr
AACAGGTGAAGAGCGATT AT
ACT GAACCT GACCGTACACAGT 
ATGATCCC
55
Paxillin Paxil FI 
Paxil Zr
CAATCCTTGACCCCTTAGA
ACTGAACCTGACCGTACATTGG 
AGACACTGGAAGTTTT
55
Cytokeratin
-19
CK19F  
CK19 Zr
C AGGTCCG AGGTT ACT G AC
ACTGAACCTGACCGTACACACT 
TT CT GCC AGT GT GTCTTC
ID-1 ID-1 FI 
ID-1 Zrl
TCAACGGCGAGATCAG
ACT GAACCT GACCGT ACAGATC 
GTCCGCAGGAA
c-Myc Myc FI 
Myc Zrl
TGCTCCATGAGGAGACAC
ACT GAACCT GACCGTACAT GAT 
CCAGACTCTGACCTTT
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Gene
RGMA
RGMB
RGMC
Primer name
RGMA rib3F
RGMA rib3R 
RGMB rib IF 
RGMB riblR  
RGMC rib3F
RGMC rib3R
T7F
BGHR
RbBMR
Primer sequence (5’ ~ 3’)
CTGCAGGCGCACCACGATGGTG 
GTGCCCTGATGAGTCCGTGAGGA 
ACT AGTGGAGATCCAGGCCAA 
GTACATTTCGTCCTCACGGACT 
CTGCAGGTCATCTGTCACAGC 
TT GGT ACTGAT GAGT CCGT GAGGA 
ACTAGTGTACAGATCAGAAA 
GTTTCGTCCTCACGGACT 
CTGCAGATCCCCCAGGTCGGT 
C ACCTCC ATT CT GAT G AGTCCGT GAGGA 
ACTAGTCCTGTAGCCTTTGAAG 
ATGGTTCTATTTCGTCCTCACGGACT 
T AAT ACG ACT C ACT AT AGGG 
TAGAAGGCAGTCGAGG 
TTCGTCCTCACGGACTCATCAG
88
2.1.3 Antibodies
2.1.3.1 Primary antibodies
The primary antibodies used are fully detailed in the table 2.1.3.1.
Table 2.1.3.1 Antibodies used in study
Antibody name Source Molecular weight (kDa) Supplier Product code
Anti-RGMA Goat 33 SANTA CRUZ BIOTECHNOLOGY, INC. Sc-46482
Anti-RGMB Goat 47.5 SANTA CRUZ BIOTECHNOLOGY, INC. Sc-46487
Anti-RGMC Goat 45 SANTA CRUZ BIOTECHNOLOGY, INC. Sc-46491
Anti-FAK Mouse 125 BD Biosciences BD 610088
Anti-Paxillin Mouse 68 BD Biosciences BD 610051
Anti-Caspase3 Rabbit 32/11/17/20 SANTA CRUZ BIOTECHNOLOGY, INC. Sc-7148
Anti-C-Myc Mouse 67 SANTA CRUZ BIOTECHNOLOGY, INC. Sc-70465
Anti-GAPDH Mouse 37 SANTA CRUZ BIOTECHNOLOGY, INC. Sc-47724
TAK1 Rabbit 70 SANTA CRUZ BIOTECHNOLOGY, INC. Sc-7162
P38 Mouse 38 SANTA CRUZ BIOTECHNOLOGY, INC. 7972
JNK1 Rabbit 46 SANTA CRUZ BIOTECHNOLOGY, INC. 571
ERK1/2 Rabbit 41/42 SANTA CRUZ BIOTECHNOLOGY, INC. 93
XIAP(ILP) Rabbit 47 SANTA CRUZ BIOTECHNOLOGY, INC. 11426
Pho-Smad-1 Goat 52/56 SANTA CRUZ BIOTECHNOLOGY, INC. 12353
Pho-Smad-3 Rabbit 48 SANTA CRUZ BIOTECHNOLOGY, INC. 130218
BMPRIA Mouse 66 SANTA CRUZ BIOTECHNOLOGY, INC. 134285
BMPRIB Goat 50 SANTA CRUZ BIOTECHNOLOGY, INC. 5679
BMPRII Goat 115.2 SANTA CRUZ BIOTECHNOLOGY, INC. 5683
Pho-
Serine/threonine Rabbit -------
Abeam pic. ab17464
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2.1.3.2 Secondary antibodies
The secondary antibodies used for western blotting, immunohistochemistry and 
immunocytochemistrywere horseradish peroxidise (HRP) conjugated which are 
shown in table 2.1.3.2
Table 2.1.3.2 Secondary antibodies used in this study
Antibody name Source
Molecular weight 
(kDa) Supplier
Product code
Anti-rabbit (whole 
molecule) IgG peroxidise 
conjugate
Goat
polyclonal
antibody
Dependent on 
primary Sigma-Aldrich A-9169
Anti-goat (whole 
molecule) IgG peroxidise 
conjugate
Rabbit
polyclonal
antibody
Dependent on 
primary Sigma-Aldrich A-5420
Anti-mouse (whole 
molecule) IgG peroxidise 
conjugate
Rabbit
polyclonal
antibody
Dependent on 
primary Sigma-Aldrich A-9044
2.1.3.3 Inhibitors, activators and proteins
Inhibitors and recombinant proteins used in this study are listed in table 2.1.3.3
Table 2.1.3.3 Inhibitors and recombinant proteins
Product Concentration used Supplier Catalogue number
Specific Inhibitor o f  
Smad3 (SIS3) 3pmol/ml Merck Chemicals Ltd. 566405
Recombinant human 
protein BMP7 (rh- 
BMP7)
40ng/ml R&D Systems 354-BP
SIS3: A cell-permeable pyrrolopyridine compound that selectively inhibits TGF-PI-dependent Smad3 
phosphorylation and Smad3-mediated cellular signaling with no effect on Smad2, p38 MAPK, ERK, 
or PI 3-K signalling.
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2.1.4 General reagents and solutions 
Antibiotics
Penicillin (120mg/ml)
Six hundred milligrams o f Crystapen Injection Benzylpenicillin sodium (Britannia 
Pharmaceuticals limited, Surrey, UK) was dissolved into 5ml Sterile Injection water 
(B.Braun, Germany).
Streptomycin Sulphate (250mg/ml)
Five grams of Streptomycin Sulphate was dissolved into 20ml sterile injection water, 
filtered through 0.2pm Minisart filter and store at -20°C until required.
Solutions for cell maintenance and detachment
0.05MEDTA
Distilled water was used to dissolve lg  KCL (Fisons Scientific Equipment, 
Loughborough, UK), 5.72g Na2H P 04, lg  KH2P 0 4, 40g NaCl and 1.4g EDTA 
(Duchefa Biochemie, Haarlem, The Netherlands) to make a final volume o f 5L. The 
PH was adjusted to 7.4 and the solution autoclaved and prior to use.
Trypsin (25mg/ml)
Five hundred milligrams of Trypsin was dissolved into 20ml 0.05M EDTA, mixed 
and filtered through a 0.2pm Minisart filter (Sartorius, Epsom, UK), aliquoted to
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250pl samples and stored at -20°C for until required. For use in cell culture one 
250pl aliquot was diluted in a further 10ml o f 0.05M EDTA solution and used for 
cell detachment.
Tissue culture medium for general use:
DMEM / Ham’s F12 with L-Glutamine medium purchased from PAA Laboratories, 
Somerset, UK.
Serum:
Heat inactivated foetal calf serum was also purchased from PAA Laboratories, 
Somerset, UK.
Other solutions for Cell culture:
Balanced salt solution (BSS)
NaCl 79.5g, KC1 2.2g, KH2P0 4 2 .1g, and Na2HP0 4 l . lg  was dissolve in distilled 
water to make a final volume o f 10L. Adjust pH to 7.2.
Solutions for RT
DEPC water
Diethyl pyroncarbonate (DEPC) was added 250pl to 4750pl distilled water. 
Autoclaved before use.
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Solutions for DNA detection
5X Tris, Boric acid, EDTA (TBE)
Distilled water were used to dissolve 540g of Tris-Cl (Melford Laboratories Ltd., 
Suffolk, UK), 275g Boric acid (Duchefa Biochemie, Haarlem, The Netherlands) and 
46.5g of disodium EDTA and make up to a final volume of 10L. Stored at room 
temperature and diluted to IX concentrate prior to use in agarose gel electrophoresis.
Ethidum bromide
Ten milliliter distilled water was used to dissolve O.lg o f Ethidium Bromide powder. 
Container was wrapped in aluminium foil to protect solution from sunlight and stored 
safely before use.
Solutions for protein extraction
Lysis Buffer
Two millimoles CaCL, 0.5% Triton X-100, 1 mg/ml Leupeptin, 1 mg/ml Aprotinin 
and 10 mM sodium orthovanadate were dissolved into distilled water, stored at 4°C 
until required.
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Solutions for western blot
10% Ammonium Persulfate (APS)
One gram of ammonium persulfate were dissolve in 10ml of distilled water, 
separated into 2.5ml aliqoutes and stored at 4°C until required.
10X Running buffer
Tris 303g, 1.44Kg Glycine and lOOg SDS were dissolve into distilled water to a final 
volume of 10L. The 10X stock solution was diluted to IX strength in distilled water 
before use.
Transfer buffer
Tris 15.15g, 72g Glycine (Fisher Scientific, Leicestershire, UK) were dissolved in 
distilled water before adding and 1L Methanol. This was made up to a 5L final 
volume.
1 OX TBS
Tris 121.1 g and 400.3g NaCl were dissolve in distilled water, made up to a final 
volume of 5L and adjust pH to 7.4.
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Ponceau S stain
Supplied directly by Sigma.
Amido black stain
Amido black (Edward Gurr Ltd., London, UK) 2.5g were dissolved in 50ml Acetic 
acid (Fisher Scientific, Leicestershire, UK) and 125ml Ethanol (Fisher Scientific, 
Leicestershire, UK), added 325ml distilled water and mixed well.
Amido black destain
Acetic acid 100ml were mixed with 250ml Ethanol and 650ml distilled water. 
Coomasie blue stain
One gram of Coomassie blue was dissolved in 400ml of Methanol and 100ml of 
Acetic acid, made up to a final volume o f 1L using distilled water.
Coomasie blue destain
Five hundred millilitres o f Methanol were mixed with 100ml o f Acetic acid, made up 
to a final volume of 1L.
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Solutions for cell and tissue staining
Wash buffer: 20X Optimax wash buffer (Biogenex, California, USA) was diluted 
1:20 to form a working solution.
DAB chromagen
The DAB chromagen was prepared by mixing the following reagents in order, 2 
drops of wash buffer, 4 drops DAB (Vector Laboratories Inc., Burlingame, USA) and 
2 drops o f H2O2 to 5ml of distilled water. The mixture was shaken well after the 
addition o f each reagent.
ABC Complex
The ABC complex was prepared using a kit obtained from Vector Laboratories Inc., 
Burlingame, USA. 4 drops o f reagent A were added to 20ml of wash buffer, followed 
by the addition of 4 drops o f reagent B and thorough mixing. The ABC complex was 
then left to stand for approximately 30 minutes before use.
Solutions for cloning work
LB agar
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Ten grams of tryptone, 5g yeast extract, lOg NaCl and 15g agar were dissolved in 
distilled water to a final volume of 1L and adjusted to pH 7.0. Autoclaved and cooled 
slightly before adding selective antibiotic (if required) and pouring into 10cm petri 
dish plates (Bibby Sterilin Ltd., Staffs, UK) and allowing to cool and harden, inverted 
and stored at -4°C.
LB broth
Ten grams of tryptone (Duchefa Biochemie, Haarlem, The Netherlands), 5g yeast 
extract (Duchefa Biochemie, Haarlem, The Netherlands) and lOg NaCl were dissolve 
in distilled water to a final volume o f 1L and adjust to pH 7.0. The medium was 
autoclave and allowed to cool before adding selective antibiotic (if required), stored 
at room temperature.
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2.2 Cell Culture and storage
2.2.1 Preparation of growth medium and maintenance of cells
Cells were routinely maintained in DMEM / Ham’s F12 medium base 
supplemented with streptomycin, penicillin and 10% (v/v) foetal calf serum. 
Transfected cell lines, containing the pEF6 plasmid, were cultured initially in 
selection medium containing 5pg/ml blasticidin S and then later were routinely 
cultured in a maintenance medium containing 0.5pg/ml blasticidin S.
Cells were maintained and grown in either 25cm2 or 75cm2 tissue culture flasks 
(Greiner Bio-One Ltd, Gloucestershire, UK) in an incubator at 37.0°C, 5% CO2 and 
95% humidity. All tissue culture techniques were carried out following aseptic 
techniques inside o f a class II laminar flow cabinet. Cells were routinely sub cultured 
when reaching 80 -  90% confluency as described below.
2.2.2 Trypsinisation and counting of cells
When cells reached approximately 80 -  90% confluency, medium was removed 
and the cells rinsed briefly with EDTA. Following this, adherent cells were detached 
from the tissue culture flask by incubating with trypsin/EDTA for several minutes. 
Once detached the cell suspension was placed in 20ml universal container (Greiner 
Bio-One Ltd, Gloucestershire, UK) and a cell pellet was collected by centrifuging at 
1600 RCF for 5 minutes. The cell pellet was resuspended in an appropriate volume
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of fresh medium before either determining cell numbers per millilitre (for use in 
cellular assays) or transferring a small volume of cell suspension into new tissue 
culture flask.
A haemocytometer counting chamber allows the number o f cells in a 
previously determined volume of suspension fluid to be calculated. Cells were 
counted on a Neubauer haemocytometer counting chamber using an inverted 
microscope (Reichet, Austria) under 10 x magnification. The dimensions o f each 16 
square area, containing cells to be counted, is 1mm x 1mm x 0.2mm which allowed 
the number o f cells per milliliter to be determined using the following equation:
Cell number / ml = (number o f cells counted in 16 squares -*■ 2) x (1 x 104)
This allowed the number of cells per millilitre to be determined and accurate numbers 
o f cells to be seeded in the in vitro and in vivo cellular functional assays.
2.2.3 Storage of cell lines in liquid nitrogen
Low passage cells were first trypsinised from a large 75cm2 flask using 
EDTA/Trypsin and pelleted by centrifuge. These cells were then resuspended in the 
required volume (dependent on the number o f samples to be frozen) o f a protective 
medium consisting o f 10% dimethyl sulphoxide (DMSO) in normal growth medium. 
Following resuspension, cells were alliquoted into pre-labeled 1.8ml cryotubes (Nunc,
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Fisher Scientific, Leicestershire, UK) in 1 ml volumes and stored overnight at -81°C 
in a deep freezer. Cells were later transferred to liquid nitrogen tanks for long term 
storage.
2.2.4 Resuscitation of cell lines
Cells were placed in a water bath at 37°C immediately after their removal from 
liquid nitrogen. The outside o f the cryotube was cleaned thoroughly with a sterile 
swab and placed in a universal container containing 10ml of pre-warmed medium to 
immediately dilute the DMSO present. The universal containers were then 
centrifuged at 1600 RCF for 5 minutes to pellet the cells. The medium was then 
aspirated to remove any traces o f DMSO and the cell pellet was resuspended in 5m 1 
o f pre-warmed medium and placed into a fresh 25cm3 tissue culture flask and 
incubated for 4 - 5 hours. Following incubation, the flask was examined under the 
microscope to obtain an estimation o f the number of healthy adherent cells, the 
medium was then changed to remove any dead cells which did not survive the 
freezing/resuscitation process. The flask was then returned to the incubator and 
standard sub-culture techniques carried out when further necessary.
Cell viability was tested usinga Trypan blue exclusion test as necessary. 20ul of 
cell suspension was mixed with lOOul o f 1% Trypan Blue (lgram  of Trypan blue 
dissolved in 100ml o f BSS. Spin the solution before use). The percentage o f non- 
viable cells (blue under the microscope) was calculated.
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2.3 Methods for Detection of mRNA
2.3.1 Total RNA isolation
Total RNA was extracted using ABgene Total RNA Isolation Reagent (TRIR) 
Kit and protocol (ABgene, Surrey, UK). Desired cells were previously cultured in 
25cm2 flasks until 85-90% confluent, the medium was then removed and 1ml of 
TRIR was added to the cell monolayer. A plastic cell scraper was used to completely 
detach the cells and collect the lysate. The cell lysate was then passed through a 
transfer pipette several times before being transferred into a 1.8ml eppendorf. The 
mixture was kept at 4°C for 5 minutes before adding 0.2ml chloroform and 
vigorously shaking the samples for 15 seconds. Samples were then centrifuged in a 
refrigerated centrifuge (Boeco, W olf laboratories, York, UK) at 4°C and 12,000g for 
15 minutes. The upper aqueous phase, containing RNA, was carefully removed and 
added to a pre-labelled eppendorf containing an equal volume of isopropanol, the 
samples were then stored at 4°C for 10 minutes before centrifuging at 12,000g and 
4°C for 10 minutes. At this stage RNA will be precipitated out o f solution as a pellet 
in the bottom of the eppendorf. The RNA pellet was washed twice after the 
supernatant was discarded in 75% ethanol (prepared in a 3:1 ratio o f absolute ethanol: 
DEPC water). Each wash consisted o f the addition o f 1ml of 75% ethanol, vortexing 
and subsequent centrifugation at 4°C and 7,500g for 5 minutes. Ethanol was removed 
from the eppendorf after the final wash. The pellet was placed in a Techne, 
Hybridiser HB-1D drying oven (W olf laboratories, York, UK) at 50°C to briefly dry 
and remove any remaining ethanol. Finally, the pellet was dissolved in 50 -  lOOpl 
(depending on pellet size) o f DEPC water before proceeding to quantify the RNA
present in the sample. DEPC is a histidine specific alkylating agent and inhibits the 
action of RNases which rely on histidine active sites for their activity. DEPC water 
was used in RNA isolation to reduce the effects of any RNases that may be present.
2.3.2 Reverse transcription (RT)
After isolation, UV1101 Biotech Photometer (WPA, Cambridge, UK) was used 
to detect ssRNA (pg/pl) and to quantify RNA in a 1 in 10 dilution, based on the 
difference in absorbance at 260nm wavelength compared to a DEPC blank. All 
samples were measured in a Stama glass curvette (Optiglass limited, Essex, UK).
Following RNA isolation and quantification, 0.5|ng of RNA was converted into 
complementary DNA (cDNA) using an iScript cDNA Synthesis Kit (Bio-Rad 
laboratories Inc, UK), following their one-Step RT-PCR protocol.
For each reaction, a sufficient volume of RNA (0.5pg) suspended in DEPC water 
(isolated previously) was added to nuclease-free water to make up a total volume of 
15pl in a thin-walled 200|Ltl PCR tube. The following were then added into each tube 
(per reaction):
• 5X iscript reaction mix 4 pi
• iScript reverse transcriptase 1 pi
After mixing gently and centrifuging, the samples were placed in a T-Cy 
Thermocycler (Creacon Technologies Ltd, The Netherlands) and underwent the 
following procedures:
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• 5 minutes at 25°C
• 30 minutes at 42 °C
• 5 minutes at 85 °C
• Hold samples at 4 °C
Samples were stored at -20°C after being diluted 1:3 with PCR water, ready for 
further use. The cDNA generated was tested using conventional PCR probing for p- 
actin expression to confirm successful reverse transcription.
2.3.3 Polymerase chain reaction (PCR)
PCR was carried out using a REDTaq ReadyMix PCR Reaction mix (Sigma, 
Dorset, UK). Primers were designed using the Beacon Designer programme (Palo 
Alto, California, USA) and were synthesised by Invitrogen (Paisley, UK), based on 
the full sequence o f the gene o f interest. Primers were diluted to a concentration of 
lOpM before use in the PCR reaction. Twenty microlitre reactions were set up for 
each sample to be tested as follows:
• 2X REDTaq ReadyMix PCR Reaction mix lOpl
• Specific Forward primer (lOpM) lpl
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• Specific Reverse primer (1 OpM) lpl
• PCR water 6pl
• cDNA 2pl
When the above reaction had been set up in a 200pl PCR tube (ABgene, Surrey, 
UK), they were mixed briefly and centrifuged before being placed in a T-Cy 
Thermocycler (Creacon Technologies Ltd, The Netherlands) and subjected to the 
following temperature shifts:
• Stage 1: Initial denaturing period -  94°C for 5 minutes
• Stage 2: Denaturing step -  94°C for 1 minute
Annealing step -  reaction specific temperature for 2 minutes 
Extension step -  72°C for 3 minutes
• Stage 3: Final extension period -  72°C for 10 minutes
Stage 2 was repeated over 38 cycles. Specific reaction annealing temperatures
together with primer sequence data is detailed in table of section 2.1.2.
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2.3.4 Agarose gel DNA electrophoresis
Once the DNA had been amplified through the sufficient number o f cycles in 
the thermocycler, the sample was separated according to size using agarose gel 
electrophoresis. Agarose gels were made by adding the required amount (0.8% or 2%) 
of agarose (Melford Chemicals, Suffolk, UK) to TBE solution. The mixture was 
heated to fully dissolve, poured into the electrophoresis cassette and allowed to set 
around a plastic comb creating loading wells. Once set, the gel was submerged in 
TBE running buffer, 8pl o f a 1Kb ladder (Invitrogen, Paisley, Scotland) or lOpl of 
sample was then added to the wells. The samples were loaded into either 0.8% 
(samples greater than approximately 500bp) or 2% (samples less than 500bp) agarose 
gels, dependent on the predicted size o f the DNA products. The samples were then 
separated electrophoretically at 95V for a period of time to allow sufficient 
separation of the samples.
2.3.5 Real time quantitative PCR
The real time quantitative PCR was carried out to determine the levels o f RGM 
transcripts in the breast cancer cohort and cell lines. The assay was based on the 
Amplifuor technology and primers were designed using Beacon Designer software 
which included complementary sequence to universal Z probe (Intergen Inc., Oxford, 
United Kingdom), as previously reported (Jiang et al., 2005a; Parr et al., 2004). 
Primers used for RGMs quantitation and housekeeping GAPDH are listed in section
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2.1.2. Each lOpl reaction contains 5 pi o f Hot-start Q-master mix (Abgene), 10 pmol 
of specific forward primer, 1 pmol reverse primer which has the Z sequence, 10 pmol 
of FAM-tagged universal Z probe (Intergen Inc., Oxford, United Kingdom), and 
50ng cDNA. The Q-PCR was carried out using IcyclerlQ™ (Bio-Rad, Hemel 
Hemstead, England, UK), which is equipped with an optic unit that allows real time 
detection of 96 reactions. The following condition was used in the reaction: 94°C for 
12 minutes, 60 cycles of 94°C for 15 seconds, 55°C for 40 seconds (the data capture 
step) and 72°C for 20 seconds. The levels o f the transcripts were generated from an 
internal standard that was simultaneously amplified with the samples. Cytokeratin-19 
(CK19) or GAPDH was used to normalise cellularity during the analysis o f the RGM 
expression related to clinical data. Data are shown in Chapter 3 as either the number 
o f transcripts (mean number o f RGM transcript per 50ng total RNA) or as RGM: 
CK19 ratio.
2.4 Methods for Detection of Proteins
2.4.1 Sodium dodecyl sulphate polyacrylamide gel electrophosis (SDS- 
PAGE) and western blot analysis
2.4.1.1 Cellular lysis and protein extraction
Upon reaching sufficient confluency, the medium was removed and changed 
into cold BSS buffer (leaving in ice). The cell monolayer was detached from the flask 
using a sterile cell scraper. Both the detached cells and buffer were then transferred to 
a universal container using a sterile transfer pipette. The cell suspension was then
1 0 6
centrifuged for 5 minutes at 1800 RCF to pellet cells and protein at the bottom of the 
universal container. Following centrifugation, the medium was aspirated off and the 
cells were lysed in 120 -  250pl (depending on pellet size) of lysis buffer before being 
transferred to a 1.8ml eppendorf (Alpha Laboratories, Hampshire, UK) and placed on 
a Labinco rotating wheel (W olf laboratories, York, UK) for 1 hour. The lysis 
solution was then spun at 13,000 rpm in a microcentrifuge for 15 minutes, and the 
supernatant was transfer to a fresh eppendorf to await for quantification.
2.4.1.2 Protein quantification
Protein concentration was quantified using Bio-Rad DC Protein Assay kit (Bio- 
Rad laboratories, Hammelhempstead, UK) following the microplate method as 
described below. Firstly, a range o f standard samples of known concentrations were 
set up using a serial dilution o f a lOOmg/ml Bovine Serum Albumin (BSA) standard 
(Sigma, Dorset, UK), standards were serially diluted from lOOpg/ml to 0.05pg/ml in 
lysis buffer.
Five microlitre o f either the sample or standard was added to a fresh well with 
25 j l i 1 of ‘Reagent A+S’ and 200pl o f reagent B. ‘Reagent A+S’ was prepared by 
mixing each millilitre of reagent A with 20jnl o f reagent S and was used as samples 
contained detergent. Following addition o f all the reagents, samples were mixed 
briefly and then left for approximately 45 minutes to allow the colorimetric reaction 
to fully occur.
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Absorbance of samples and standards at 620nm was then read using an ELx800 
plate reading spectro photometer (Bio-Tek, W olf laboratories, York, UK). Sample 
final concentrations were determined by a standard curve based on the absorbances 
of the BSA standards. All samples were then diluted to the desired final 
concentration of between 1 -2m g/m l with appropriate amount of lysis buffer and 
further dilution in a 1:1 ratio with 2x Lamelli sample buffer concentrate. Samples 
were then boiled and stored at -20°C prior to use.
2.4.1.3 Sodium Dodecyl Sulphate PolyAcrilamide Gel Electrophoresis 
(SDS-PAGE)
OmniPAGE VS 10 vertical electrophoresis system (OminPAGE, W olf 
Laboratories, York, UK) were used in this procedure. Resolving gels were made up 
in a universal container and transferred to glass plates held in place in a loading 
cassette. The percentage of the gel is depending on the predicted size o f the protein 
of interest. Once the resolving gel had set, the stacking gel was prepared and added 
onto the top of the resolving gel. A plastic comb was placed in the unset stacking gel 
and the mixture was left to harden and form a gel.
The amount of each ingredient required to make up 15ml (enough for two gels) 
for 8%, 10% and 15% resolving gels is indicated below:
Table 2.4.1.3A Components for resolving gels
Component 8% gel 10% gel 15% gel
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Distilled water 6.9ml 5.9ml 3.4 ml
30% acrylamide mix 4.0ml 5.0ml 7.5 ml
1.5M Tris (pH 8.8) 3.8ml 3.8ml 3.8 ml
10% SDS 0.15ml 0.15ml 0.15ml
10% ammonia 0.15ml 0.15ml 0.15 ml
persulphate
0.009ml 0.006ml 0.006 ml
TEMED
The components and quantities required to prepare 5ml of stacking gel solution 
(enough for two gels) are shown below:
Table 2.4.1.3B Components for stacking gels
Com ponent Stacking gel
Distilled water 3.4ml
30% acrylamide mix 0.83ml
1.0M Tris (pH 6.8) 0.63ml
10% SDS 0.05ml
10% ammonia persulphate 0.05ml
TEMED 0.005ml
Once both resolving and stacking gels had set, the loading cassette was placed 
into an electrophoresis tank. The combs were then carefully removed after rinsed in 
IX running buffer. 8-10pl o f molecular weight marker or 18pl o f protein samples 
was added to the wells in order. The proteins were then separated according to
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molecular weight using electrophoresis at 125 V, 40mA and 50W for a vaiying length 
of time (dependent on protein size and gel percentage).
8% gels were used to detect proteins with a molecular weight ranging between 
50 -  lOOkDa and 10% gels were used when protein sizes were predicted to be 
between 20 -  80kDa.
2.4.1.4 Western blotting
Following PAGE of the protein samples, they were transferred to Hybond 
nitrocellulose membrane (Amersham Biosciences UK Ltd, Bucks, UK) using 
Western blotting. Gels were removed from the electrophoresis tank and unclipped 
from the loading cassette. The stacking gel was cut away and the resolving gel placed 
on top of a nitrocellulose membrane (face up) in a SD10 SemiDry Maxi System 
blotting unit (SemiDRY, W olf Laboratories, York, UK). The gel to membrane 
transfer sandwich was finished with 3X filter papers underneath and above 
respectively. The setting up for protein transfer was:
Negative Electrode -► 3X Filter Papers -► Membrane — Gel -*■ 3X Filter Papers -♦ 
Positive Electrode
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3mm chromatography paper (Whatman International Ltd., Maidstone, UK) was used 
as filter paper. Electro-blotting was undertaken at 15V, 500mA, 8W over a 40mins - 
1 hour period (depending on the molecular weight). Once complete membranes were 
removed and stored in 5% skimmed milk, 0.05% polyoxyethylene (20) sorbitan 
monolaurate (Tween 20) in TBS at 4°C until required for specific antibody probing.
Optional:
Membranes were placed in Ponceau S solution for several minutes to allow 
visualisation of protein bands on the membrane, the membrane was then cut into the 
required number o f sections before washing off the stain several times in the 10% 
milk solution used for blocking.
Membranes were transferred to 50ml falcon tubes (Nunc, Fisher Scientific, 
Leicestershire, UK), placed in a 1:250 specific primary antibody made up in 3% milk 
solution (3% milk powder, 0.1% Tween 20 in TBS) and rotated on a roller mixer 
(Stuart, W olf laboratories, York, UK) after blocking at room temperature 1 hour or 
4°C overnight (specific details on antibodies used are outlined in table 2.1.3.1). After 
the 1 hour incubation period, the primary antibody solution was removed and the 
membrane subjected to three 15 minute washes with 3% milk to ensure complete 
removal o f the primary antibody. Following these washes, the secondary antibody of 
the appropriate species tagged with HRP (horse raddish peroxidate) was added in 
fresh 3% milk solution to the membrane at a concentration o f 1:1000 and left for 1 
hour. The membrane was then subjected to two 10 minute washes with T-TBS (TBS 
containing 0.05% tween 20) followed by two 10 minute washes with TBS. After
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these washes chemiluminescent detection o f the antibody-antigen complex was 
undertaken using Supersignal West Dura system reagents (Pierce Biotechnology, 
Rockford, Illinois, USA) and UVITech imager (UVITech, Inc., Cambridge, UK). The 
membranes were subjected to a number o f exposure times and images captured. 
These images were then further analyzed using the UVIband software package 
(UVITEC, Cambridge, UK) which allows the protein bands detected on the screen to 
be quantified and also allow the standardisation of samples, when run in conjunction 
with housekeeping proteins such as GAPDH, the expression of which should be 
similar within the same cell types. Western blotting was repeated at least twice and 
bands from both repeats quantified and standardised separately. Quantification and 
standardisation was repeated three times and mean values calculated.
Membranes were also stained in Amido black stain following completion of 
antibody probing and kept as a record. Again membranes were placed into the Amido 
black solution for several minutes before being removed and placed in Amido Black 
destain solution to remove background staining. The membranes were then left 
overnight to dry completely and stored as a record.
2.4.2 Immunoprecipitation of phosphorylated proteins
Duplicate sets o f 3 X 106 cells were grown in large 75cm3 flasks overnight. 
Serum hunger was then induced by replacing the normal supplemented medium with 
5ml o f serum free medium and incubating the cells at 37°C for 2 hours. Each o f the
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duplicate flasks was then subjected to a separate treatment for 1 hour or maintained 
as control. The cells were collected and lysed in 300pl SDS-free lysis buffer followed 
by rotation on wheel for 1 hour. One hundred microliters o f this cell lysate solution 
was taken to run GAPDH and probe total protein. Two hundred microliters was left 
for immunoprecipitation.
50pl of phospho-S/T antibody was added (previously diluted 1:5 in SDS-free 
lysis buffer) to the standardised protein solution (lOOul) and the samples were placed 
on a rotating wheel for 1 hour. 50pl o f conjugated A/G protein agarose bead solution 
(20% Protein A agarose beads, 20% Protein G agarose beads, 60% SDS-free lysis 
buffer, Both A and G agarose beads were obtained from Santa cruz biotechnology 
Inc., California, USA) was then added and the samples returned to the rotating wheel 
for another hour. The samples were then centrifuged at 8,000rpm for 5 minutes and 
the supernatant discarded, the beads were then washed three times through the 
addition of 1ml o f SDS-free lysis buffer, centrifuged at 8,000rpm for 5 minutes and 
subsequently the supernatant was removed. IX sample buffer 50pl was then added to 
the samples before boiling for 5 minutes. The samples were then stored at -20°C prior 
to use in SDS-PAGE and as western blot mentioned above.
2.4.3 Immunohistochemical (IHC) and Immunocytochemical (ICC) 
staining
Frozen sectioning o f breast and prostate tissues was kindly undertaken by Mr Gareth 
Watkins who also contributed to the staining o f prostate sections. Frozen tissues were
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cut into 5 pm sections using a cryostat (Leica Microsystems (UK) Ltd., Bucks, UK) 
and were left at room temperature for 30 minutes to dry. Once dried the sections 
were fixed in a 1:1 mixture o f acetone and methanol for 20 minutes before staining or 
storing at -20°C until use.
For ICC, Cells were seeded at a density o f 20,000 cells per well in 200pl o f normal 
medium, in a 16 well chamber slide (Lab-Tek, Nagle Nunc Int., Illinois, USA). After 
cell seeding, the cells were incubated for 24 hours before fixing the cells in 4% 
formaldehyde in BSS for at least 20 minutes. The slides were ready to use or stored at 
-20°C for future use.
The tissue sections and cells were allowed to reach room temperature and rehydrate 
before staining was carried out. When reaching RT, the sections were then placed in 
Phosphate Buffered Saline (PBS) for 5 minutes and a reservoir was created around 
the individual sections (to contain the various staining solutions) using a Dako water 
proof marker pen; cells were rehydrated in BSS for 20 minutes before permeablising 
the cells in 0.1% triton X I00 for 5 minutes.
Non-specific binding was blocked through the addition of Optimax wash buffer 
containing horse serum (1 drop o f horse serum per 5ml o f wash buffer) to the 
samples for 20 minutes. The samples were then washed in wash buffer 3 times before 
the addition of the primary antibody at an appropriate concentration (made up in 
wash buffer containing serum and tested before use) for 1 hour at room temperature. 
Unbound primary antibody was then removed by washing the sections 3 times in 
wash buffer before adding a universal secondary antibody (Vectorstain ABC Kit,
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Vector Laboratories Inc., Burlingame, USA) for 30 minutes at room temperature (4 
drops o f universal secondary per 5ml wash buffer). Again unbound secondary 
antibody was removed by washing the sections in wash buffer 3 times. The sections 
were then incubated with the ABC complex for 30 minutes at room temperature, 
washed 3 times in wash buffer and incubated with the DAB chromogen for 5 minutes 
in the dark. The DAB was removed by placing the samples in running tap water for 2 
minutes before finally counterstaining the sections with Mayer’s Haemotoxylin for 1 
minute and placing the sections in running water for 5 minutes.
2.4.4 Immunofluorescent staining
Cells were seeded at a density o f 8,000 cells per well in 200pl o f normal 
medium, in a 16 well chamber slide (Lab-Tek, Nagle Nunc Int., Illinois, USA). After 
cell seeding, the cells were incubated for 24 hours and subjected to treatment before 
fixing the cells in ice-cold pure ethanol at -20°C for 20 minutes. Cells were then 
rehydrated in BSS for 20 minutes at room temperature before permeablising the cells 
in 0.1% triton X I00 (in a BSS buffer) for 5 minutes. Non-specific binding was then 
blocked for 20 minutes by placing MenaPath Autowash buffer (A. Menarini 
Diagnostics, Berkshire, UK) solution (diluted 1:20 in distilled water) containing 
horse serum (2 drops per 5 ml diluted wash buffer) over the cells. Following the 
blocking stage the cells were washed twice with diluted wash buffer solution. 
Specific staining was then undertaken through the addition of a specific primary 
antibody (made up in wash buffer containing serum) for 1 hour on an orbital shaker
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platform (Biddy Sterilin Ltd., Staffordshire, UK) (1:100). From this step, the 
chamber slide was either placed in a dark box or wrapped using a Aluminium foil in 
order to keep the slide in dark. The primary antibody was then removed and the cells 
washed three times in diluted wash buffer. The appropriate FITC conjugated 
secondary antibody was then added to the cells (1:150) and the slides were incubated 
on a rotating platform in the dark for 1 hour before removing the secondary and 
washing the cells three times with diluted wash buffer. After this protocol had been 
completed the well compartments were broken from the chamber slide, the cells were 
covered with Fluoro-save (Merck Chemicals Ltd., Nottingham, UK), a fluorescent 
saving buffer, and cover slips added over the top. These slides were then placed at - 
4°C overnight in the fridge to allow the fluoro-save to harden before visualizing any 
staining under a fluorescent microscope (Olympus, Japan) using a GFP filter. 
Representative pictures were then taken at xlOO objective magnification using the 
Optimas 6 software package. The experiment was repeated three times and 
representative data was presented (See Chapter 9).
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2.5 TOPO Cloning
2.5.1 Knockdown of gene transcripts using ribozyme transgenes
The expression o f RGM was down-regulated at the messenger RNA level using 
ribozyme transgenes that specifically targeted and cleaved the RGM mRNA 
transcript. Hammerhead RNAs are frequently used structure. The hammerhead 
ribozyme functions as a enzyme, carries out a very simple chemical reaction that 
results in the breakage o f the substrate strand of RNA, the cleavage-site nucleotide. 
Much of the experimental work carried out on hammerhead ribozymes has used a 
minimal construct. The minimal hammerhead ribozyme is composed of three base 
paired helices, separated by short linkers o f conserved sequence. The cleavage 
reaction occurs between helix III and I (Figure 2.1 secondary structure of 
hammerhead). The best target sites o f high efficiency for cleavage were found to be 
ATC, GTC and TTC.
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Figure 2.1 Secondary structures and sequences o f the minimal (A) and full-length (B) 
hammerhead ribozymes.
Conserved and invariant nucleotides are shown explicitly. Watson-Crick base-paired helical 
stems are represented as ladder-like drawings. The red arrow depicts the cleavage site, 3' to 
Cl 7, on each construct. (Source from:
http://upload.wikimedia.Org/wikipedia/en/8/89/Minimal_and_full_length_hammerhead_sequ 
ences.png)
The secondary structure o f the transcript of interest was predicted using 
Zuker’s RNA mFold software (Zuker, 2003). The second structures o f human RGMA, 
RGMB and RGMC generated for the present study were shown in Figures 2.1a, 2.1b, 
and 2.1c respectively. A suitable GUC or AUC ribozyme target site was then selected 
from within the secondary structure and the ribozyme designed to specifically bind 
the sequence surrounding this target codon. This allowed the hammerhead catalytic 
region o f the ribozyme to interact and accurately cleave a specific GUC or AUC 
sequence within the target mRNA transcript. Once designed the oligos for the
ribozyme transgenes were synthesised by SigmaGenesis as sense/antisense strands 
(ribozyme transgene sequences are shown in table 2.1.2) and combined into the 
transgene using touchdown PCR. The touchdown PCR conditions were as follows:
• Step 1: Initial denaturing period -  94°C for 2 minutes
• Step 2: Denaturing step -  94°C for 30 seconds
• Step 3: Various annealing steps -  72°C/68oC/64oC/60oC/55°C for 30 seconds.
• Step 4: Extension step -  72°C for 30 seconds
• Step 5: Final extension period -  72°C for 7 minutes
Step 2 - 4  was repeated over 65 cycles, composed of 10, 10, 10, 10, 25 cycles 
respectively depending on annealing temperature.
On completion of the generation, the ribozyme PCR products were separated on a 2% 
agarose gel, in order to visualise the success of the amplification. These PCR 
products were later inserted into the pEF6 plasmid using the TOPO cloning reaction 
described later.
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Figure 2.1 A The predicted secondary structure o f human RGMA mRNA, from 
which the anti-RGMA ribozymes were designed.
The secondary structure of human RGMA mRNA was predicted using Zuker’s mfold 
programme. The arrows (red) indicate potential target sites chosen for the ribozyme 
transgenes.
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Figure 2.1B The predicted secondary structure o f human RGMB mRNA, from which 
the anti-RGMB ribozymes were designed.
Figure 2.1 C The predicted secondary structure o f human RGMC mRNA, from 
which the anti-RGMC ribozymes were designed.
2.5.2 TOPO TA cloning reaction
Cloning o f all ribozyme transgenes and expression sequences was completed 
using the pEF6/V5-His TOPO TA Expression Kit (Invitrogen, Paisley, UK) in 
accordance with the protocol provided. This kit allows fast and effective cloning of 
Taq polymerase amplified products for expression in mammalian cells. The 
following TOPO cloning reaction was set up in a pre labelled PCR tube for each 
ribozyme transgene or expression sequence used:
• PCR product (ribozyme or expression sequence) -  4pl
• Salt solution -  1 pi
• TOPO vector -  1 pi
(Salt solution contains: 1.2M NaCl and 0.06M MgCl2/50 pi)
This reaction was then gently mixed and incubated at room temperature for no 
more than 5 minutes. Following this incubation the reaction was stored in ice until 
the next s tep - One Shot Chemical Transformation.
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2.5.3 Transformation
Five microlitre o f completed TOPO cloning reaction was added to a vial o f One 
Shot TOP 10 Chemically Competent E. coli and gently mixed. The mixture can be 
stirred using the pipette tip but pipetting up and down will damage the bacteria. The 
vial was then incubated for 30 minutes on ice, before being heat-shocked at 42°C for 
30 seconds and immediately placed back into ice. Two hundred and fifty microlitre 
o f room temperature SOC medium was next added to each tube; the tubes were then 
capped and shake horizontally at 37°C and 200rpm on a horizontal orbital shaker 
(Bibby Stuart Scientific, UK) for 1 hour. Following this incubation period the 
bacteria o f the tube was spread onto two selective agar plates (containing lOOpg/ml 
ampicillin) at both a high and low seeding density and allowed to grow overnight at 
37°C in an incubator. The pEF6 plasmid contains two antibiotic resistance genes that 
allow only cells containing the plasmid to grow under ampicillin and blasticidin S 
selection, a schematic o f the plasmid is shown below (Figure 2.2).
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pEF6/V5-His- 
TOPO®
5840 bpComments for pEF6/V5-His-TOPO'5840 nucleotides
EF-1a promoter: bases 470-1653 
T7 promoter/priming site: bases 1670-1689 
TOPO' Cloning site: bases 1760-1761 
V5 epitope: bases: 1826-1867 
Polyhistidine (6xHis) tag: bases 1877-1894 
BGH reverse priming site: bases 1917-1934 
BGH polyadenylation signal: bases 1923-2147 
f1 origin of replication: bases 2193-2621 
SV40 promoter and origin: bases 2626-2970 
EM-7 promoter: bases 3012-3078 
Blasticidin resistance gene: bases 3079-3477 
SV40 early polyadenylation signal: bases 3635-3765 
pUC origin bases 4148-4821 (complementary strand) 
bla promoter: bases 21-105 (complementary strand)
Ampicillin (bla) resistance gene: bases 4966-5826 (complementary strand)
Figure 2.2 The figure summarizes the features o f the pEF6/V5-His-TOPO vector.
The vector is supplied linearized between base pairs 1,760 and 1,761. This is the TOPO 
Cloning site. Unique restriction sites flanking the TOPO Cloning site are shown.
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2.5.4 Selection and analysis of colonies
Following overnight incubation the plates were examined for colony growth, 
success o f plasmid generation and correctness o f the cloned products. Colonies which 
grow on the selective plates should contain the pEF6 plasmid, however these colonies 
need to be tested to confirm the ribozyme has inserted into the plasmid in the correct 
orientation to allow transcription o f the sequence.
In order to check the orientation, the colonies were tested using PCR with 
primers specific to either the plasmid or the ribozyme. The size o f the product 
obtained using the plasmid specific primers; T7F and BGHR will give an indication 
of the size of the inserted sequence and can be used to check that the full sequence 
had been inserted without degradation. Whilst T7F vs BGHR will give an indication 
o f whether the complete full sequence had inserted, it cannot be used to indicate the 
orientation of the sequence. Thus in order to check correct size and orientation of the 
sequence a mixture o f plasmid specific and sequence specific primers were used. To 
check the ribozyme sequences, a combination of T7F vs RbBMR (the forward 
ribozyme sequence) and BGHR vs RbBMR (the reverse ribozyme sequence) were 
used. There are approximately 90bp between the T7F promoter and the beginning of 
the insert, thus correct orientation and ribozyme size (based on approximate 
ribozyme size o f 50bp) would be confirmed by a band of approximately 140bp in the 
T7F vs RbBMR reaction. Likewise a band of approximately 140bp in the BGHR vs 
RbBMR would indicate incorrect orientation of the sequence.
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Ten discrete colonies were randomly selected for orientation analysis and 
marked and labelled on the plates. For each colony, two PCR reactions were carried 
out as follows:
Ribozyme orientation reaction 1
• 8pl - 2X REDTaq ReadyMix PCR Reaction mix
• 1 pi -  BGHR plasmid specific reverse primer
• 1 pi -  Ribozyme specific reverse primer (RbBMR)
• 6pl -  PCR water
Ribozyme orientation reaction 2
• 8pl - 2X REDTaq ReadyMix PCR Reaction mix
• 1 pi -  T7F plasmid specific forward primer
• 1 pi -  Ribozyme specific reverse primer (RbBMR)
• 6pl -  PCR water
A sample o f selected colonies was picked from the plate using a sterile pipette tip and 
dipped into both set o f mixes before the addition of the specific primers. Each
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reaction mix was then placed in a thermal-cycler and subjected to the following 
conditions:
• Step 1: Initial denaturing period -  95°C for 10 minutes
• Step 2: Denaturing step -  94°C for 1 minute
• Step 3: Annealing step -  55°C for 1 minute
• Step 4: Extension step -  72°C for 1 minutes
• Step 5: Final extension period -  72°C for 10 minutes
The mixture was then run on a 2% agarose gel and visualized under ultra violet light. 
Colonies showing correct orientation o f the insert were picked off the plate and used 
to inoculate 10ml of ampicilin selective LB broth and incubated overnight whilst 
being horizontally shaken at 225 RPM.
2.5.5 Purification and quantification of plasmid DNA
Plasmid extraction was carried out using the Sigma GenElute Plasmid MiniPrep Kit
and following the provided protocol. LB broth 5ml with the correct colony cultured
overnight (described above), was spun at 3,000 RCF in at 4°C to obtain a pellet of
bacteria and the supernatant was discarded. The bacterial pellet was then resuspended
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in 200|il of resuspension solution (containing RNase A) and mixed through pipetting. 
Lysis solution 200|il was then added and the container was inverted 5 - 6  times. This 
stage was finished within 5 minutes before adding 350pl of the neutralisation 
solution, inverting 4 - 6  times and centrifuging at 12,000 x g in a microcentrifuge. 
Plasmid DNA was next bound to the column by transferring the cleared lysate to a 
Mini Spin Column placed inside a collection tube, spinning at 12,000 x g for 30 
seconds -  1 minute and discarding the flow through. Next 750pl of wash solution 
(containing ethanol) was added to the column before spinning at 12,000 x g for 30 
seconds -  1 minute and again discarding flow through. An additional spin at 12,000 x 
g for 30 seconds -  1 minute was then undertaken to remove any remaining flow 
through before transferring the Mini Spin Column to a fresh collection tube and 
eluting the plasmid DNA through the addition o f 80pl of elution solution and 
spinning at 12,000 x g for 1 minute. (The empty column was eluted again with lOOul 
PCR water and collected as back up.) The eluted plasmid solution was then run on a 
0.8% agarose gel to confirm presence and correct size of the plasmid.
2.5.6 Transfection via electroporation into mammalian cells
Following plasmid purification and quantification, the extracted plasmid was 
used to transform the prostate cancer PC-3 and breast cancer MDA-MB-231 cell 
lines. Confluent PC-3 or MDA-MB-231 wild type cells were detached from tissue 
culture flasks using trypsin/EDTA, pelleted and counted following resuspension as 
previously described. One million cells in 800pl were then added in an
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electroporation curvette (Eurgenetech, Southampton, UK) together with l-3 |ig  o f the 
purified plasmid. This was mixed briefly before being subjected to an electrical pulse 
of 310V and 1500 capacitance from an electroporator (Easyjet, Flowgene, Surrey, 
UK). Following this pulse the cell and plasmid suspension was quickly transferred 
into 10ml o f pre-warmed medium in a flask and placed in an incubator to allow any 
surviving cells to fully recover from the electroporation process.
2.5.7 Establishing a RGM knockdown mutant and Selection of plasmid 
positive cells
As previously described, the pEF6 plasmid used to transform the cells encodes 
two antibiotic resistance genes. The ampicillin resistance gene allows initial selection 
o f prokaryotic bacterial cells containing the plasmid. The plasmid also contains a 
blasticidin S resistance gene. Blasticidin S is a potent microbial antibiotic that 
inhibits protein synthesis in both prokaryotes and eukaryotes and is used to 
specifically select for mammalian cells containing the pEF6 plasmid. The use o f two 
antibiotic resistance genes allows more accurate selection of the plasmid positive 
cells throughout the cloning.
Following overnight incubation, the cells were subjected to an initial 5 day 
period of intense selection. During this 5 day period, the cells were incubated in 
medium that had been supplemented with 5pg/ml o f the blasticidin S antibiotic to kill 
off all cells that did not contain the pEF6 plasmid. After this initial intense selection 
finished the cells were maintained in maintenance medium containing 0.5pg/ml of
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blasticidin S, this places a selection pressure on the cells to maintain the plasmid and 
results in long term transformation of the cells.
All cells were tested initially, and estimated the efficiency and stability o f both 
the transformation and the ribozyme transgene using RT-PCR and Western blot 
analysis for long periods o f use.
2.6 In vitro Cell function Assays
2.6.1 Cell growth assay
Cells were detached from the culture flask and cell density (per milliliter) was 
determined as mentioned previously. Cells were then seeded into a 96 well plate 
(Nunc, Fisher Scientific, Leicestershire, UK) at a density of 3,000 cells per well in 
200pl of normal medium. Triplicate plates were set up to obtain a cell density 
reading following 1, 3 and 5 day incubation periods. Following the appropriate 
incubation period, the medium was removed and cells were fixed in 4% 
formaldehyde in BSS for at least 5 minutes before staining in 0.5% (w/v) crystal 
violet in distilled water, for 5 minutes. The excessive staining was washed off with 
water and the plate was left to air dry. The stain was then extracted from the cells 
using 10% acetic acid and cell density determined by measuring the absorbance on a 
plate reading spectrophotometer (ELx800, Bio-Tek, W olf laboratories, York, UK) at 
540nm. Cell growth was presented as percentage increase and calculated by
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comparing the absorbances obtained for each incubation period using the following 
equation:
Increased Percentage = [(day 3 or 5) — day 0] absorbance / day 0 absorbance X 
100
Within each experiment at least 6 duplicate wells were set up and the entire 
experiment protocol was repeated three times.
2.6.2 Invasion assay
The invasive ability o f the cells used in this study was determined using an in 
vitro Matrigel invasion assay. This assay measures the cells capacity to degrade and 
invade through an artificial basement membrane and migrate through the 
polycarbonate membrane o f the insert with an 8pm pore in diameter. The 
experimental protocol used for these experiments was modified from that described 
in (Albini et al., 1987; Parish et al., 1992). 24 well cell culture plate inserts (BD 
Biosciences, Oxford, UK) containing 8pm pores were coated with 50pg of an 
extracellular matrix protein solution, Matrigel (BD Biosciences, Oxford, UK). The 
working Matrigel solution was made up in serum free medium to a concentration of 
50pg per lOOpl, added to the inserts and allowed to set in a drying oven. Once dried,
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these inserts were placed into sterile 24 well plates and the artificial membrane was 
rehydrated in lOOpl o f serum free medium for 40 minutes before use. Once 
rehydrated the serum free medium was removed and 1ml o f normal medium was 
added to the well outside the insert in order to sustain any cells that may have 
invaded through the insert. Fifteen thousand cells in 200pl o f normal medium were 
then added to the insert over the top of the artificial basement membrane. The plate 
was then incubated for 72 hours at 37°C, 5% CO2 and 95% humidity.
After 72 hours, the inserts were removed from the plate and the inside o f the 
insert (which was initially seeded with cells) was cleaned thoroughly with tissue 
paper. Any cells which had invaded through the membrane and passed to the 
underside of the insert were fixed in 4% formaldehyde (v/v) in BSS for 5 minutes 
before being stained in 0.5% crystal violet solution (w/v) in distilled water. These 
cells were allowed to air dry and could then be counted under the microscope under 
x40 objective magnification. Several random fields were counted per insert before 
being photographed. Duplicate inserts were set up for each test sample. The 
experimental procedure was repeated three times.
2.6.3 Cell-matrix adhesion assay
This assay was modified from the technique described previously (Jiang et al., 
1995a). The capacity of tumour cells to adhere to an artificial Matrigel basement 
membrane was examined using an in vitro Matrigel adhesion assay.
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One hundred microlitre o f serum free medium contained 5pg of Matrigel was added 
to each well of a 96 well plate and dried in an oven to form an artificial basement 
membrane. This membrane was then rehydrated with lOOpl of serum free medium 
for 40 minutes before use. 45,000 cells were seeded onto the Matrigel basement 
membrane in 200pl o f normal medium or treatment and incubated for 40 minutes. 
The medium was then removed and the membrane was washed five times with 150|li1 
o f BSS solution to remove only loosely attached cells. Adherent cells were then fixed 
in 4% formaldehyde (v/v) in BSS for at least 5 minutes before being stained in 0.5% 
crystal violet solution (w/v) in distilled water. Adherent cells were then counted 
under the microscope under x40 objective magnification at random fields. At least 
three duplicate wells were set up per sample, the entire experiment was repeated 
three times.
2.6.4 Motility assay (Cytodex beads)
Cellular motility was assessed using a cytodex-2 bead motility assay as 
described before (Jiang et al., 1995b). Half million cells for each cell line were 
incubated in 10ml o f growth medium containing lOOpl o f cytodex-2 beads (GE 
Healthcare, Cardiff, UK) for 3.5 hours to allow the cells to adhere to the beads. The 
beads were then washed twice in 5ml o f normal growth medium to remove non­
adherent or dead cells. Following the second wash the beads carrying the cells were 
resuspended in 1ml of growth medium. 200pl of this solution was then transfered
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into a 24 well plate containing a further 800pl o f normal medium and incubated 
overnight. Following incubation any cells that had migrated from the cytodex-2 
beads to the surface o f the plate were fixed in 4% formaldehyde (v/v) for 5 minutes, 
stained with 0.5% crystal violet (w/v) and visualised under x40 objective 
magnification following removal o f cytodex-2 beads through several extensive 
washes with BSS. Several random fields were counted per well and duplicate wells 
were set up per sample. The entire experimental procedure was repeated three times.
2.6.5 Wounding (Migration) assay
A wounding/migration assay was also used to assess the migratory properties 
o f the prostate cancer cells. This technique has been modified from a previously 
described method (Jiang et al., 1999).
Cells were grown in a 24 well plate and upon reaching confluence the 
monolayer o f cells was scraped with a 21G needle. The floating cells were washed 
off gently and 2ml pre-warmed medium contains HEPES buffer was added. After 
wounding the cells were given 15 minutes to recover before the closure o f the wound 
via the migration o f cells was measured. The 24 well plate was placed on a heated 
plate (Lecia GmbH, Bristol, UK) to maintain a constant temperature o f 37°C. The 
wound was tracked and recorded using a CCD camera attached to a Lecia DM IRB 
microscope (Lecia GmbH, Bristol, UK) through taking pictures every 15mins over a 
90 minute period. The images saved at 0, 15, 30, 45, 60, 75 and 90 minute time
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points. Cell migration was then measured using Optimus 6 motion analysis software: 
the distance between the two wound fronts at 10 random points per incubation time 
was calculated. The arbitrary values obtained were then converted into pm by 
multiplying the value by 22.4. The distance that the wound fronts had migrated into 
the wound at each time point could then be determined by subtracting the distance 
between the two fronts at any given time point from that at the initial 0 minute 
experimental start point. The experimental procedure was repeated in triplicate.
2.6.6 ECIS assay
We used the electric cell-substrate impedance sensing (ECIS) system (Applied 
Biophysics, Inc., Troy, NY) to conduct the attachment and wounding assay. Cells 
were cultured in 8W1E ECIS arrays (Applied Biophysics), in which each well for 
cell culture contains a small gold film circular electrode (5 x 1(T4 cm2) and a larger 
(0.15 cm2) counter electrode. We seeded cells at a density of 70,000 cells per  well in 
the arrays (rehydrated using HEPES medium for half an hour before use) in medium 
with HEPES buffer. The cells were incubated for more than 4 hours to allow 
attaching. The increased resistance was measured every 5 seconds to show the 
attachment of cells to the electrode surface. Once the cells fully attached, the 
monolayer was electrically wounded by applying an elevated voltage pulse with a 
frequency o f 30 kHz, amplitude of 4 V for 10 s.Ddead and detached cells floated off 
from the small active electrode. Cells surrounding the small active electrode that had 
not been submitted to the elevated voltage pulse then migrated inward to replace the
cells killed. The impedance showed the attachment of cell to cell. Cell migration was 
assessed by continuous resistance measurements for upto 30 hours.
2.6.7 Flow cytometric analysis of apoptosis
Prior to undertaking any flow cytometry analysis, the calibration o f the flow 
cytometry was verified using Partec Calibration Beads 3pm (Partec GmbH, 
Germany). A small sample o f beads (1-2 drops) was diluted in 2ml o f BSS and run 
on the machine under standard calibration settings pre-stored on the machine. Correct 
calibration of the flow cytometer resulted in a main peak at 100 (log 3) for FSC and 
SSC and a main peak at 100 (log 4) in FL1 -  FL3. Once the calibration o f the 
machine had been verified experimental analysis of test samples was conducted.
Apoptosis was assessed in various cell lines using the Vybrant Apoptosis Assay 
Kit following the provided experimental protocol. The medium was removed from 
the cells and stored on ice. Cells were washed in EDTA, trypsinised, harvested and 
placed in a universal container together with the previously removed cellular medium. 
This suspension was then centrifuged at 1600 RCF to pellet viable as well as dead 
cells, before counting the cells and resuspending 1 x 106 cells/ml in IX annexin 
binding buffer (made through the dilution o f the provided 5X annexin binding buffer 
by distilled water). To each lOOpl aliquote o f cells, 5pl of the provided FITC annexin 
V and 1 pi of a previously prepared lOOpl/ml Propidium Iodide (PI) solution was 
added. The PI working solution was prepared by diluting the 1 mg/ml PI stock
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solution provided in 45pl of IX annexin binding buffer. Annexin V (a 35-36 KD 
Ca2+-dependent phospholipid-binding protein which has high affinity for 
phosphatidylserine) labelled with a fluorophore can identify apoptotic cells by 
binding to PS (phosphatidylserine), which is translocated to plasma membrane outer 
leaflet when apoptosis happens. PI is a red-fluorescent nucleic acid binding dye 
which permeates through integral membrane to stain dead cell nucleic acids but not 
the live cells and the apoptotic cells.
Following the addition o f FITC annexin V and the PI working solution cells 
were incubated for 15 minutes at room temperature in the dark. Next 400pl of 
annexin-binding buffer was then added to the lOOpl cell aliquots, mixed gently and 
stored on ice. The samples were then analysed as soon as possible using flow 
cytometry, measuring the emission at 530nm (FL-1) and >575nm (FL-3). The cell 
population will separate into three groups, low fluorescence or live cells, green 
fluorescence or apoptotic cells and red and green fluorescence of dead cells. Prior to 
analysis of test samples using flow cytometry, the flow cytometry instrument was 
configured using unaltered wild type cells to assess background fluorescence and 
normal, representative cell populations.
2.6.8 Cell cycle analysis
Cells from the culture flasks were collected by trypsinisation and pooled with the 
cells floating in the medium which contained detached mitotic, apoptotic and dead 
cells. The cells were then centrifuged and washed twice with cold PBS and 
resuspended lx  106to lxlO7 in 0.5ml o f PBS. This was followed by the addition of
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4.5ml of 70% ethanol at 4°C for more than 2 hours, t he cells were fixed and 
permeabilized to make them accessible to propidium iodide (PI). After fixation, the 
cells were then washed with PBS and stained with PI (for DNA staining) by 
resuspending in a 1ml PI solution containing Triton x 100 (for additionally 
permeabiiization) and RNase A (to inhibit the interference of double-stranded RNA 
sections).
After 30 mins at room temperature in the dark, the fluorenscence of PI was detected 
using the flow cytometer and the cell cycle analysis was performed using the 
FlowMax software package.
2.7 Statistical Analysis
For statistical analysis experiments were repeated three separate times and at 
least duplicate each time. Results data were then analyzed using the Minitab 14 
statistical software package. The statistical comparisons between the test and control 
cell lines were made using either a Students two tailed t-test if the data were found be 
normalised and have equal variances or a non-parametric Mann-Whitney test if the 
data were not normalised.
In all cases, each test cell line was compared to the pEF6 control cell line (cells 
containing a closed pEF6 plasmid only) as this also confirmed that it was the 
ribozyme/expression sequence that was responsible for any changes seen and not the 
pEF6 plasmid itself.
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Chapter 3
Aberrant expression of RGMs in cancer
cells and tissues
140
3.1 Introduction
As discussed in Chapter 1, the RGMs (repulsive guidance molecules) are a 
group of GPI (glycosylphosphatidylinositol)-linked cell-membrane-associated 
proteins that have recently been described. RGMs has been shown to be two-chain 
protein bound to the cell membrane through a GPI-anchor and contains other 
domains as: a signal peptide, an RGD site, a von Willebrand factor (vWF) domain 
and a hydrophobic region (Monnier et al., 2002; Samad et al., 2005; Samad et al., 
2004). RGMs have been shown to be expressed at the central nervous system and 
peripheral tissues, including heart, liver, lung, skin, kidney and testis, at least in the 
adult rat. (Babitt et al., 2005; Metzger et al., 2005; Monnier et al., 2002; Niederkofler 
et al., 2004; Samad et al., 2004; Schmidtmer and Engelkamp, 2004)
RGMA is initially found to mediate repulsive axonal guidance and neural tube 
closure, while DRAGON (RGMB) contributes to neuronal cell adhesion through 
homophilic interactions. The H JV  (RGMC) gene is mutated in juvenile 
hemochromatosis, a disorder o f iron overload. Lately, a role of RGMs as co-receptors 
for bone morphogenetic proteins (BMPs) has been revealed (Samad et al., 2005).
Bone Morphogenic Proteins (BMPs) are oestrogenic factors abundant in bone 
matrix which play an important role in bone metastasis of cancer. BMPs are 
predominantly responsible for osteoblast differentiation and bone matrix production 
and mineralization (Jikko et al., 1999; Li et al., 1996; Sampath et al., 1992). The 
BMPs are also reported to be related to in vitro growth, apoptosis, adhesion and
migration in breast cancer and prostate cancer (Alarmo and Kallioniemi; Kwon et al.; 
Ye et al.).
During the bone metastasis, osteoblast differentiation induced by BMPs is 
mediated mainly via the Smad-signalling pathway, whereas chondrogenic 
differentiation may be transmitted by Smad-dependent and independent pathways 
(Fujii et al., 1999). Regulations o f cancer cells by BMPs and BMP signalling 
molecules are also mainly through Smad-dependent pathway, including proliferation, 
apoptosis and cell aggressiveness. RGMs work as BMP co-receptors which 
participate in BMP signalling pathway therefore should also be involved in cancer 
development and progression.
However, the expression o f RGMs in cancer remains unclear. To get the first 
hand data to evaluate the role o f RGMs in cancer, the work presented in this chapter 
examined the expression profile o f RGM in tissues and cell lines. The RNA transcript 
levels were assessed associated with clinical breast cancer patient prognostic 
indicators.
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3.2 Materials and methods
3.2.1 Cell lines
Cell lines were employed for this study as outlined in section 2.1.1. Cells were 
routinely cultured in DMEM / Ham’s F12 with 1-Glutamine (PAA Laboratories, 
Somerset, UK) supplemented with streptomycin, penicillin and 10% foetal bovine 
serum (PAA Laboratories, Somerset, UK) and incubated at 37.0°C, 5% C 02 and 
95% humidity.
3.2.2 Tissues and patients
All the cancer tissues and normal background tissues were collected during the 
operative procedure and snap-frozen in liquid nitrogen immediately before storage at 
-80°C until used. The presence o f tumour cells in the tissues was verified by a 
consultant pathologist (ADJ) using H&E staining of frozen sections. All protocols 
were reviewed and approved by the local ethical committee and all patients gave 
written informed consent.
3.2.3 Tissue processing and preparation of RNA and cDNA
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Tissue samples were homogenized in RNA extraction reagent (TRI reagent, Sigma- 
Aldrich Ltd, Poole, England, UK) to extract total RNA. The concentration o f RNA 
was determined using a spectrophotometer. 0.5pg RNA was used in a 20pl reverse 
transcription reaction to generate cDNA using a RT kit (AbGene Laboratories, Essex, 
England).
3.2.4 Screening of RGM transcripts expression in cancer cell lines using 
RT-PCR
Primers were designed using the Beacon Designer software (version 2, Biosoft 
International, Palo Alto, California, USA), to amplify regions of human RGMs that 
have no significant overlap with other known sequences, with the amplified products 
spanning over at least one intron, based on sequence accession numbers. PCR 
products were separated on agarose gel and photographed using a digital camera 
mounted over a UV transluminator. GAPDH was used as a housekeeping gene. All 
the primers used were detailed in 2.1.2
3.2.5 Immunohistochemical Staining of RGM in Prostate Specimen
Briefly, frozen prostate tissues were cut into 5pm sections using a cryostat (Leica 
Microsystems (UK) Ltd., Bucks, UK). Immunohistochemical staining was performed 
by using specific primary antibodies against RGMA, RGMB and RGMC. This was
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based on the method previous described (Martin et al., 2003b). Positive controls were 
not available as we were unable to obtain tissue sections that had been confirmed to 
express RGMs. Negative controls Were performed.
Statistical analysis
Normally distributed data was analyzed using the two sample T-test while non- 
normally distributed data was analyzed using the Mann-Whitney and Kruskal-Wallis 
tests.
3.3 Results
3.3.1 The expression of RGMs in human tissues and cell lines
To examine the expression o f RGMs in both prostate and breast cancer, 
conventional RT-PCR was employed to screen a variety of human breast cancer and 
prostate cancer cell lines together with some samples of other cell types and tissues. I 
found that transcripts o f RGMA, B and C were expressed in prostate cancer cell lines 
(PC-3, DU-145, PZ-HPV-7, PNT1A, PNT2-C2), whereas only RGMB was 
detectable in some breast cancer cell lines, such as MDA-MB-231, MDA-MB-436, 
BT-474, BT-482, BT-549 (Fig.3.3.1A). RGMB levels were higher in the breast 
cancer tissues compared to the normal mammary tissues, whilst RGMA and RGMC 
showed similar levels in both. (Fig.3.3.1B)
RGMA was widely expressed in prostate cell lines (CAHPV10 and LNCAP 
plus the five mentioned above) and a range o f human cell lines of various origins
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including cervical cancer (A431, Hela), Keratinocyte (HaCaT), Colorectal cancer 
(HT-115), Fibroblast (MRC5), Endothelial (HECV), MDA-MB-435s and normal 
human polymorphonuclear cells (OMN) from healthy volunteers. The transcript level 
o f RGMA was barely detected in the breast cancer cell lines but was detected in both 
the normal breast and breast cancer tissues (Fig. 3.3.IB). Additionally, ovary, liver, 
skin and colorectal tissues showed weak expression of RGMA and none in prostate 
tissues (Table 3.3.1.1).
In addition to its expression in most prostate cancer cell lines (except for 
CAHPV10) and most breast cancer cell lines, RGMB was expressed in cervical 
cancer (Hela, A431), bladder cancer (RT-112, EJ-138), colorectal cancer (HRT18, 
HT-115), fibroblast (MRC5), and pancreatic cancer cells (PANC1). In lung cancer 
cell lines (SKMES1, A549) and endothelial cells (HUVEC), RGMB transcript levels 
were detected but slightly weaker (Fig, 3.3.1 A).
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1. MDA157 11. MDA231 21. MRC5 31. P2-HPV-7 41. CorL23
2. MCF-7(new) 12. A431 22. HECV 32. PNT1C 42. CorL47
3. MCF-7(origina!) 13. HaCaT 23. HUVEC 33. PNT2C2 43. CaP
4. BT474 14. RT112 24. PMN 34. MRC5 44. CaP
5. BT482 15. EJ138 25. U937 35. MDCK 45. BRCa
6.MCF10A 16. HeLa 26. PL1 36. OV1 46. NB(uormal breast)
7. MDA436 17. HRT18 27. PC3 37. SKMES1
8. BT549 18. HT115 28. DU 145 38. A549
9. 2R751 19. PANC1 29. CAHPV10 39. CorL677
10.MDA435S 20. MiaPaCa 30. LNCAP 40. CorL88
Figure 3.3.1 A Expression o f RGM transcripts in cell lines of human origin and 
human tissues.
RGMA, B and C were found in many cell lines and tissues through RT-PCR.
1-35 and 38 are cell lines and the others are tissues (OV: ovary tissues, Corl: colorectal 
tissues, CaP: prostate cancer tissues, BRCa: breast cancer tissues, NB: normal breast). The 
numbers after tissue abbreviation are patients’ code.
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Figure 3.3.1 B Expression of RGM transcripts in human tissues 
RGMA, B and C are detected in many tissues in the screening through RT-PCR. L is ladder.
1-4: placenta, 5-7: ovary, 8-9: normal breast tissues, 10: omentum, 11: liver, 12-13: skin, 14: 
colon cancer, 15: normal mucosa, 16 and 17: miscellaneous, 18: bone, 19-20: breast cancer 
tissue, 21-23: prostate cancer tissues.
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Interestingly, only RGMB was detected in the breast cancer cell lines. 
Furthermore, I found that RGMB was not detectable in a breast epithelial cell line, 
MCF10A an immortalised normal mammary epithelial cell lines. RGMB was 
otherwise found to be expressed by the breast cancer cell lines, including MDA436 
and BT-474 which were derived from primary tumour of invasive ductal carcinoma, 
and MDA-MB-231 isolated from metastasis of invasive ductal carcinoma. 
Additionally, RGMB mRNA was only shown in breast cancer tissues and hardly 
detected in normal/background breast tissues. RGMB transcript levels were observed 
in prostate, ovary, omentum, liver and colon tissues (Table 3.3.1.1).
As with RGMA, RGMC was weakly expressed in breast cancer cell lines. 
RGMC was detected in most prostate cancer cell lines (extremely weak in PZ-HPV- 
10 and LNCAP) and other cell lines including MDA-MB-435s, cervical cancer 
(A431, Hela), leukocyte (PMN), keratinocyte (HaCaT) and colorectal cancer (HT- 
115). RGMC mRNA was detected in both normal breast and cancer tissues, with no 
obvious difference in expression levels. In other tissues, there was a visible RGMC 
level in prostate as well as placenta, ovary and skin (Table 3.3.1.1).
Notably, the RGMA, B and C all have expression in cell line MDA435s. 
However, whether the MDA435s is a cell line o f breast cancer or melanoma remains 
controversial.
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Table 3.3.1.1 RGMs expression detected in different tissues
RGMs Tissue types with RGM  transcrip t detected
RGMA breast, ovary, liver, skin, colon
RGMB breast, prostate, ovary, omentum, liver, colon
RGMC breast, prostate, placenta, ovary, skin
In summary, in the human tissues tested in this study, RGMA was found in both 
breast cancer and normal/background tissues but not in breast cancer cell lines; whilst 
RGMA was detected in prostate cancer cell line but not prostate tissues in the 
screening (Table 3.3.1.2). RGMB was shown in both breast (cancer) and prostate 
tissues and cell lines. Similar to the pattern o f RGMA, RGMC was not detected in 
breast cancer cell lines but in breast tissues, however, it was found in both prostate 
tissues and prostate cancer cell lines.
Table 3.3.1.2 The expression o f RGMs in breast and prostate tissue and cell lines
RGMs\Tissue Normal breast Breast cancer Prostate
RGMA + + —
RGMB — + +
RGMC + + +
Cell line Breast cancer Prostate cancer
RGMA — +
RGMB + +
RGMC - +
3.3.2 The expression of RGMs in prostate tissues
To further investigate the expression of RGMs in prostate tissues, we examined the 
protein levels o f all three RGMs using immunohistochemistry. Nineteen prostate 
tissue samples were used in this study. The left panel displays the representative 
sample with less aggressiveness which had a Gleason score of 6 (Fig 3.3.2). The right 
panel shows a more aggressive sample of Gleason score 8 (>7). The 
immunochemical staining of RGMC protein revealed stronger staining in prostate 
cancer cells compared to prostate epithelial cells (Fig 3.3.2 C). As shown in Fig 3.3.2 
C, the RGM protein was mainly confined to the cytoplasm of cancer cells and some 
of the mesenchymal cells on the periphery o f the tumour area.
The similar pattern was shown in the IHC staining of RGMB. The RGMB 
proteins were subtly stained in the prostate cancer cells compared to the normal cells. 
However, RGMA showed little staining in both the normal prostate and the prostate 
cancer cells.
k
RGMA Negative control
Normal Tumour
X 40
X 100
X 200
X 400
V
■ M -  V
Figure 3.3.2 A IHC staining o f RGMA in prostate specimens.
There was no significant staining of RGMA protein by IHC in the normal (left panel) and 
tumour (right panel) prostate specimens. The graph on the right shows the semi­
quantification of IHC staining of RGMA, RGMB (Figure 3.3.2B) and RGMC (Figure 
3.3.2C).
■ Background 
* Tumour
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N e g a t i v e  c o n t r o l
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Tumour
Figure 3.3.2 B IHC staining o f RGMB in prostate specimens.
RGMB showed subtle staining in the prostate tumour tissues (right) compared to no staining 
in the background tissues (left). The staining o f  RGMB is significantly higher in tumour 
tissues shown by the semi-quantification o f  IHC (shown on the right bottom).
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RGMC N e g a t i v e  c o n t r o l
Normal Tumour
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X 100
X 200
X 400
■ Background 
Tumour
RGMB
Figure 3.3.2 C IHC sta in ing  o f  R G M C  in prostate specim ens.
The staining o f  RGMC protein is slightly higher in the prostate tumour tissues (right) 
compared to the normal tissues (left) shown by the pictures. The staining o f  RGMC was 
mainly confined in the cytoplasm and the marginal ground (X  400 magnification). The 
staining o f  RGMC is significantly higher in tumour tissues shown by the semi-quantification 
o f  IHC (shown on the right bottom).
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3.4 Discussion:
Initially, I screened for the expression o f RGMA, RGMB and RGMC in a panel 
of tissues and cell lines using RT-PCR. RGMA and RGMC were barely found in 
breast cancer cells. Although no detection in the breast cancer cell lines, RGMA and 
C were detected in breast tissues. RGMA is widely expressed in prostate cancer cell 
lines, cervical cancer cell lines, keratinocyte, colorectal cancer cell lines, fibroblast, 
endothelial, leukocyte and MDA435s and tissues including ovary, liver, skin and 
colon. RGMB has expression in cervical cancer, bladder cancer, colorectal cancer, 
fibroblast, pancreas cancer, lung cancer cells and endothelial cells while with 
expression in breast cancer tissues and prostate, ovary, omentum, liver and colon 
tissues. RGMC was found in prostate cancer cells, MDA435s, cervical cancer cells, 
leukocyte, keratinocyte, colorectal cancer cells and prostate tissues as well as 
placenta, ovary and skin. The RGMs have been reported to be expressed in heart, 
lung, liver and skin before (Babitt et al., 2005; Metzger et al., 2005; Monnier et al., 
2002; Niederkofler et al., 2004; Samad et al., 2004; Schmidtmer and Engelkamp, 
2004), however, in our study, I found RGMB was absent in skin and RGMC was not 
detected in liver in contrast to all the three members: RGMA, RGMB and RGMC.
RGMA was expressed in all seven prostate cell lines (CAHPV10, Hz-HPV-7, 
PC-3, DU-145, Pz-HPV-7, PNT1A and PNT2-C2). The seven prostate cell lines used 
in this study represent different clinical characteristics of prostate cancer according to 
their origin. Pz-HPV-7, PNT1A and PNT2-C2 are immortalised prostate epithelial 
cell lines. PC-3, DU-145, LNCAP and CAHPV10 are prostate carcinomas amongst
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which CAHPV10 is derived from a primary tumour and the other three from various 
metastatic sites. PC-3, DU-145 and LNCAP have been widely regarded as more 
aggressive in phenotype than CAHPV10 cells. Among these three aggressive prostate 
cancer cell lines, LNCAP is androgen sensitive, whilst PC-3 and DU-145 are 
androgen insensitive. These cell lines have been used as different models for in vitro 
prostate cancer research for decades and as such are well characterised. RGMA has 
higher levels of expression in the less aggressive cell line CAHPV10, compared to 
the more aggressive PC-3, DU145 and LNCAP cell lines. This is contrast to the 
expression o f RGMB which is absent in CAPHV10 cells. RGMC was expressed in 
PC-3, DU-145 and CAHPV10 cells, and absent in LNCAP cells.
In prostate tissues, RGMB and RGMC transcript levels were detected during 
tissue screening and showed subtle staining o f protein in prostate cancer tissue 
sections, compared with normal prostate specimens (using IHC staining). Although 
RGMA mRNA was seen in prostate cancer cell lines, it was difficult to detect in 
tissues and the protein level o f RGMA is also weaker in the prostate specimens than 
the other RGMs. The expression pattern o f RGMs thus remains inclusive and the role 
of RGMs played in prostate cancer warrants further investigation.
Compared to the epithelial cell line (MCF10A), MDA436, BT-474 and MDA- 
MB-231 are more aggressive cell lines derived from breast carcinoma, with the 
MDA-MB-231 being most aggressive which is isolated from metastasis. In breast 
cancer, RGMB mRNA level was unique in breast cancer cell lines. Moreover, the 
mRNA level of RGMB observed from tissue screening was higher in breast cancer 
tissue, compared to normal/background tissues. However, RGMA and RGMC were
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detected in breast cancer tissues but not in cell lines. This probably reflects the nature 
o f diversity and aberration o f RGM expression in cancer cells. To further investigate 
the association o f RGMs with breast cancer, the expression o f RGMs in breast cancer 
will be further elucidated in the following chapter.
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Chapter 4
Expression of RGMs in breast cancer 
and their association with 
characteristics of the disease
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4.1 Introduction
As described in the previous chapter, RGMA, B and C were found to be widely 
expressed in many cancer cell lines and tissues. To reveal the role o f RGMs in breast 
cancer, we have already examined the mRNA expression o f RGMs in breast cancer 
cell lines and tissues (Chapter 3). RGMA and RGMC were not detected in breast 
cancer cells during screening. Although no detection in the cell lines, RGMA and C 
were shown in breast tissues. Only the RGMB mRNA level was detected in breast 
cancer cell lines, and higher in more aggressive cell lines. Moreover, the mRNA level 
of RGMB observed from tissue screening was higher in breast cancer tissue, 
compared to normal/background tissues. In order to further investigate the RGMs 
expression in breast cancer, the protein levels o f RGMs were examined in breast 
tissues using immunohistochemical staining.
Furthermore, the transcript level o f RGMs was also assessed with clinical 
prognosis o f breast cancer. A panel o f breast tissues from a cohort o f patients with a 
median followup o f 120 months was determined in this study. The transcript levels of 
RGMA, B and C were determined in breast cancer and normal/background tissues 
and analyzed against predicted prognosis o f the patients, using the Nottingham 
Prognostic Index (NPI), Tumour Nodal Metastasis (TNM) staging, tumour grade and 
survival status (clinical outcome). The RGMs have shown their interesting roles in 
breast cancer according to these analyses related to clinical data.
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4.2 Materials and methods
4.2.1 Tissues and patients
All the cancer tissues and normal background tissues were collected during the 
operative procedure and snap-frozen in liquid nitrogen immediately before storage at 
-80°C until used. Patients were followed routinely in the clinic and the median 
followup period for the study cohort was 120 months (last followup June 2004). The 
presence o f tumour cells in the tissues was verified by a consultant pathologist (ADJ) 
using H&E staining o f frozen sections. All protocols were reviewed and approved by 
the local ethical committee and all patients gave written informed consent.
4.2.2 Determination of RGM transcripts in breast tissues using 
quantitative PCR
Tissue samples were homogenized in RNA extraction reagent to extract total RNA 
and 0.5pg RNA was used to generate cDNA using a RT kit. Real time quantitative 
PCR (RT-QPCR) was carried out to determine the levels of RGMs' transcripts in the 
breast cancer cohort. The transcript level was subsequently analyzed against clinical 
data. The assay was based on the Amplifuor technology and primers were designed 
by Beacon Designer software as we previous reported (Jiang et al., 2005a; Parr et al., 
2004). Cytokeratin-19 (CK19) was used as internal control. The protocol and primers 
used for RGMs quantification were listed in section 2.1.2 and 2.3.5.
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4.2.3 Immunohistochemical Staining of RGM in Breast Specimen
Immunohistochemical staining was performed by using specific primary antibodies 
against RGMA, RGMB and RGMC on frozen breast tissues. This was described in 
chapter 3 and based on the method previous reported (Martin et al., 2003b). Positive 
controls were not available as we were unable to obtain tissue sections that had been 
confirmed to express RGMs. Negative controls were performed.
Statistical analysis
Normally distributed data was analyzed using the two sample T-test while non- 
normally distributed data was analyzed using the Mann-Whitney and Kruskal-Wallis 
tests.
4.3 Results
4.3.1 The expression levels of RGMs examined in breast tissues and 
normal tissues
Protein expression o f RGMA, RGMB and RGMC was examined in 
normal/background and cancer tissues using immunohistochemical staining. 
Although RGMB was detected in breast cancer tissues but not in normal breast 
tissues, the staining o f RGMA, B and C protein in the breast cancer tissues did not
1 6 1
differ from that of normal tissues (Fig.4.3.1 A, B and C). Only RGMC are shown 
some staining in the cytoplasmic region o f breast cancer cells, however the staining 
was weak. Twenty three breast specimens were examined in this study, whilst two of 
them were normal breast tissues. The representative images were shown in figure- 
4.3.1. The transcript expression level o f RGMs was also determined using a panel o f 
breast tissues. Quantified using Q-PCR, with a median patient followed up of 120 
months.
The details o f the patients used in this experiment were listed in the tables 
below (Table 4.3.1). Where insufficient sample quantities were available for the 
reaction or the sample was invalid > the data was eliminated before analysis took 
place. Consistent with the protein level shown in tissue screening, the transcript 
levels o f RGMB was significantly higher in patients with breast cancer (p=0.038), as 
compared to normal/background tissues (Fig.4.3.2.1 B l). A similar trend was also 
seen in the examination o f RGMA level in normal (Mean±SEM 12729±7850) and 
tumour (Mean±SEM 18223±5504) tissues (Fig.4.3.2.1 A l). However, RGMA and 
RGMC didn’t show significant differences (p value is 0.57 and 0.22 respectively), in 
the comparison between normal and cancer tissues (Fig.4.3.2.1 A l and  C l).
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Figure 4.3.1 A IHC staining o f  RGMA in breast specimens. The left panel shows 
the breast tissues with a low aggressive nature and the right panel shows breast 
cancer tissues with high malignity. There is no significant difference in the staining 
o f RGMA proteins between the breast cancer tissues and background tissues as the 
graph shown on the right displayed the semi-quantification o f IHC staining.
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Figure 4.3.1 B IHC staining o f RGMB in breast specimens. There is no specific 
staining of RGMB proteins shown in the breast cancer tissues or background tissues. 
The graph on the right shows the semi-quantification o f IHC which also indicated 
non-significant differences.
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Figure 4.3.1 C IHC staining o f RGMC in breast specimens. No significant 
differences in RGMC staining were seen between breast cancer tissues and 
background tissues. The graph on the right shows the semi-quantification o f IHC 
staining and also indicates non-significant diferences.
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Figure 4.3.2.1 The transcript level o f RGMs in breast cohort analyzed against 
clinical data . The graphs show the mean copy number o f the genes and the error bars 
represent the SE Mean o f individual experiments. Data was calculated based on three 
experiments performed independently and a two sample T-test was used to identify 
significance levels.
A l: There is a decreased trend of transcript level of RGMA in normal breast tissues (Mean 
copy numbertSE 12729±7850) compared to breast cancer tissues (18223±5504), although 
it’s not significant (p=0.57).
Bl: The transcript level of RGMB was significantly higher in patients with breast cancer 
(n=94), compared to the normal ones (n=29). (5381±2321 vs 20660±7055, P=0.043)
Cl: RGMC transcript level was higher in normal breast tissues (1616±1110) compared to 
cancer tissues (220±111), though P is not significant (0.22).
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Figure 4.3.2.2 The transcript level o f  RGM in breast cohort analyzed against NPI
The graphs show the mean copy number of the genes and the error bars represent the SE 
Mean of individual experiments. Data was calculated based on three experiments performed 
independently and a two sample T-test was used to identify significance levels.
A2: The expression pattern of RGMA in data related to NPI was not definitive.
B2: The patients with good prognosis group had a trend of lower levels of RGMB 
(Mean±SEM 8602±3179 for NPI1), compared to that with moderate (10325±4678, p=0.76) 
and poor (21245±18926, p=0.52) prognosis, however, this is not significant.
C2: There was no defenitive pattern shown in the NPI data associated with RGMC transcript 
level.
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Figure 4.3.2.3 The transcript level o f RGMs in breast cohort analyzed against tumour 
grade
The graphs showed the mean copy number o f the genes and the error bars represented 
the SE Mean of individual experiments. Data was calculated based on three experiments 
performed independently and a two sample T-test was used to identify significance levels.
A3: There was no trend in expression pattern of RGMA related to tumour grade.
B3: The transcript level of RGMB was higher in patients of tumour grade 3 (52647±34745), 
compared to tumour grade 1 (2831±1090) and tumour grade 2 (7050±3298), although p value 
is not significant (p=0.21 and 0.25).
C3: There was no specific pattern shown in the tumour grade data.
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Figure 4.3.2.4 The transcript level o f RGMs in breast cohort analyzed against TNM 
stages
The graphs showed the mean copy number of the genes and the error bars represented the SE 
Mean of individual experiments.
A4: The RGMA transcript level in the TNM stage 1 was (Mean±SE 0.508±0.292), the stage 
2 was (12253±8626), stage 3 was (7750±6263) and stage 4 was (13635±6384).
B4: Even though the transcript level of RGMB was highest in the patients with TNM stage 3, 
it was not significant when compared with any TNM stages, (as p=0.12 when comparing 
with TNM1)
C4: The RGMC had decreased levels in the increased TNM stages, however, the TNM1 data 
was absent and all the p values were not significant. (p=0.2 for TNM2 vs TNM3, p=0.084 for 
TNM2 vs TNM4 and p=0.097 for TNM3 vs TNM4)
1 6 9
30000
25000
20000
15000
10000
5000
0
A5
RGMA
30000
25000
20000
15000
10000
5000
RGMB
J_ _
Good prognosis Poor prognosis Q 5  Good prognosis Poor prognosis
450
400
350
300
250
200
150
100
50
RGMC
o
C5 Good prognosis Poor prognosis
Figure 4.3.2.5 The transcript level o f RGMB in breast cohort analyzed against 
clinical outcome.
A5: The transcript level of RGMA was significantly lower in breast cancer patients with poor 
prognosis (n=27) (Survival statues 2/3/4), compared to good prognosis (Survival statues 1/ 
Disease free) (n=73). (5381 ±2321 vs 20660±7055, P=0.043)
B5: The transcript level of RGMB showed no significant difference, although it was lower in 
patients with good clinical prognosis (10857±3364) than poor clinical prognosis 
(17642±10778Xp=0.55).
C5: There was no obvious trend shown in the data of clinical prognosis (outcome), with 
similar expression level in patients with good prognosis (245±153) and poor prognosis 
(201±132).
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4.3.2 The association of mRNA level of RGMs and prognosis
The levels o f RGMs transcripts were further analyzed against the predicted 
prognosis of the patients, using the Nottingham Prognostic Index (NPI). Based on 
NPI scores, patients were divided into three groups; with good prognosis (NPI 1, 
<3.4), moderate (NPI 2, 3.4-5.4) and poor prognosis (NPI 3, >5.4).
Fig 4.3.2.2 A2 shows that the expression pattern o f RGMA in data related to 
NPI is not definitive. The RGMA expression was increased in the patients o f NPI2 
group from NPI1 (whereas is not significant, p=0.64) but decreased in NPI3 
(Fig.4.3.2.2 A2). However, the level o f RGMA with poor prognosis (NPI3: 
2071 ±882) is relatively lower, when compared to those with good and moderate 
prognosis (vs NPI1: 19129±7439, p=0.027) (vs NPI2: 26324±13149, p=0.075). It is 
different from that the patients with good prognosis group have lower levels of 
RGMB (Mean±SEM 8602±3179 for NPI1), compared to that with moderate and poor 
prognosis: 10325±4678 of NPI2 group and 21245± 18926 of NPI3 group (all the P > 
0.5) (Fig.4.3.2.2 B2). There was no specific pattern was shown in the data related to 
NPI scores of RGMC, as the transcript level decreased in NPI2 (55±35) but increased 
in NPI3 (733±479), comparing with NPI1 (179±168) (Fig.4.3.2.2 C2).
In addition to NPI, the association o f RGMs expression to Tumour Nodal 
Metastasis staging (TNM) and tumour grade were also analysed as further indicators 
o f prognosis.
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The RGMA level in the patients with tumour grade 1 was 6340±2391 and 
increased in tumour grade 2 (30831± 13085) and decreased again in the tumour grade 
3 (7750±6263) (Fig.4.3.2.3 A3). The same trend was observed in the connection to 
tumour grade in RGMC (11.7±8.8 for tumour grade 1, 289±275 for tumour grade 2 
and 103±52 for tumour grade 3) (Fig.4.3.2.3 C3). There was a different pattern 
shown in the data when comes to RGMB (2831±1090 for Gradel, 7050±3298 for 
Grade2 and 52647±34745 for Grade3) (Fig.4.3.2.3 B3), which was distinct from 
RGMA and RGMC.
The RGMA transcript level was very low in the TNM1 (0.508±0.292) 
compared to the TNM2 (12253±8626), TNM3 (7750±6263) and TNM4 
(13635±6384), however, there is little changes between the three (Fig.4.3.2.4 A4). 
There is no definitive pattern seen in the progressing TNM stages related to RGMB. 
The RGMB expression appears highest level in TNM3 status with much lower level 
in TNM2 and TNM4 and lowest in TNM1, p>0.1 in all cases (Fig.4.3.2.4 B4). Even 
though there’s no trend shown in the data related to the patients prognosis as NPI and 
tumour grade (C2 and C3), the RGMC expression decreased in the increased TNM 
stages (Fig.4.3.2.4 C4), from TNM2 (412±231) to TNM3 (103±52) (p=0.2) and from 
TNM3 (103±52) to TNM4 (0.126±0.076) (0.097), as the sample o f TNM1 was 
absent.
These data indicated that there was no obvious trend in RGMA expression 
associated with tumour progression (the increased NPI score, TNM staging and 
tumour grade). However, as the higher expression in tumour tissues, RGMB 
transcript level also gradually increased in the patients with poorer prognosis and
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higher NPI index and tumour grade, although these changes did not reach a level of 
significance (p > 0.2 in all cases). This may be due to the high variances obtained 
from the data and a relatively small sample in some instance (Table 4.3.1). Although 
statistical significance was not reached, the trend in RNA transcript levels 
demonstrated that RGMC might have decreased levels in patients with breast cancer, 
particularly in those with higher TNM staging and poor prognosis.
The transcript level of RGMs in breast cancer and clinical outcome
The association o f RGMs transcript expression with clinical outcomes o f the 
patients was also analyzed based on the follow-up data. The patients with poor 
prognosis, including those with local recurrence (Survival status 2), metastatic 
disease (Survival status 3) and those who died from breast cancer (Survival states 4) 
had significant lower transcript levels o f RGMA (5381±2321, p=0.043) compared to 
that of patients who had remained disease free (Survival status 1) (20660±7055) 
(Fig.4.3.2.5 A5). In fact, the patients o f survival status 1 have highest RGMA 
expression which is significantly higher than those o f Survival status 3 (265 8± 1996, 
p=0.016) and 4 (2898±897, p=0.015), however not changed much in Survival status 2 
(12648±8499, p=0.48).
When look at the survival status related to RGMB, the transcript level of 
RGMB in patients remained disease free (10857±3364 Survl) is much higher than 
those with local recurrence (1714±1082 Surv2) and metastatic disease (71.2±41 
Surv3) (p=0.012 and p=0.002 respectively)(Table 4.3.2). However, the RGMB
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expression is increased and reached the highest in the patients died from breast 
cancer (27697± 17042). Although the decreased pattern is not consistent within all the 
four survival status, if  combined four together, the RGMB was increased in patients 
with poor clinical outcome compared to those with good clinical outcome (Survl vs 
Surv2/3/4) (10857±3364 v* 17642±10778), whilst the p-value is 0.55 (Fig.4.3.2.5 
B5).
There are no particular pattern shown in the follow-up data o f RGMC, 
however, if taken together, RGMC showed higher expression in patients who 
remained disease free (245±153), with lower expression in those with metastatic 
disease or local recurrence or died from breast cancer (201±132) (p=0.83) 
(Fig.4.3.2.5 C5).
The details o f RGMs transcript level in patients with breast cancer was listed 
below (Table 4.3.2). Two sample T-Test was used here.
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Table 4 .3 .1  C l i n i c a l  a n d  p a t h o l o g i c  in f o r m a t io n
Clinical group Sample volume (total 139)
RGMA RGMB RGMC
Tissue sample
Normal 28 29 28
Tumour 106 94 106
NPI
1 (NPI score < 3.4) 54 51 54
2 (NPI score 3.4-5.4) 32 29 32
3 (NPI score > 5.4) 15 11 15
Tumour grade
1 17 17 17
2 33 33 33
3 7 6 7
TNM staging
I 2 2 2
II 32 24 32
III 7 6 7
IV 4 3 4
Survival status
Disease free (Survl) 73 69 73
with metastases (Surv2) 7 6 7
with local recurrence (Surv3) 5 2 5
Died o f  breast cancer (Surv4) 15 13 15
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Table 4.3.2 The transcript level of RGMs in breast cancer
Clinical data Transcripts (Mean±SE)
RGMA RGMB RGMC
Tissue sample
Normal 12729±7850 4220±1586 1616 ± 1110
Tumour 18223±5504 12166±3434 220±111
NPI
1 (NPI score < 3.4) 19129±7439 8602±3179 179±168
2 (NPI score 3.4-5.4) 26324±13149 10325±4678 55±35
3 (NPI score > 5.4) 2071±882 21245±18926 733±479
T umour grade
1 6340±2391 2831±1090 11.7±8.8
2 30831±13085 7050±3298 289±275
3 7750±6263 52647±34745 103±52
TNM staging
I 0.508±0.292 801±801
II 12253±8626 4401±2033 412±231
III 7750±6263 52647±34745 103±52
IV 13635±6384 4741 ±4729 0.126±0.076
Survival status
Disease free (Survl) 20660±7055 10857±3364 245±153
with metastases (Surv2) 12648±8499 1714±1082 11.2±7.1
with local recurrence (Surv3) 2658±1996 71.2±41 749±689
Died o f  breast cancer (Surv4) 2898±897 27697±17042 108±64
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4.4 Discussion
The mRNA level of RGMB observed from tissue screening was higher in 
breast cancer tissues, compared to normal/background tissues. Moreover, RGMB 
mRNA level was higher in the more aggressive breast cancer cell lines. This agrees 
with the expression analysis o f the clinical data, where the transcript levels o f RGMB 
were significantly higher in breast cancer tissues than in normal/background tissues 
as verified by RT-QPCR. Interestingly, only RGMB was detected in the breast cancer 
cell lines, whilst RGMA and C had no visible expression at the mRNA level. In 
addition, the protein levels o f RGMA and RGMC showed no significant differences 
between normal and tumour breast tissues. Therefore, RGMB might be tentatively 
identified as an important factor contributing to the progression o f human breast 
cancer, a role unique to this member o f the RGM family of proteins.
No significant difference was shown from the data analyzed using predicted 
prognosis of patients, by indicators such as NPI, TNM staging and tumour grade. 
Trends indicated that increased RGMB expression was associated with higher NPI 
status and tumour grade, i.e. more aggressive breast tumours. The patients with good 
survival status (remaining disease free after 120 months) had higher RGMA levels 
than those with poor prognosis (local recurrence, metastatic disease or patients who 
had died from breast cancer). Therefore, RGMA might be perceived to have a more 
protective role against the progression o f human breast cancer.
In conclusion, RGMB might function as a key factor in breast cancer related to 
the disease progression if only inferred from the differences in expression pattern
between the normal breast and breast cancer tissues. RGMA and RGMC was not 
detected in the breast cancer cell lines and appeared to have little correlation with 
patient prognosis. Although the RGMA showed a putative beneficial correlatsion 
with disease progression, its expression was very low in both normal and tumour 
tissues (as observed from IHC staining) and there were no statistical differences 
between tissues (Q-PCR analysis). These data offer an intriguing glimpse o f how the 
RGM family might operate in human breast cancer, indicating that a further 
investigation of the role o f RGMB in breast cancer was necessary. The high 
expression of RGMB in many human breast cancer cell lines, lends itself to a 
knockdown study.
Although the expression profile o f RGMs in breast and prostate cancer cell 
lines (described in chapter 3) and human tissues is only a preliminary study which is 
not sufficient to reveal the role o f RGMs in cancer, this nonetheless indicates that a 
comprehensive study should be carried out. For a further study, two cell lines were 
chosen, PC-3 (prostate cancer) and the MDA-MB-231 (breast cancer), to create the 
RGMs knockdown variants, due to their strong expression of RGM and highly 
aggressive phenotype. The role o f RGMA, B and C in breast cancer and prostate 
cancer will be explored in the following chapters.
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Chapter 5
Knockdown of RGMs in prostate 
cancer cells and the influence on 
cellular functions
1 7 9
5.1 Introduction:
As mentioned in chapter 3, RGMs were detected in many prostate cancer cell 
lines and prostate tissues. Furthermore, RGMB and RGMC showed stronger staining 
in more aggressive prostate cancer tissues compared to the prostate specimens with 
less Gleason scores. The aberrant expression of RGMs in prostate cancer indicated an 
interesting role RGMs might have.
In addition, RGMs were reported as co-receptors of BMPs, while BMPs are 
key factors that have profound impact on prostate cancer and bone metastasis. BMPs 
were implicated in prostate cancer through regulation on the BMP signalling pathway 
activated by BMPs. For example, BMP-7 and BMP9 inhibit the proliferation o f PC-3 
prostate cancer cells via inducing apoptosis through BMP receptors and Smad- 
dependent pathway (Miyazaki et al., 2004; Ye et a l, 2008), while BMP-10 inhibits 
the growth o f prostate cancer cells via Smad independent signalling in which XIAP 
and ERK1/2 are involved (Ye et al., 2009). These BMPs can also prevent prostate 
cancer cell migration and invasiveness. Therefore, RGMs might also be involved in 
the prostate cancer development and metastasis through the participation in BMP 
signalling pathway.
As described in Chapter 3, all 3 RGMs are expressed in prostate cancer cell 
lines. To investigate the role o f RGMs in prostate cancer, the present study 
successfully knocked down RGMA, B and C in PC-3 cells, a cell line originally 
derived from prostate bone metastasis. Using these genetically modified cells, in vitro
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cellular function assays were conducted to explore the role of RGMs in prostate 
cancer.
5.2 Materials and methods
5.2.1 Materials
Polyclonal goat anti-RGMA, anti-RGMB and anti-RGMC antibody were obtained 
from Santa Cruz Biotechnology (Santa Cruz, California, USA). All the primers used 
are shown in table 2.1.2 and were synthesized and provided by Invitrogen (Paisley, 
UK). The cell line PC-3 used in this study was routinely maintained in DMEM-F12 
medium supplemented with 10% fetal calf serum and antibiotics.
5.2.2 Generation of RGM ribozyme transgenes
RGMA, B and C expression were knocked down in PC-3 using anti-human 
respective hammerhead ribozyme transgenes which were described in section 2.5.1. 
The transgenes were generated through touchdown PCR and cloned into pEF6/His 
TOPO mammalian expression plasmid vectors (Invitrogen Inc., Paisley, UK). 
Control empty plasmid vectors and the ribozyme transgenes were then transfected 
into PC-3 cells and the cells underwent selection with 5pg/ml blasticidin for 
approximately two weeks, and knockdown of specific RGM were then confirmed 
before further use.
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5.2.3 Real Time Quantitative PCR
The real time quantitative PCR was carried out to determine the levels o f RGM 
transcripts in the control and RGM knockdown cells. The protocol and primers used 
for RGMs quantitation and housekeeping GAPDH were listed in section 2.1.2 and 
2.3.5.
5.2.4 Protein extraction, SDS-PAGE and Western blot analysis
Protein was extracted following cell lysis using lysis buffer listed in section 2.1.4. 
The protein concentration was then quantified using the DC Protein Assay kit (BIO­
RAD, USA) and a spectrophotometer (BIO-TEK, ELx800). Equal amounts o f protein 
from each sample were loaded onto 8% polyacrylamide gel and following SDS- 
PAGE, the proteins were transferred onto nitrocellulose membranes subjected to 
blocking, and probing with the specific primary (1:200), and the corresponding 
peroxidise-conjugated secondary antibodies (1:2000). The protein bands were 
eventually visualized using the SupersignalTM West Dura system (Pierce 
Biotechnology, USA). Detail is described in section 2.4.
5.2.5 In vitro cell growth assay
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The cells were seeded into a 96 well plate at a concentration of 3,000 cells per well, 
and incubated for periods of up to 5 days. The cells were then stained with crystal 
violet, and measured the absorbance. The results were shown as growth rate which 
was calculated by normalization against the base absorbance measurements at day 0.
5.2.6 In vitro cell-matrix adhesion assay
45,000 cells were seeded onto the 96 well plate coated with Matrigel basement 
membrane in 200pl o f normal medium and incubated for 40 minutes. After wash, 
adherent cells were fixed and visualized under the microscope under x40 objective 
magnification and random fields counted.
5.2.7 In vitro cell invasion assay
Transwell inserts (upper chamber) with an 8pm pore size were coated with 50 
pg/insert o f Matrigel and air-dried, before being rehydrated with normal medium. 
Then, 2x104 cells were added to each well. After 72 h, cells that had migrated to the 
other side o f the insert through the matrix were fixed and stained with 0.5% (w/v) 
crystal violet. The invaded cells stained with crystal violet were counted under 
microscope.
1 8 3
5.2.8 In vitro ceil motility assay using Cytodex-2 beads
Cellular motility was assessed using a cytodex-2 bead motility assay. 5 x 105 cells for 
each cell type were incubated in 10ml of growth medium containing lOOpl of 
cytodex-2 microcarrier beads (GE Healthcare, Cardiff, UK) for 3.5 hours to allow the 
cells to adhere to the beads. After washing the beads were resuspended in growth 
medium, seeded into a 24 well plate and then incubated overnight at 37°C. Cells that 
had migrated from the beads and adhered to the base of the well were fixed in 4% 
formaldehyde (v/v), stained with 0.5% crystal violet (w/v) and counted under x40 
objective magnification.
5.2.9 ECIS-based migration assay
We used the electric cell-substrate impedance sensing (ECIS) system (Applied 
Biophysics, Inc., Troy, NY) to conduct the attachment and wounding assay. PC-3 
cells were cultured in 8W1E ECIS arrays (Applied Biophysics). PC-3 cells were 
seeded at a density o f 70,000 cells/well in the arrays. The cells were incubated for 4 
hours and the resistance was recorded every 20 seconds. Cell migration was assessed 
by continuous resistance measurements for 30 hrs after applying an elevated voltage 
pulse.
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Statistical analysis
Normally distributed data was analyzed using the two sample T-test while non- 
normally distributed data was analyzed using the Mann-Whitney and Kruskal-Wallis 
tests.
5.3 Results:
5.3.1 Construction of ribozyme transgene targeting at human RGMs and 
knockdown in PC-3 cell line
To test the potential role o f RGMs in prostate cancer cells, the following cell 
variants from the established cell lines were created: RGM (A/B/C)-knockdown PC-3 
prostate cancer cell lines using the ribozyme transgenes specific to human RGMs. 
The ribozyme transgenes (ribzymel, 2 and 3) targeting RGMA, RGMB and RGMC 
respectively were generated through touchdown PCR (Figure 5.3.1.1). The RGM 
ribozymes were inserted into vector and cloned into bacteria (Figure 5.3.1.1). The 
colonies positive for the ribozyme were selected to extract the plasmid used for cell 
line transfection (Figure 5.3.1.1). As shown in Fig.5.3.1.2 and 5.3.1.3, despite the 
empty plasmid control PC-3 cells being positive for RGMs, RGM ribozyme 
transgenes successfully reduced up to 98% o f the expression of RGMs in the prostate 
cancer cells at transcript level (Fig.5.3.1.3) or markedly reduced from protein level 
(Fig.5.3.1.2). (RGMA rib3, RGMB rib l, RGMC rib3 were chosen)
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.
Figure 5.3.1.1 The generation of ribozyme transgenes specific to RGM
The ribozyme transgenes (ribzymel, 2 and 3) targeting at RGMA, RGMB and RGMC 
respectively was generated through conventional PCR (first line). The RGM ribozymes were 
inserted into vector and cloned into bacteria. The colonies positive (positive band followed 
by one negative band) for the ribozyme were selected (second line) following by the plasmid 
extraction. The quality of the plasmid extracted was shown in the third line.
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RGMs Knockdown in PC-3
PC-3
RGMA
pEF RGM 
Control Knockdown
pEF RGM 
Control Knockdown
pEF RGM 
Control Knockdown
RGMB RGMC
GAPDH
Figure 5.3.1.2 The expression o f RGMs in genetic manipulation of PC-3
Western blotting demonstrated reduced expression of RGMA, RGMB and RGMC (protein) 
in the respective RGM knockdown cells, compared to empty pEF6 plasmid control cells 
(upper panel). GAPDH was included as an internal control, (lower panel)
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Figure 5.3.1.3 The expression of RGMs in genetic manipulation of PC-3
The knockdown of RGMs was verified by real time quantitative PCR. (Left)The RGMA was knocked down (Mean±STD. 1.05E+05 ± 1.20E+04) 
98% from control cells (5.76E+06 ± 1.05E+06). (p=0.007)
(Middle) RGMB expression was reduced 30% from PC-3 control cells (2.92E+06 ± 0.6E+06) in cells transfected with RGMB ribozyme 
(2.06E+06 ± 0.5E+06), though P value is 0.15.
(Right) RGMC was eliminated 73% from PC-3 cells (6.42E+01 ± 111) compared to control cells (2.39E+02 ± 404), though P value is not 
significant (0.51) due to the big variances.
Expression levels shown were normalized using the level of housekeeping gene GAPDH.
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5.3.2 Influence on cell-matrix adhesion by knockdown of RGMs in 
prostate cancer cells
Using these genetically modified cells, in vitro cell function analysis was 
conducted. The matrix adhesion assay (n=6) and the attachment assay of ECIS (n=4) 
were used to verify the ability o f cells adhere to the membrane surface. In the 
adhesion assay, reduced expression o f RGMs (RGMA, B and C) in these cells 
rendered the cells more readily to adhere, compared to the control cells. The number 
o f cells adhered to matrix for PC-3ARGMA (Mean ± Std. 26.93±13.23), p c -3 argmb 
(30.67±12.43), PC-3argmc (30±12.43) were increased, compared to pc-3pEF/His 
(16.67±8.09) (p=0.028 for RGMA, p=0.003 for RGMB and p=0.005 for RGMC) 
(Fig.5.3.2 A l).
The Attachment assay using ECIS displayed the highest speed o f RGMB 
knockdown cells to attach: all the three RGM knockdowns cells showing a higher 
rate of adherence than pEF control (Fig.5.3.2 A2 left). When comparing the RGMs 
knockdown cell lines with control cells based on the normalized data at same time 
point obtained in individual experiments, the average increased impedances which 
represent the increased attachment o f cells in RGMA knockdown cells were (Mean ± 
SEM) 0.83±0.56 and RGMB knockdown cells were 10.78±4.82 and RGMC 
knockdown cells were 0.23±4.00 (Fig.5.3.2 A2 right). However, only RGMB 
knockdown showed the significance at this time point (p=0.01, while p=0.64 for 
RGMA and p=0.93 for RGMC).
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Taken together, the knockdown o f RGMs in PC-3 cells enabled the cells to 
become more adhesive (Figu.5.3.2 A for three respective RGM knockdown cells). 
Three independent experiments were performed.
5.3.3 Effect on in vitro growth of prostate cancer cells by RGMs
Using the same cells, I further tested the rate of cell growth over a 5-day period 
(n=6). Three independent experiments were performed. The representative data of 
Day 3 was shown here (Fig.5.3.2B). Compared to control cells (2.03±0.17), RGMA 
knockdown cells (2.23±0.16) did not showed a signficant difference in the rate o f cell 
growth (p=0.07). In contrast, RGMB knockdown (Mean ± Std. 2.70±0.30) and 
RGMC knockdown (2.89±0.73) cells showed a signficant increase in cell growth, 
compared to the pEF control cells (p<0.01 RGMB vs pEF, p=0.02 RGMC vs pEF). 
This indicated cells that had lost RGMs by way of ribozyme transgenes displayed a 
faster rate o f growth, compared with cells transfected with control vectors on the 
Day3 (Fig.5.3.2 B).
5.3.4 Effect on in vitro motility and mobility of prostate cancer cells by 
RGMs
Furthermore, the three RGM knockdown cells all displayed an increased motility, 
when counting the cells moved from beads to matrix in a fixed period (Fig 5.3.2 C). 
Cells with RGM knockdown displayed a higher motility rate after wounding 
examined by cytodex-2 beads motility assay (n=6). The number o f migrated cells in 
RGMA knockdown was 36±9.2 (Mean ± Std.), in RGMB knockdown was 46.4±7.06,
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and RGMC knockdown was 45.54±28.46, compared with 20.2±4.06 in pEF control 
cells. However, only the increase in the RGMB knockdown cells was statistically 
significant (p<0.01).
Using the ECIS based cell migration assay (n=4), the migration rate is obviously 
much higher o f PC-3ARGMB cells among these cell lines, while the RGMA and RGMC 
knockdown has no significant difference compared with pEF control (Fig.5.3.2 D 
left). When comparing the normalized data at the comparable time point, the average 
impedance in RGMB knockdown cells was significantly higher than the pEF control 
cells (74.6±7.07 vs 13.37±23.71, RGMB vs pEF, p=0.009). However, the RGMA 
and RGMC knockdown cells did not show such significance when comparing with 
pEF control cells (p=0.94 and p=0.22 respectively) (Fig.5.3.2 D right). This is thus 
consistent with the observations made with the carrier beads assays.
5.3.5 Effect on in vitro invasion of prostate cancer cells by RGMs 
knockdown
The in vitro invasion assay was also utilized to further investigate the effects on 
invasion caused by RGM knockdown cells. The number o f invaded cells though 
matrix after RGMA knockdown (Mean ± Std. 29.71±5.53), RGMB knockdown 
(29.43±6.70) and RGMC knockdown (29±6.45) were almost similar to the pEF 
control (31.4±5.13) cells (p=0.6 RGMA vs pEF, p=0.59 RGMB vs pEF, p=0.52 
RGMC vs pEF) (Fig.5.3.2 E). Although the profound effect has been shown by 
RGMs in cell adhesion and mobility, the genetic modification did not seem to alter 
the PC-3 cells’ property o f invasiveness (n=7).
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Figure 5.3.2 A l: Impact o f RGM knockdown on PC-3 cell-matrix adhesion
Matrix Adhesion in PC-3ARGMs cells (reduced RGMs expression) were increased, as 
demonstrated by the cell-matrix adhesion assay. Significantly higher number of PC-B^0^  
(26.93± 13.23), PC-3ARGMB(30.67± 12.43), P C ^ ™ 0 (30± 12.43) cells adhered to cell matrix, 
compared to PC-3pEF/His (16.67±8.09). * P < 0.05 vs PC-3pEF/His.
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Figure 5.3.2 A2: Effects o f RGM knockdown on cell-matrix adhesion.
Attachment of PC-3 control and RGM knockdown cells to the ECIS central electrode over a 
4-hour period. pc-3ARGMB cells were the quickest to attach, with subtle increases in RGMA 
and C knockdown compared to control cells. The time interval was every 20 seconds per 
time point. More than three independent experiments were conducted and the representative 
data was displayed (left).
The mean normalized impedance at the comparable time point (1169) was shown in the 
graph (right side), calculated from the individual experiments. The error bars represented SE 
Mean of these experiments. The increased impedance in RGMA knockdown was 0.82±0.56, 
while RGMB was 10.78±4.82 and RGMC was 0.23±4.0, based on pEF control cells (p=0.64 
for RGMA vs pEF, p=0.01 for RGMB vs pEF, p=0.93for RGMC vs pEF). * P < 0.05 vs PC-
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Figure 5.3.2 B. Impact o f RGM knockdown on cell growth.
Absorbance of Day 3 is shown, which represented cell density. The reduction of RGMB and 
C in PC-3 significantly promoted growth rate (2.69±0.30, 2.89±0.73 respectively), compared 
to control cells (2.03±0.17) (p < 0.05). The growth of PCO ^01^  was also subtly increased 
(2.23±0.17), while p is 0.07. More than three independent experiments were conducted and 
representative data was displayed. * P < 0.05 vs PC-3pEF/His.
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Figure 5.3.2 C. Impact o f RGM knockdown on motility
Cell migration following RGM knockdown was assessed using the cytocarrier bead assay. 
Although the higher average values were seen to be increased compared to the control cells 
(20.2±4.06) in PC-3ARGMA (Mean±SEM 36±9.2) and (45.54±28.46), only the
motility of p c o ^ 01^  (46.4±7.06) was found to be significantly higher (p=0.005). The graph 
shows means values of the repeated experiments and the error bars present the standard error 
of the mean. * P < 0.05 vs PC-3pEF/Ws.
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Figure 5.3.2 D. ECIS analysis o f  the impact o f RGM knockdown on cell migration.
In an ECIS-based wounding assay, PC-3ARGMB cells showed a marked increase in 
migration (left). The experiments were repeated three times. The time interval was 20 
seconds per time point. The mean o f normalized impedance at the comparable time 
was calculated based on individual experiments and shown in the graph (right). Two 
sample T-test was used to identify significance levels. Error bars represent the 
standard errors o f the mean. Only RGMB knockdown cells showed a significant 
difference compared to control cells.
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5.4 Discussion
The current study generated ribozyme transgenes targeting the RGMs and 
tested the impact o f genetically manipulating expression o f RGM in a prostate cancer 
cell line on the biological behaviour o f these cells, assessed by changes in the growth, 
adhesion, invasion, motility and migration.
The RGMs were all found to be expressed in PC-3 prostate cancer cells. In this 
study, ribozyme methodology was employed to genetically reduce/knockdown the 
expression o f RGMs in PC-3 cells, the success o f which was confirmed using mRNA 
and protein analyses. The loss o f RGMs by way of hammerhead ribozyme transgenes 
resulted in accelerated cell growth and enhanced adhesion in vitro. Interestingly, the 
effects on cellular behaviour were most significant in RGMB knockdown cells. The 
knockdown of RGMB significantly enhanced the prostate cancer cell capacity, 
namely increased growth, adhesive, motility and mobility. RGMC knockdown did 
not significantly affect cell motility and mobility, however, had a considerable effect 
on cell growth.
This indicated that RGMs (especially RGMB) are associated with inhibitory 
effects on tumour cell growth. The expression of RGMB may also induce a decreased 
capacity for PC-3 cells to attach to the basement membrane. The present study has 
also demonstrated that loss o f RGMB resulted in more in vitro motility and mobility, 
compared with control cells. An increase in RGMB expression might inhibit prostate 
cancer cells ability to leave the primary tumour and migrate and attach to the matrix 
membrane o f metastatic site. That indicated the RGMB may play a key role in the
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control o f the aggressiveness o f prostate cancer via mechanism(s) yet to be identified. 
Hence, RGMB may be a potential anti-metastasis molecule, which is o f critical 
importance in the development o f prostate cancer therapies.
The inhibitory role o f RGMs might be contrary to the expression postulated 
from the in prostate cancer specimens (IHC staining in Chapter 3). RGMA showed 
little difference in staining intensity between the tumour and normal prostate tissues. 
However, it is interesting to note that RGMB and C had a week protein staining in 
prostate cancer cells cytoplasm and in the nearby stroma and stromal cells. Thus, it is 
presently challenging in linking the pattern of tissue expression and the cell fuction 
tests. Therefore, the mechanism o f the RGMs in vitro need be investigated further to 
confirm their effects on tumour.
Presently, it is not entirely clear by which mechanism RGMs mediated the 
biological behaviours o f prostate cancer cells. We have developed hammerhead 
ribozyme transgenes targeting the three RGMs. Further studies will utilize the 
ribozyme constructs to investigate the role o f RGMs in human breast cancer cells. 
Moreover, further investigation o f RGMs and the signal transduction o f BMPs will 
be investigated in the following chapters.
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Chapter 6
The knockdown of RGMB in breast 
cancer and influences on cellular 
behaviours
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6.1 Introduction:
As previously described, the RGMB had aberrant expression in breast tissues 
and the transcript level o f RGMA might be associated with good prognosis. However, 
all the RGMs showed no obvious staining difference o f protein in the breast tissues. 
Due to the interesting expression pattern that the RGMs showed in the tissues from 
the breast cancer patient cohort and the association o f RGMs with clinical prognosis, 
the present study went on to investigate further the role of RGMB in human breast 
cancer. To date, there have been no reports on either the expression profile or 
possible role o f this protein in any cancer type.
BMPs as RGM ligands have been implicated in the breast cancer and bone 
metastasis. However, in some cases, BMP has been shown to play a dual role in these 
disease processes. For example, the same BMP ligand within the same cancer type 
seems to act differently depending on the study and the types o f analyses and can be 
both promotion and inhibition o f breast cancer progression. BMPs are also critical 
during epithelial-mesenchymal transition (EMT), via which they may contribute to 
the metastatic process (Alarmo et al., 2008; Alarmo et al., 2009; Buijs et al., 2007a; 
Cassar et al., 2009; Takahashi et al., 2008). RGMs which were involved in the BMP 
signalling might also have impact on breast cancer through regulation on BMP 
signalling pathway or target genes by themselves. However, there have been no 
reports concerning their implications in cancer spreading. Therefore, our study aimed 
to be the first to characterise the role o f RGM in human breast cancer.
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It was found that only RGMB was expressed in human breast cancer cell lines, 
whereas little or no expression o f RGMA and RGMC at mRNA and protein levels in 
these cells, fiowever MDA-MB-435s cell was an exception in that all three RGMs 
were detected. Currently, there is a controversy as to whether the cells is indeed a 
breast cancer cell line. A few recent studies reported that the cell line may have been 
a cell line developed from (or mixed with) a metastatic cell line from melanoma 
(Ellison et al., 2002; Ross et al., 2000). Thus, MDA-MB-435 cells were not used in 
the present study for this reason. The transcript level o f RGMB was higher in breast 
tumour than in normal breast tissues. However, results did not indicate that the 
difference in expression were associated with poor prognosis. It appeared from our 
initial data that RGMB may play an important role in breast cancer, a role which 
might make it distinct from the other RGM family members. We decided to create 
RGMB knockdown in the human breast cancer cell line MDA-MB-231, a cell with 
an extremely aggressive phenotype The impact of loss o f RGMB on breast cancer 
cell behaviour in vitro was subsequently investigated, in order to further reveal the 
potential role o f this protein in human breast cancer.
6.2 Materials and methods
6.2.1 Establishment of MDA-MB-231 RGM knockdown variants
RGMB expression was knocked-down in MDA-MB-231 using anti-human RGM 
hammerhead ribozyme transgenes which were generated through touchdown PCR
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and described in chapter 5. Control empty plasmid vectors and the ribozyme 
transgenes were then transfected into MDA-MB-231 cells and the cells underwent 
selection with 5pg/ml blasticidin for approximately two weeks before further use.
6.2.2 RNA isolation and RT-PCR
RNA isolation and RT were carried out as described in previous chapters. This was 
then used as a template for PCR.
6.2.3 Protein extraction, SDS-PAGE and Western blot analysis
Protein was extracted following cell lysis using lysis buffer listed in section 2.1.4. 
Equal amounts o f protein from each sample were loaded onto 8% polyacrylamide gel 
and following SDS-PAGE, the proteins probed with the specific primary (1:200), and 
the corresponding peroxidise-conjugated secondary antibodies (1:1000). Protocol is 
described in section 2.4.
6.2.4 In vitro cell function assays
The in vitro cell growth, adhesion and invasion assay and ECIS-based attachment 
assay were carried out as described in chapter 5. A wounding/m igration assay was
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also used to assess the migratory properties o f the breast cancer cells. This technique 
has been modified from a previously described method (Jiang et al., 1999). Cells 
were grown upon reaching confluence the monolayer of cells was scraped with a 21G 
needle. The wound was tracked and recorded using a CCD camera attached to a 
Lecia DM IRB microscope (Lecia GmbH, Bristol, UK) through taking pictures every 
15mins over a 90 minute period. The distance cell migrated was measured and 
converted into pm. The distance that the wound fronts had migrated into the wound 
at each time point could then be determined based on the start time point.
Statistical analysis
Normally distributed data was analyzed using the two sample T-test while non- 
normally distributed data was analyzed using the Mann-Whitney and Kruskal-Wallis 
tests.
6.3 Results
6.3.1 Knocking down of RGMB in human breast cancer cells.
To investigate the role o f RGMB in breast cancer, MDA-MB-231 cells were 
used which had high levels o f expression o f RGMB. The wild type MDA-MB-231
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cells are highly aggressive cell line derived from metastasis of invasive breast ductal 
carcinoma. The specific ribozyme transgene targeting at RGMB (as used in the 
prostate cancer study) were utilized for genetically reducing the expression o f RGMB 
in MDA-MB-231 cells (MDAargmb). To reiterate our earlier results, it was 
confirmed that RGMA and RGMC were not expressed in MDA-MB-231 wild type- 
cells (as cell line screening).
As shown in Fig.6.3.1.1, the expression of RGMB mRNA was completely 
eliminated from MDA-MB-231 cells by the ribozyme transgene, in comparison to the 
level of expression seen in the wild type (MDAWT) cells and MDA-MB-231 empty 
plasmid control (MDApEF/Hls) cells.
It was also determined if there was a reduction o f protein levels in the 
(MDAargmb) cells following knockdown o f RGMB. Western blot analysis was used 
as shown in Fig.6.3.1.2. There was a significant reduction of RGMB protein in 
MDAargmb cells, in comparison to the MDApEF/Hls.
Immunocytochemical (ICC) staining o f RGMB in these transfected cells also 
confirmed the successful knockdown of RGMB. The staining o f RGMB protein in 
MDApEF/His cells was markedly stronger than in the cells transfected with RGMB 
ribozyme. As shown in the Fig.6.3.1.3, the staining of the protein in the MDApEF/Hls 
was mainly confined in the cytoplasm, while the staining in the RGMB knockdown 
cells was obviously reduced.
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Figure 6.3.1.1 The mRNA level of RGMB in wild type MDA231 and the cells 
transfected with pEF empty plasmid and RGMB ribozyme.
The RGMB expression was elim inated from m R N A  level. The mRNA o f  RGM B detected in 
the RT-PCR is 536 bps.
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Figure 6.3.1.2 The RGMB expression was reduced in RGMB knockdown cells from 
protein level compared to the control cells, proved by western blot.
The size of RGMB protein shown in the result is 47.5 kDa. The ladder was indicated on the 
right.
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Figure 6.3.1.3 ICC staining o f RGMB proteins in RGMB knockdown cells and pEF 
control cells. The Staining of RGMB was reduced in RGMB knockdown cells, compared to 
control cells. Arrows indicate the staining of RGMB in the cytoplasm.
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6.3.2 Influence on cellular growth after knockdown of RGMB
The influence o f RGMB knockdown on cell proliferation was verified using in 
vitro growth assay (n=6). Cell growth was significantly increased in MDAargmb 
(Mean±STd. 170.92±34.90) (absorbance) on Day 3, compared to MDAWT 
(128.41±15.07, P=0.02) and MDApEF/His (127.66±7.28, P=0.01). There was also a 
marked increase in cell growth on Day 5 in MDAargmb (461.65±75.16), PO .Ol vs 
MDAwt 303.43±48.07 and MDApEF/His 311.74±44.72. Three independent 
experiments were performed (each with n=6) and the representative data presented 
here (Fig.6.3.2 A).
This suggested that knockdown o f RGMB in MDA-MB-231 cells promoted 
their growth rate during 5 days incubation.
6.3.3 Impact of RGMB knockdown on invasion in vitro
The invasiveness o f M DA-M B-231 cells was also determined using an in vitro 
invasion assay after knockdown o f RGMB (n=6). The loss o f RGMB had no 
significant effect on the invasiveness o f MDA-MB-231 cells. Although the number 
of cells invaded for MDAargmb (Mean±STd. 176.33±33.08) was increased, compared 
to MDApEF/Hls (138.67±94.51), the increase was not reached statistical significance 
(P=0.54) (Fig.6.3.2 B). The increase o f invasion in RGMB knockdown cells was also 
not significant comparing with the MDA-M B-231 wild type cells.
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6.3.4 The influence of RGMB knockdown on adhesion
The effect o f elimination of RGMB in MDA-MB-231 cells on cell-matrix 
adhesion, was assessed using an in vitro adhesion assay (n=6). (Fig.6.3.2 C). The 
absorbance o f adhered MDAargmb cell was significantly increased (1.33±0.15), 
compared to MDApEF/Hls (0.85±0.09) (p<0.001). The absorbance o f RGMB 
knockdown cells was higher than it in wild type cells (0.76±0.16), which was also 
significant.
Moreover, the ability o f MDAargmb cells to attach to the electrode surface was 
also faster than control cells, using the ElCS-based attachment assay, however, the 
increase was not as significant as the cell-matrix assay (Fig.6.3.2 D left). When 
comparing the MDA-MB-231 pEF with RGMB knockdown cells at the final time 
point, the resistance o f RGMB knockdown cells (Mean ± SEM 225.258±42.25) is 
higher than pEF control cells (168.275±22.62), although the increase did not reach 
statistical significance, as p=0.055.
6.3.5 The effect of RGMB knockdown on migration assay
The reduced RGMB expression was found to affect the mobility o f MDA-MB- 
231 cells in the wounding assay (Fig.6.3.2 E). The healing and migration speed of 
MDAargmb after wounding (the middle o f the pictures) was obviously higher 
compared to the control cells (Fig.6.3.2 E left). More than three points at the front
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edge were measured under microscope (Fig.6.3.2 E right) and converted to the 
migrated distance based on the Time 0. The MDAargmb cells migrated 83.89 pm at 
the final time point (120 minutes) while the highest migration distance o f pEF control 
cells was 24.93 (p=0.005). The experiments were repeated three times and the 
representative data was displayed here.
2 1 1
0D ay3
^Day5
Mean (D3/D5) St.D (D3/D5) P value (vs RGMB KO, D3/D5)
RGMB rib 170.92/461.64 34.90/75.16 —
pEF 127.65/311.74 7.28/44.72 0.020/0.002
WT 128.41/303.43 15.07/48.07 0.014/0.001
Figure 6.3.2 A RGMB knockdown on cell growth in breast cancer
The growth rate of MDA231 cells over 3 and 5days period was increased after the loss of 
RGMB, compared to wild type and empty plasmid control cells. Table on the bottom 
displays statistical information of the analyses. The growth rate was calculated based on the 
data of Day 0. Three experiments were carried out and representive data shown. Two-sample 
T-test was used to determine significance levels.
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RGMB rib 176.33 33.08 —
pEF 138.67 94.50 0.53
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Figure 6.3.2 B RGMB knockdown on invation of breast cancer cell.
No significant difference was seen between the invasiveness of the control cells and RGMB 
knockdown cells. The number of cells invaded through the matrix has no significant 
differences between the RGMB knockdown and control cells. Table on the bottom displayed 
statistical information of the analyses. Three experiments were carried out and representive 
data shown. Two-sample T-test was used to determine significance levels.
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Figure 6.3.2 C RGMB knockdown on matrix adhesion of breast cancer cells.
The adhesive capacity was markedly increased in RGMB knockdown cells, compared both to 
wild type and pEF control cells. Table on the bottom displayed statistical information of the 
analyses. Three experiments were carried out, and the representive data were shown. Two- 
sample T-test was used to determine significance levels.
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Figure 6.3.2 D ECIS-based attachment assay.
The experiments were repeated more than three times and the left graph showed the mean of 
normalized impedance at comparable time point. The attachment of RGMB knockdown cells 
was also increased, although this was not significant when comparing the final time point, 
p=0.055. Two sample T-test was utilised at that time point. (Right panels) The standard 
errors of the individual experiments at each time point (part of the curve).
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Figure 6.3.2 E Migration o f  RGMB knockdown cells.
The left showed the distance of the cells moved after wounding measured at more than three 
consistent points every 15 minutes. The migration speed of MDA-MB-231 cells was 
markedly increased after RGMB knockdown (p=0.005 comparing at the final time point, 
using two sample T-test). The error bars displayed the standard deviation at each time point. 
The right showed the pictures taken under microscope at the beginning and the end.
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6.4 Discussion:
The current study first successfully knocked down the expression o f RGMB in 
MDA-MB-231 cells, a highly aggressive cell line derived from invasive breast cancer, 
which had high endogenous levels o f RGMB, but negligible/no expression o f either 
RGMA orRGM C.
As demonstrated in Chapter 3, analysis o f the expression o f RGMB in human 
breast cancer tissues indicated that RGMB has a detrimental role in breast cancer. 
However, analysis of the biological functions of RGMB in human breast cancer cells 
as presented in this chapter contradicted the initial and clinical observations. It has 
been shown that the knockdown o f RGMB promoted MDA-MB-231 cell 
proliferation, adhesion and migration capacity in vitro, but have little effect on 
cellular invasion. These results indicated that RGMB has an inhibitory control on 
some phenotypic traits cellular o f MDA-MB-231 cells. RGMB might inhibit breast 
cancer cells growth and their ability to attach and migrate. The reasons for these 
differences remain unclear. It could be possible that there is involvement o f an RGM 
antagonist or any other mechanisms in vivo, that controls the function o f RGMB in 
human breast cancer, despite the higher levels o f RGMB expression. Furthermore, 
RGMs are indicated the co-receptors for BMP proteins. It is quite possible that the 
impact of RGMs on cancer and cancer cells should be read together with the presence 
and the status of BMPs and indeed other co-activing proteins. It would be necessary 
therefore, to confirm the effect o f RGMB in human breast cancer via further 
investigation o f the mechanisms that might be involved.
Interestingly, the unique effect o f RGMB in breast cancer showed a similar 
functional trait for RGMB as that observed in prostate cancer (shown in Chapter 5). It 
was therefore vital that further investigation of the mechanisms by which RGMs 
execute their functions be undertaken. The role of RGM in cancer might be 
associated with their participation in the BMP signalling pathways (Kanomata et al., 
2009a) which have been shown to be involved in the development o f metastatic 
breast cancer (Alarmo et al., 2008). The mechanisms by which RGMs are 
regulated/regulate other proteins in the BMP pathways are demonstrated in the 
following chapter.
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Chapter 7
The mechanisms underlying the impact 
of RGMB on cellular adhesion and 
motility in breast cancer
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7.1 Introduction
As discussed in the previous chapters, knockdown of RGMB played a 
prominent role in breast cancer promoting the adhesion and motility o f breast cancer 
cells (MDA-MB-231). In order to determine which mechanism may be related to 
these changes in cellular behaviour, the genes involved in these mediations in 
MDAargmb knockdown cells were further investigated.
Breast cancer and prostate cancer are mainly adenocarcinomas. Normal 
epithelium shows a strong and well-established network of cell-to-cell contacts that 
accounts for both the proper development and the functionality of epithelial 
structures. These cellular contacts greatly limit the ability of epithelial cells to move 
or migrate. During the last steps o f the process of tumour development, epithelial 
tumour cells lose this restriction, with an associated loss of epithelial characteristics 
(Guarino et al., 2007). Epithelial-mesenchymal transition or transformation (EMT) is 
a series of changes in cells characterized by loss o f epithelial phenotype such as cell­
cell adhesion (E-cadherin), and acquiring mesenchymal phenotype, such as N- 
cadherin and smooth muscle actin (SMA) which leads to more aggressive behaviour 
of cancer cells. Several transcription factors such as Snail, slug and twist, and RhoC 
have been indicated in the procedure o f EMT.
In the previous chapters, RGMB was also been shown to increase the adhesive 
ability o f cell-matrix attachment. The loss o f cell-cell contacts induced by EMT and 
the gain o f cell-matrix adhesion facilitate the tumour cells to leave original tumour 
site and attach to matrix surface o f metastasis site.
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Focal Adhesion Kinase (FAK), also known as protein tyrosine kinase 2 (PTK2), 
is a focal adhesion-associated protein kinase typically located at structures known as 
focal adhesions, and is involved in cellular adhesion and the cell spreading process. 
Focal adhesions are multi-protein structures that link the extracellular matrix (ECM) 
to the cytoplasm cytoskeleton. Additional components o f focal adhesions include 
paxillin, which is tyrosine-phosphorylated by FAK.
Considering the role o f RGMB in cell-matrix adhesion, the present study 
investigated the regulation o f these two candidate molecules (FAK and paxillin) 
which may be responsible for the increased adhesiveness o f human breast cancer 
cells by RGMB knockdown. Furthermore, the expression of EMT markers and these 
transcription factors was examined in MDA-MB-231 wild type and transfected cells, 
to explore the involvement o f EMT in the effects on cell mobility induced by RGMB 
knockdown. As the paramount role o f Snail is its involvement in EMT and cancer 
metastasis, it was o f great importance to discover that RGMB knockdown 
significantly increased the expression of Snail and to further investigate which signal 
pathway might be involved in this regulation.
RGMs have been reported to be co-receptors of BMPs (Kanomata et al., 2009a), 
while BMPs have been involved in cancer progression and bone metastasis. BMP7 
has been reported to promote MDA-MB-231 cells migration and invasion (Alarmo et 
al., 2009) and also associated with bone metastasis (Alarmo et al., 2008). However, 
BMP7 has also been reported to inhibit EMT via Smad-3 (Buijs et al., 2007a; Cassar 
et al., 2009). The regulation on the genes (Focal adhesion and EMT transcription 
factors) by RGMB might be associated with their involvement in BMP signalling
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pathways. The present study stimulates the cells with rh-BMP7 to investigate the 
regulation of RGMB knockdown on the target genes.
FAK has been reportedly regulated by TGF-p via Smad2/3 (Walsh et al., 2008). 
Snail also has been shown to be upregulated by TGF-p, possibly viaSmad2/3 or a 
non-Smad signalling pathway or via cooperation with Ras-MAPK signalling in 
NMuMG cells, although ERK/JNK is not involved (Miyazono, 2009). Therefore, in 
order to verify if the regulation o f FAK and paxillin expression is through the Smad- 
3 dependent pathway, the smad-3 activation was blocked in the transfected cells by 
treatment with SIS3 (specific inhibit smad-3) (3pmol/ml, 30 mins) (Jinnin et al., 
2006). The expression and activation profile o f downstream signalling molecules 
were examined.
2 2 2
7.2 Materials and Methods:
7.2.1 Materials
Recombinant protein BMP7 (rh-BMP7) was purchased from R&D Systems. Specific 
Inhibitor of Smad3 (SIS3) was purchased from Merck Chemicals Ltd.
7.2.2 Western blot and SDS-PAGE
Protein samples were loaded onto 8% or 10% polyacrylamide gel following SDS- 
PAGE, and probed with the specific primary (1:200), and the corresponding 
peroxidise-conjugated secondary antibodies (1:2000). Detailed procedure is 
described in section 2.4.
7.2.3 RT-PCR
RNA of the cells subjected to treatments was isolated following a protocol as 
described in Section 2.3. 0.5jng o f the isolated RNA was used for each reverse 
transcription reaction to synthes cDNA, which was as the template for PCR 
procedures.
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7.3 Results
7.3.1 Focal adhesion kinase (FAK) during ~RGMB mediated cell-matrix 
adhesion
The expression o f FAK and paxillin in RGMB transfected cells (not treated) 
was examined, to confirm the pro-cell-matrix adhesion effect caused by RGMB 
knockdown. As seen in Fig.7.3.1.1A, FAK and Paxillin expression were obviously 
increased by the RGMB knockdown MDA-MB-231 cells, which were further 
confirmed at mRNA level as shown in Fig.7.3.1.1BL This indicates that the loss of 
RGMB lead to upregulating the expression of FAK and Paxillin, probably at the 
transcription level.
To further test the role o f FAK and RGMB in cell-matrix adhesion, the cells 
were treated with rh-BMP7 (40ng/ml, 60mins). As shown in Fig.7.3.1.2, the total 
FAK and Paxillin expression were upregulated in the MDAargmb cells, compared to 
the control. After treatment with rh-BMP7, the protein levels o f these two molecules 
are to some degree increased, while the upregulation in MDAargmb cells was 
enhanced. This suggests the increase o f BMP7 might trigger the downstream 
signalling pathway which played positive role in the regulation on FAK expression.
After Smad-3 was blocked (SIS3 3pM, 30mins) (Fig.7.3.1.2), the upregulation 
of FAK was not eliminated but was instead increased. The activation of FAK 
(phosphorylated-FAK) was also tested in the same experimental setting. It was 
interesting to note that the phosphorylated FAK, p-FAK, showed a similar pattern to
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total FAK after treatment. This suggest that regulation of the target genes (FAK and 
Paxillin) by RGMB in breast cancer is unlikely through Smad-3 activation.
Therefore, I investigated the Smad-1 and Smad-3 phosphorylation in the 
transfected cells under these conditions. I found that RGMB knockdown slightly 
promoted Smad-1 and Smad-3 activation and that this effect is more obvious after 
treatment with rh-BMP-7 (40ng/ml, 30mins) (Fig.7.3.1.2, 7.3.1.3), However, after 
Smad-3 was blocked by SIS3 (3pM, 30mins), the phosphorylation of Smad-1 in 
RGMB knockdown cells was markedly increased, compared to control cells 
(Fig.7.3.1.3), while the Smad-3 pathway was partially maintained by RGMB 
knockdown (Fig.7.3.1.2), This indicated that BMP-7 might have the ability to 
activate both Smad-1/5/8 and Smad-3 pathways, by the participation o f RGMB 
knockdown. Altogether, when the Smad-2/3 pathway was blocked, RGMB 
knockdown facilitated BMP signalling through the Smad-1/5/8 dependent pathway.
The activation of Smad-1 after blocking of Smad-3 was consistent with the 
pattern of upregulation o f FAK and Paxillin in SIS3 treated RGMB knockdown cells. 
Taken together, the activation o f Smad-1 signal pathway by RGMB knockdown 
might be related to the stimulated FAK and Paxillin expression and activation. 
Additionally, the Smad-2/3 pathway triggered by BMP might not have significant 
effect on FAK and Paxilllin, as there was no obvious reduction in FAK and Paxillin 
levels after Smad-3 was blocked (comparison between the MDA-MB-23 l ApEF/Hls 
cells).
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Figure 7.3.1.1A The protein level of FAK and Paxillin in MDA231 cells transfected 
with empty plasmid and RGMB ribozyme.
The Paxillin and FAK protein levels were upregulated in RGMB knockdown cells. The 
arrows on the right showed the position of ladders.
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Figure 7.3.1.1 B mRNA level o f FAK and Paxillin in control and RGMB 
knockdown cells.
The conventional PCR result confirmed the RGMB knockdown induced the expression of 
FAK and Paxillin from mRNA level. NC: negative control.
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Figure 7.3.1.2 The pattern o f activated Smad-dependent pathway molecules in 
control and RGMB knockdown cells and the association with FAK and Paxillin 
expression.
The Smad-3-dependent pathway was activated by stimulation of BMP7 (40ng/ml, 30mins), 
which could be blocked by S1S3 (3jiM, 30mins). The upregulation of the expression of FAK 
and Paxillin and phosphorylated FAK (P-FAK) by RGMB knockdown was partially 
enhanced after BMP7 treatment (40ng/ml, 60mins)
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Figure 7.3.1.3 Activated Smad-1 levels in the transfected cells with treatment.
The activated Smad-1 level was upregulated in RGMB knockdown cells and this is enhanced 
in cells exposed to BMP7 (40ng/ml, 30mins) alone or with Smad-3 inhibitor (SIS3). This 
indicated the RGMB knockdown resulted in an enhanced Smad-1 dependent pathway. The 
graph shows the intensity quantification of P-Smad-1 against corresponding GAPDH bands.
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7.3.2 Influence of RGMB on the molecular events leading to EMT
As mentioned in the previous chapter, knockdown of RGMB significantly 
increased the motility o f breast cancer cell line MDA-MB-231, one o f the hallmarks 
of EMT. Here, it was further shown that the EMT regulators Snail, Twist, Slug and 
RhoC all showed higher mRNA level in MDA-MB-231ARGMB cells compared to pEF 
control (Fig.7.3.2.1),
As the important role o f Snail in EMT and Snail can be upregulated by TGF-p 
via Smad-2/3, to investigate whether Smad-3 signalling pathway of BMP participated 
in this, the phosphorylation o f Smad-3 was blocked in the RGMB transfected cells. 
However, I found that the mRNA level o f Snail was inversely increased after Smad- 
3 was inactivated (Fig.7.3.2.2), After knockdown of RGMB, Snail level was the 
highest in the cells with blocked Smad-3, indicating that Smad-3 may work as an 
inhibitory factor here and RGMB knockdown might inhibit these effects. Together 
with the activation profile o f Smads induced by RGMB knockdown as discussed 
above (Fig.7.3.1.2 and Fig.7.3.1.3), it was suggested that Snail was activated mainly 
by a Smad-1 dependent BMP signalling pathway in MDA-MB-231 cells and that the 
activation can be further enhanced by RGMB knockdown after smad-3 was blocked.
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Figure 7.3.2.1 The expression o f EMT regulators altered by RGMB knockdown in 
MDA-MB-231.
The Snail and Twist were significantly upregulated in MDA-MB-231 RGMB knockdown 
cells compared to the pEF control. NC: negative control.
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Figure 7.3.2.2 mRNA level of Snail in the transfected cells with treatment.
The RT-PCR (left) shows the Snail was upregulated 25% after RGMB was knocked down 
when calculating the intensity (right), which is enhanced after Smad-3 was blocked by SIS3 
(upregulated 50%).
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7.4 Discussion:
FAK and paxillin are known as integrin- and growth factor-associated tyrosine 
kinases promoting cell-matrix adhesion. It also has been shown that when FAK was 
blocked, breast cancer cells become less metastastic due to decreased mobility (Chan 
et al., 2009). The potential role o f FAK in cancer cells has lead to the recent 
development o f using anti-FAK small molecule in the treatment o f cancer. FAK 
activation elicits intracellular signal transduction pathways that promote the turn-over 
of cell contacts with the extracellular matrix, a key to cell migration. FAK also has a 
role in cell survival (Lim et al., 2008). As shown in our study, RGMB knockdown 
increased FAK and Paxillin expression and activation and increased the MDA-MB- 
231 cell's ability to adhere. It was proposed that the RGMB-FAK-matrix adhesion 
link may be associated with the regulation on BMP Smad-dependent pathway.
RGMB knockdown seems to activate Smad-1 and (partially) Smad-3 pathways, 
which was enhanced by BMP7 stimulation. More interestingly, Smad-1 dependent 
pathway was switched on after Smad-3 was blocked.
There has been little work to date carried out on the regulation o f FAK by
BMPs. However, FAK expression has been shown to be induced by TGF-0 via
Smad-2/3 or P38 in IEC-6 cells (Walsh et al., 2008). The increase o f FAK expression
in MDAargmb cells was not blocked by Smad-3 silence in our study, which suggests
the regulation on FAK is not due to the activation of Smad-3. However, we found
that in the MDA-MB-231 cells, FAK (p-FAK) and Paxillin expression levels were
elevated by BMP7. Moreover, RGMB knockdown mainly enhance the Smad-1
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dependent pathway and had relatively weaker effect on the Smad-3 signalling. The 
FAK and paxillin expression might be upregulated by RGMB knockdown in breast 
cancer cells and enhanced by paracrine BMP7 and these might be linked to the 
activated Smad-1 by RGMB knockdown (See Fig. 10.1).
Breast cancer progression is associated with aberrant DNA methylation and the 
expression of genes that control the epithelial-mesenchymal transition (EMT), a 
critical step in malignant conversion. Snail, the transcriptional repressors o f E- 
Cadherin was upregulated in the MDA-MB-231ARGMB cells which enabled the cells to 
lose cell-cell adhesion and increase their motility, possibly contributing to their 
metastatic phenotype. Through the stimulation of cell migration and invasion, cell- 
substrate adhesion, intravasation, and extravasation, as well as cell survival, tumour 
metastasis is also accelerated through immunosuppression during EMT induced by 
the transcription factor Snail. The preliminary data presented here indicate that 
knockdown o f RGMB is also associated with a rise in Snail, a transcription factor 
also known to be key to the EMT process. This interesting observation adds further 
evidence to the role o f RGMB in the regulation of cellular motility, which partly 
contributed to the EMT process. Although the Snail has been proved to be induced 
by TGF-p, there is no direct evidence to show that Smad-3 is required for the 
stimulation o f Snail. As it have been shown here, in breast cancer cells MDA-MB- 
231, the upregulaiton of Snail is not blocked by the inactivation o f Smad-3, but 
inversely increased. The mechanism involved might be similar to that in the 
regulation o f FAK and Paxillin.
Altogether, RGMB knockdown regulated the expression of target genes (FAK, 
Paxillin, Snail, c-Myc and Caspase-3 (see next Chapter)) greatly associated with 
involvement in BMP signalling pathway. The upregulation of FAK, Paxillin and 
Snail by RGMB knockdown, which possibly followed the activation of Smad-1 
dependent pathway, not only promote cell adhesion, motility and mobility, but also 
contribute to the cascade o f proteins involved in cell growth. It has been shown that 
FAK facilitates cell survival through enhanced p53 degradation (Lim et al., 2008) 
and involvement in regulation o f Bcl-2 (Bouchard et al., 2008). Snail also regulates 
on cell survival in cancer cells (Emadi Baygi et al., 2010; Ulianich et al., 2008). The 
mechanisms underlying the cell growth regulated by RGMB knockdown and the 
signalling pathway RGMB involved in will be continually discovered in the 
following chapter.
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Chapter 8
Mechanisms underlying the functions of 
RGMs in breast cancer proliferation
2 3 6
8.1 Introduction:
As discussed in the previous chapters, the knockdown of RGMB was found to 
significantly promote the proliferation of breast cancer cells (MDA-MB-231). 
Because o f the prominent role played by RGMB especially in breast cancer, the 
MDA-MB-231ARGMB knockdown cells were further investigated in order to determine 
what mechanism may be responsible for the changes in cellular behaviour observed.
RGMs were reported to be co-receptors o f BMPs (Kanomata et al., 2009a). 
However, in my present study, the knockdown of RGMB has been shown to switch 
on Smad-1 dependent pathway and this was enhanced by stimulation with exogenous 
BMP7. BMP7 has been reported to protect MDA-MB-231 cells from apoptosis 
(Alarmo et al., 2009) and also associated with bone metastasis in breast cancer 
(Alarmo et al., 2008). However, it has also been reported to induce MDA-MB-231 
cells death via Smad-3 (Buijs et al., 2007a; Cassar et al., 2009). Additionally, it has 
also been shown that BMP7 and oestrogen together can inhibit MCF-7 proliferation 
through suppressing p38 mitogen-activated protein kinase activation, but BMP7 alone 
does not alter cell growth (Takahashi et al., 2008). Although the exact role/function 
of BMP7 in breast cancer remains controversial, the available evidence still indicates 
that BMP7 is implicated in the tumour cell proliferation and cell death. The 
mechanism of RGMs regulation on tumour cell proliferation by the participation in 
BMP signalling remains unclear as the dual role o f BMPs played in cancer.
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Apoptosis, a key event in regulation o f cell population, may be involved in the 
effect of RGMB knockdown on cell growth was first investigated in current study. It 
has been proved that the marked effect was due to an anti-apoptotic effect with subtle 
regulation on cell cycle. As Caspase-3 is an executioner caspase indicative o f end- 
stage apoptosis, the level of caspase-3 was examined in these transfected MDA-MB- 
231 cells. The gene (c-Myc) which might have effects on cell apoptosis and cell cycle 
was further investigated.
RGMB knockdown has been found to be involved in the BMP Smad-dependent 
signalling pathways, as described in the previous chapters. Additionally, the impact 
o f RGMB on Smad-independent pathways was also investigated in this study, while 
the Smad-independent pathway has been shown to be associated with the regulation 
of apoptosis, where the ERK, p38 and JNK pathways amongst the key regulation 
events (Cocolakis et al., 2001; Hassan et al., 2005; Iyengar et al., 2006; Kumar et al., 
2004; Yang et al.). The BMP Smad-independent pathway (MAPK pathway) is a 
chain activation, in which MAPK (as JNK, ERK 1/2, P38) is activated by MAP2K, 
which is activated by MAP3K (as TAK1), which is regulated by MAP4K (mitogens, 
as ILP).
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8.2 Materials and Methods:
8.2.1 Apoptosis analysis using Flow cytometry
In order to detect cells undergoing apoptosis, this current study used the Vybrant® 
Apoptosis Assay Kit (Invitrogen, Inc., Paisley, UK) which contains recombinant 
fluorescent conjugated annexin V (FITC annexin V) and Propidium Iodide (PI) 
solution. This was repeated three times and the number of apoptotic cells including 
both early (Q4) (FITC-annexin V stained) and late apoptotic cells (Q2) (both FITC- 
Annexin V and PI stained) in each sample was determined by using a flow cytometer 
and FlowMax software package. Detailed method is provided in Chapter 2, section 
2.7.7.
8.2.2 Cell cycle analysis using Flow cytometry
For the cell cycle analysis, MDA-MB-231 cells transfected with control plasmid and 
RGMB ribozyme were collected, fixed, permeabilized with 75% ice-cold ethanol, 
and stored at 20 °C. The cells were resuspended in 1 ml lysis buffer (0.1% Triton X- 
100, 0.05 mg/ml propidium iodide, and 1 mg/ml RNase A) and after incubation for 
30 min at 37 °C, the cells were analyzed in the flow cytometer. The count of cells in 
each sample was determined according to the staining of PI. This was repeated and 
the mean percentages o f cells in G0/G1, S and G2/M phases were calculated.
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8.2.3 Hoechst staining for apoptosis
The cells were incubated either with DMEM media containing 10% FCS or without 
serum for a period of 48 hours, before both the adherent cells and those floating in 
the culture medium were harvested and washed in PBS. The cell pellet was then re­
suspended in 20ng/ml Hoechst solution and incubated in darkness for 15 minutes. 
The cells were centrifuged and re-suspended with BSS before being counted and 
documented under a fluorescent microscope. The nucleolus was stained and a 
percentage for apoptotic cells was then calculated based on the cellular morphology 
changes happened during apoptosis including blebbing, loss o f cell membrane 
asymmetry and attachment, cell shrinkage, nuclear fragmentation, chromatin 
condensation.
8.2.4 Immunoprecipitation of phosphorylated proteins
Duplicate sets o f 3><106 cells were grown in large 75cm3 flasks overnight. Serum 
starvation was then induced at 37°C for 2 days. Each of the duplicate flasks was then 
subjected to a separate treatment or maintain as control. lOOpl o f cell lysate solution 
lysed in 300pl SDS-free lysis buffer was taken to run GAPDH or probe total protein. 
200pl was left for immunoprecipitation. The phosphorylated protein was 
immunoprecipitated by pho-S/T antibody and conjugated A/G protein agarose beads,
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and then use for SDS-PAGE as western blot mentioned in previous chapters 
(Chapter4).
8.2.5 ICC
Cells were seeded at a density o f 20,000 cells per well in 200pl of normal medium, in 
a 16 well chamber slide. The immunocytochemical staining was then performed 
following a protocol in Section 2.4.3. Dilution of primary antibody against c-Myc 
was 1:100.
8.3 Results:
8.3.1 RGM knockdown and its impact on cell growth and apoptosis
8.3.1.1 RGMB knockdown resulted in inhibition of apoptosis in cancer 
cells
The proportion o f apoptotic cells was analyzed by using flow cytometry (Fig. 
8.3.1.1A). Apoptotic index refers to total apoptotic population including both early 
apoptotic cells (Q4) and late apoptotic cells (Q2). There was only a small proportion 
of apoptotic cells seen in both MDAargmb cells (6.47%) and MDApEF/Hls (8.39%) 
control cells under normal culture condition, i.e. in DMEM supplemented with 10% 
FCS. However, a remarked difference in apoptosis between these cells was seen after 
48 hours serum starvation. MDA-MB-231ARGMB cells had a far smaller proportion of
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apoptotic cells (8.22%) compared to that o f control cells (27.84%) which had more 
apoptotic cells induced by serum starvation (Fig.8.3.1.1A). This was further 
confirmed by counting apoptotic cells after Hoechst staining, in which MDA-MB- 
231 ARGMB ce| |s un(ier serum starvation demonstrated a significant decrease in 
apoptotic population, p<0.05 compared to the control (Fig. 8.3.1.1B),
8.3.1.2 The effect of RGMB knockdown on cell cycle
To further understand the mechanism(s) o f RGMB knockdown stimulated 
tumour cell growth, Flow cytometry was also used to investigate the cell cycle o f  
these cells.
The Fig.8.3.1.2 displayed the cell distribution of MDA-MB-231 pEF and 
RGMB knockdown cells in G0/G1 (peakl) and G2+M (peak2) phases. The S, G2 and 
M phases represent the cell ability to propagate. There is a trend o f reduction of  
G0/G1 phase in RGMB knockdown cells (63.77%), compared to pEF control cells 
(64.62%). However, this was not significant (p=0.39). The Flow cytometry study 
indicated a non-significant effect on cell cycle progression by RGMB knockdown 
(G0/G1 -64.62%, S -  9.92%, G2+M -  25.46% in control, and 63.77%, 10.15%, and 
26.08%, respectively, in RGMB knockdown cells) (n=3).
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Figure 8.3.1.1A RGMB knockdown protected MDA-MB-231 cells survival from 
apoptosis.
The apoptotic population in MDA-MB-231 cells was analyzed using flowcytometry. The Q4 
shows early apoptotic cells and Q2 shows cells with late phase apoptosis or death. The cells 
were incubated in media containing 10% FCS as controls. The positive control (top right) 
shows hydrogen peroxide induced apoptosis. There was a markedly smaller population of 
cells undergoing apoptosis in the RGMB knockdown cells (8.22%) (Q2+Q4) after 48 hours 
serum starvation, compared to the control cells (27.84%).
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Figure 8.3.1.IB Analysis o f  apoptotic cells in MDA-MB-231 cells using Hoechst 
staining.
Yellow arrow heads pointed to the normal cells; red arrow heads pointed to the cells 
undergoing apoptosis characterized as the chromatin condensation, unsmooth nuclear surface, 
breaking into small apoptotic bodies. Apoptotic cells were counted and the bar graph presents 
the percentage of the apoptotic cells. There is a significant reduction of apoptotic cells in 
MDAargmb (0.45±0.06) compared to the control cells (0.63±0.18), under normal condition 
(p=0.04). This reduction is more obvious in the serum free induced apoptosis (0.31±0.13 vs 
0.69±0.11, p=0.000). Representative data were shown of three independent repeats. Error 
bars represent standard error of mean. SF: Serum Starvation
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Fig.8.3.1.2 Cell cycle analysis o f  RGMB knockdown cells.
Flow cytometry study indicated a non-significant effect on cell cycle progression by RGMB 
knockdown. The upper shows the two peaks representing G0/G1 and S/G2+M phase. The 
graph on the bottom shows the cell cycle distribution of MDA231 pEF and RGMB 
knockdown cells (G0/G1 -64.62%, S -  9.92%, G2+M -  25.46% in control, and 63.77%, 
10.15%, and 26.08%, respectively, in RGMB knockdown cells) (n=3). (p=0.39)
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8.3.2 Regulation of Caspase-3 by knocking down of RGMB
Fig.8.3.2 shows the total Caspase-3 proteins, an executioner caspase indicative 
o f end-stage apoptosis, are markedly reduced in RGMB knockdown cells compared 
to the control cells, (not treated). Caspase-3 is expressed in cells as an inactive 
precursor from which the p i7 and p l l  subunits o f the mature caspase-3 are 
proteolytically generated during apoptosis. The caspase-3 precursor is first cleaved to 
produce the p l l  subunit and the p20 peptide which is subsequently cleaved to 
generate the mature p i7 subunit. As seen from the Figure 8.3.2, the subunit PI 1 and 
PI 7 have almost disappeared, which are the indicators of activated caspase-3 enzyme. 
Therefore, the loss o f RGMB resulted in a decrease in protein expression o f caspase- 
3 and also activation o f the protein.
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Figure 8.3.2 The protein level of caspase-3 in MDA-MB-231 pEF and RGMB 
knockdown cells.
The caspase-3 proteins which exists in the forms of procaspase-3 and subunits: p20, pi 7, pi 1 
are all eliminated by knockdown of RGMB. The left arrows show the procaspase-3 and 
subunits. The right arrows displayed the ladder.
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8.3.3 The gene correlated with cell growth regulated by RGMB 
knockdown
As RGMB knockdown was found to be able to regulate cell growth in breast 
cancer via protecting cells from apoptosis, I further examined expression of the genes 
related to cell death in these transfected cells. C-Myc is a gene found to be implicated 
in apoptosis and cell cycle to regulate cell growth and its expression was significantly 
increased after the loss o f RGMB in MDA-MB-231 human breast cancer cells, both 
at the mRNA and protein levels.
As shown in Fig.8.3.3 A, the transcript level of c-Myc was significantly 
increased after the knockdown o f RGMB (Mean±Std. 1670 ± 831), compared to the 
control cells (140 ± 1 1 2  for WT and 230 ± 129 for pEF, p<0.05 in both cases), 
determined by real time Q-PCR. Through ICC staining, the c-Myc protein was 
confirmed to be more intensely stained in the MDAargmb cells as compared to the 
MDAApEF/Hls cells (Fig.8.3.3 B). The staining o f c-Myc was confined in the cytoplasm 
and nucleus of the breast cancer cells. This was consistent with the increased mRNA 
level in RGMB knockdown cells.
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Figure. 8.3.3 A The expression o f c-Myc is promoted in RGMB knockdown cells.
The result showed the mRNA level of c-Myc was significantly increased by the loss of 
RGMB (Mean±Std. 1670 ± 831), compared to the wild type (140 ± 112) (p=0.03) and pEF 
(230 ± 129) (p=0.04). Two sample T-test was utilised here.
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ICC staining
MDA-MB-231 pEF control MDA-MB-231 ARGMB
Figure 8.3.3 B ICC staining o f c-Myc in RGMB knockdown cells.
ICC staining confirmed the c-Myc proteins were increased in MDA-MB-231 RGMB 
knockdown cells (right) compared to the control cells (left). The staining of c-Myc was 
mianly confined to the cytoplasma of the RGMB knockdown cells.
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8.3.4 Influences on MAPK pathway
Additionally, the RGMB knockdown was found to be involved in BMP Smad- 
independent pathways, which has been implicated in cell death by previous studies. I 
have examined the total and activated protein level o f MAPK pathway molecules 
here in the transfected M DA-M B-231 cells, to reveal the associations with effect on 
cell growth.
Fig.8.3.4 shows that the total protein expression in the lysates of control and 
RGMB knockdown cells had no differences, whereas the activated ILP, TAK and 
JNK (by phosphorylation) were markedly reduced in the MDA-MB-231ARGMB cells, 
compared to the control cells. The protein levels o f ERK1/2 and P38, both total and 
activated, had not been altered by knocking down RGMB. In the current study, the 
loss o f RGMB appears to markedly weaken the TAK-JNK MAPK pathway and JNK 
is well known as its important role in cell apoptosis.
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Figure 8.3.4 The MAPK pathway regulated by RGMB.
Each protein had been examined in both cell lysate and immnunoprecipatiant for 
identification of sering/thereionine phosphrylation. The results showed total proteins of these 
MAPK signaling molecules are not affected by RGMB knockdown. The phosphorylated 
protein of ILP, TAK and JNK was reduced after the loss of RGMB which indicated the 
activation of JNK pathway was inhibited without the effects on expression, while no 
significant alteration happened on ERK 1/2 or P38 pathway.
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8.4 Discussion:
Caspase-3, also known as apopain, SCA-1, Yama and CPP32, is an aspartate 
specific cysteine protease that belongs to the subfamily o f caspases (cysteine- 
aspartic acid protease) (Cohen, 1997). Caspases play a central role in the execution- 
phase of cell apoptosis. Caspase-3 is responsible for chromatin condensation and 
DNA fragmentation, which is processed by caspases 8/9/10 and cleaves and activates 
caspases 6/7/9. The active caspase-3 enzyme is a heterodimer composed o f p l7  and 
p l l  subunits (Femandes-Alnemri et al., 1994). In this study, the subunits P l l  and 
P I7 disappeared in RGMB knockdown cells with slightly visible procaspase-3 and 
P20 residues left. This indicated that RGMB knockdown markedly reduced the 
expression and activation o f caspase-3 which in turn inhibited the apoptosis of MDA- 
MB-231 cells.
The inhibition o f apoptosis might be responsible for the pro-proliferation effect 
on breast cancer cells by RGMB knockdown. The inhibition o f caspase-3 expression 
induced by RGMB knockdown confirmed the inhibitory effect of RGMB knockdown 
on apoptosis. On the other hand, the anti-apoptotic effect of RGMB knockdown 
might be partially via regulation on the expression o f caspase-3.
It has been recently shown that there is another type o f cell death, known as 
paraptosis (Bredesen et al., 2004). In paraptosis, the absence o f ligand (as RGMA) 
induces self-activation o f its receptor (as neogenin), by a mechanism still unknown, 
and the subsequent proteolytic processing o f the receptor triggers apoptosis, which 
can be blocked by ligand binding. The RGM receptor-Neogenin is one o f such
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‘dependence receptor’s, which expose a pro-apoptotic region in the cytoplasmic 
domains and activate caspase-3, when their ligands being loss-of-fimction. This is 
contrary to the phenomena we observed in the transfected cells. Furthermore, I 
investigated neogenin mRNA levels in the transfected cells, however, there was no 
changes after RGM was knocked down. (Data not shown) Therefore, the pro- 
apoptosis effect might be caused by RGMB itself.
C-Myc is a strong proto-oncogene and works as a transcription factor in 
activating the expression o f a great number o f genes. For many years, c-Myc function 
has been linked to the control o f cell-cycle progression (Steiner et al., 1995) and to 
the inducement o f apoptosis. However, increasing evidence now shows that c-Myc 
also stimulates cell growth (Schuhmacher et al., 1999), and these two processes being 
regulated independently. It is very often found to be upregulated in many types of 
cancers and this upregulation was enhanced by RGMB knockdown in breast cancer 
cells, although there was no significant effect shown in cell-cycle analysis. The 
expression of c-Myc might still contribute to the promotion on cell growth caused by 
RGMB knockdown, as the effect o f c-Myc is diverse and the mechanism is as yet 
unclear.
In response to both the extrinsic and intrinsic apoptotic stimuli, JNK plays an 
essential role through its ability to interact and modulate the activities o f diverse pro- 
and anti-apoptotic proteins (induce BAX, inhibit Bcl2 and so on) (Dhanasekaran and 
Reddy, 2008). Through the coordinated regulation of the nuclear and mitochondrial 
events, JNK ensures the efficient execution o f apoptosis. The activation o f TAK1- 
MKK4-JNK pathway was proved to result in apoptotic cell death (Yang et al., 2004).
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In the MAPK pathway, P38, ERK1/2 and JNK pathways all have effect in the 
regulation o f apoptosis. Loss o f RGMB mainly induced JNK pathway inhibition with 
little effect on other MAPK pathways. The repressed JNK pathway might also 
contribute to the negative regulation on cell apoptosis by RGMB knockdown, which 
might promote cell growth (see figure 10.1).
Furthermore, although c-Myc has been reported that it could be repressed by 
TGF-p via Smad-3 (Yagi et al., 2002), there are also evidences to show c-Myc 
mediated apoptosis can be inhibited by the inactive form of JNK (APF) (Noguchi et 
al., 2000). Which was consistent with this in this study, considering the less effect on 
Smad-3 induced by RGMB, c-Myc might be regulated through Smad-independent 
pathway by RGMB.
Additionally, there are also studies reported TGF-p and BMP signalling 
pathways have been involved in the regulation o f cell growth in breast cancer via 
Smad-4, a common Smad required by both pathways (Forootan et al., 2007; 
Ketolainen et al:, Leeper et al:, Wu et al., 2003). Almost all these studies indicated 
the breast cancer cell proliferation is mediated by TGF-p via Smad-2/3 pathway, as a 
dual role in apoptosis (Ehata et al., 2007; Li et al., 2009a; Tan et al., 2009). Further 
investigation may elucidate coordinating role played by RGMB in Smad-1 and 
Smad-3 signal transduction
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Chapter 9
Effect on BMP signalling transduction 
by RGMs knockdown in prostate 
cancer and consequent regulation on 
BMP responsive genes
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9.1 Introduction:
As discussed in the previous chapters, the knockdown of RGMs was found to 
promote the proliferation, adhesion, motility and mobility o f prostate cancer cells 
(PC-3). RGMB and RGMC knockdown significantly induced PC-3 cells’ 
proliferation. RGMB knockdown further promoted cell mobility, and all the three 
RGMs showed significant impact on cell-matrix adhesion ability, which might 
contribute to prostate cancer metastasis. The impact of RGMA in prostate cancer was 
relatively weaker than RGMB and RGMC.
To reveal what mechanism(s) involved in the regulation o f prostate cancer by 
RGMs, the level o f one o f the BMP target genes ID-l(DNA-binding protein inhibitor) 
was investigated in PC-3 cells transfected with RGM ribozymes, as the involvement 
of RGMs in BMP signalling and BMPs are key factors in prostate cancer and bone 
metastasis (Ye et al., 2007; Ying et al., 2003). ID-1 proteins belong to the helix-loop- 
helix (HLH) transcriptional regulator family, and functions as an antagonists o f basic 
HLH transcription factors by inhibiting their ability to bind specific DNA sequences 
within target gene promoters, thereby to negatively regulate cell differentiation 
(Norton, 2000). Additionally, they have been revealed to participate in tumour cell 
growth and promote cell survival in breast cancer and prostate cancer (Forootan et a l., 
2007). Including the effects on cancer cell proliferation, ID-1 was also reported to 
promote tumour cell invasion (Gautschi et al., 2008) activated by BMP2 and 
promote migration and invasion o f prostate cancer cells activated by BMP6 (Darby et 
a l , 2008).
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BMPs were shown to be involved in prostate cancer and bone metastasis 
greatly through BMP-Smad dependent pathway (Brubaker et al., 2004; Dai et al., 
2005; Ye et al., 2008; Ye et al., 2009). Secondly, ID-1 expression was proved to be 
regulated by BMPs through BMP-Smad-Id pathway in cancer (Gautschi et al., 2008; 
Ohtani et al., 2001; Ying et al., 2003). To investigate whether the mediation of 
prostate cancer by RGMs was via BMP Smad-dependent signal pathway, I verified 
the expression and activation profile o f BMP signalling molecules in RGMs 
knockdown cells.
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9.2 Materials and Methods:
9.2.1 Western blot and SDS-PAGE
Duplicate sets o f 3*106 cells were grown in large 75cm3 flasks overnight and 
subjected to serum hunger for 2 hours and then treatment with rh-BMP7 (40ng/ml) 
for 30 minutes or no treatment. Cell lysates was collected and protein samples were 
subjected to SDS-PAGE and probed with the specific primary (1:200), and the 
corresponding peroxidise-conjugated secondary antibodies (1:2000). This is 
described in detail in section 2.4.
9.2.2 RT-PCR
Cells treated with medium containing rh-BMP7 (40ng/ml, 30mins) or normal growth 
medium were collected. RNA isolation was carried out as described before. (Section 
2.3) 0.5pg of the isolated RNA was converted into cDNA which was then used as a 
template for PCR.
9.2.3 Q-PCR
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The real time quantitative PCR (Q-PCR) was carried out to determine the levels of 
ID-1 transcripts in the control and RGM knockdown cells. The protocol and primers 
used for ID-1 quantitation and housekeeping GAPDH were listed in section 2.1.2 and 
2.3.5.
9.2.4 Immunofluorescent staining
Cells were seeded in normal medium and subjected to treatment, in a 16 well 
chamber slide (Lab-Tek, Nagle Nunc Int., Illinois, USA). Specific staining was then 
undertaken through the addition o f a specific primary antibody against ID-1 (1:200) 
and appropriate FITC conjugated secondary antibody (1:150). After this protocol had 
been completed, the cells were covered with Fluoro-save (Merck Chemicals Ltd., 
Nottingham, UK) before visualizing any staining under a fluorescent microscope 
(Olympus, Japan) using a GFP filter. The experiment was repeated three times and 
representative data is presented.
Statistical analysis
Normally distributed data was analyzed using the two sample T-test while non- 
normally distributed data was analyzed using the Mann-Whitney and Kruskal-Wallis 
tests.
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9.3Results:
9.3.1 The regulation on BMP target gene (ID-1) of RGMs knockdown in 
PC-3
The knockdown of RGMs had diverse effects on ID1 in PC-3 prostate cancer 
cells. The RGMB (Mean±Std. 4 .4x l08 ± 3.24xl08) and RGMC knockdown 
(6.49x108±3.77x108) significantly promoted the expression of ID-1 (compared to 
pEF 3.76x107±0.28x107, p<0.1 and p< 0.05 respectively) (Fig.9.3.1). The increase in 
ID-1 expression was enhanced by BMP-7 stimulation (2.94xl09 ± 2 .6x l08 for 
RGMB, 1.03xl010 ± 3 .7x l09 for RGMC) (Fig.9.3.2), compared to control cells 
(4.49xl08 ± 3.22xl07, p<0.01). There was also an increased ID-1 level in RGMA 
knockdown cells (4.93 xlO7 ± 2 .83xl07), compared to pEF control cells, although the 
p-value was not significant (0.52). The effect was also enhanced by BMP7 treatment, 
however, RGMA knockdown has not shown such marked increase as RGMB and 
RGMC (1.35xl08 ± 1.42xl08 after treatment) (Fig.9.3.1 and Fig.9.3.2), The ID-1 
levels increased 5.68 times in RGMB knockdown cells and 14.80 times in RGMC 
knockdown cells after BMP7 stimulation, compared to the levels under no treatment, 
whilst RGMA knockdown have 1.74 times increases.
Notably, BMP7 itself could stimulate the expression of ID-1. Therefore, ID-1 
was confirmed to be one o f the target genes for BMP signalling, as ID-1 expression 
has been reported to be directly regulated by BMP-Smad pathway.
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ID-1
1.20E+09
1.00E+09
8.0OE+08
6.O0E+O8
4.00E+08
2.00E+08
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pEF RGMA RGMB RGMC
rib3 rib 1 rlb3
PC-3
Figure 9.3.1 ID-1 transcripts level in the transfected cells.
The QPCR result shows ID-1 level in RGMA, RGMB and RGMC knockdown cells were 
upregulated (Mean±STd. 4.93xl07±2.83><107 for RGMA, 4.4xl08± 3.24xl08 for RGMB and 
6.49x108±3.77x108 for RGMC), compared to pEF control cells (3.76xl07±0.28xl07). 
(p=0.52, 0.09 and 0.05 respectively) Data were nonnalised against GAPDH. Two sample T- 
test was utilised here.
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ID-1
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r ib3  r i b l  r ib3
PC-3
Figure 9.3.2 ID-1 transcripts le v e ls  in the transfected ce lls  under no or BMP7 
treatment.
The ID-1 level was elevated in RGMs knockdown cells which was amplified after BMP7 
treatment (40ng/ml, 30mins) and this effect was markedly in RGMB and RGMC. Data were 
normalised against GAPDH. Two sample T-test was utilised.
2 6 3
9.3.2 The association of ID-1 expression and involvement of RGMs in 
BMP Smad-dependent signalling pathway
To investigate whether the effect in PC-3 cells was related to the role o f RGMs 
in BMP signalling, the BMP downstream signalling molecules (Smads) activation 
profile was examined, which might be associated with ID-1 expression in these 
transfected cells.
RGMB and RGMC knockdown in PC-3 cells significantly increased Smad-3 
activation (Fig.9.3.3 p-Sm ad-3) with little observable difference in RGMA 
knockdown, compared to the control cells, as confirmed by the semi-quantification 
(Fig.9.3.4) (p=0.29 for RGMA, 0.05 for RGMB and 0.008 for RGMC respectively). 
This was enhanced by stimulation o f BMP7, which indicated RGMB and RGMC 
knockdown can enhance the Smad-3 dependent pathway activated by BMP7. 
Although it has not reached the statistical significance, RGMB and RGMC 
knockdown cells further elevated P-Smad-3 level after BMP7 treatment (107653±730 
for RGMB and 143872±25556 for RGMC), compared to the level before treatment 
(93734±24708 for RGMB and 120426±22938 for RGMC, p=0.38 and 0.3 
respectively).
Additionally, the recombinant protein BMP7 was able to stimulate Smad-3 
activation, with the control cells and RGMs knockdown cells all had increased level 
o f P-Smad-3 after BMP7 treatment (p values were especially significant in pEF and 
RGMA knockdown cells, p<0.05).
2 6 4
The pattern o f Smad-3 activation was consistent with the increased ID-1 level 
in the transfected cells. Treatment o f BMP7 and RGM knockdown in prostate cancer 
cell line PC-3 did not show stimulation on Smad-1 activation (Fig.9.3.3 p-Smad-1). 
Altogether, RGM (B and C) knockdown possibly regulate the downstream gene 
expression through the enhancement on BMP-Smad-3 signalling pathway while not 
by Smad-1/5/8.
Additionally, the association o f activation o f Smad-3 and ID-1 expression was 
further supported by the Immunofluorescent staining in RGMB and RGMC 
knockdown cells (Fig.9.3.5 and 9.3.6). RGMB and RGMC knockdown cells showed 
Smad-3 activated in the nucleus or focused on the nuclear membranes with slightly 
staining in the cytoplasma. BMP7 treatment enhanced the activation o f Smad-3 in 
RGMB and RGMC knockdown cells and the effect was also existed in control cells 
but not as obvious as in the RGMs knockdown cells. Fig.9.3.6 showed the 
expression and activation o f ID-1. As a transcriptional factor, ID-1 was mainly 
stained in the nucleus. ID-1 levels were markedly increased in the nucleus o f RGMB 
and RGMC knockdown cells after BMP7 treatment, compared to the control cells.
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Control BMP7 treated
P-Sm ad-l
P-Smad-3
GAPDH
Figure 9.3.3 Smadl and Smad3 activation in the transfected cells under no or BMP7 
treatement.
Activated Smad-3 expression were upregulated after RGMB and RGMC were knocked down 
and this is enhanced by stimulation of BMP7 (40ng/ml, 30mins), while there is no significant 
change in phosphoryated Smad-1 levels.
1: PC-3 pEF
2: PC-3 ARGMA
3: PC-3 A RGMB
4: PC-3 ARGMC
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Figure 9.3.4 Quantification o f P-Smad-3 level showed in the western.
RGMB and RGMC knockdown cells showed significantly higher level of activated Smad-3 
compared to the pEF control cells (*), which was enhanced by BMP7. The RGMA and 
control cells were also stimulated activation of Smad-3 by BMP7, compared to the level 
under no treatment (p<0.05) (A).
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P-Smad-3
BMP7
treated
Figure 9.3.5 IFC staining o f activated Smad-3.
IFC staining showed the staining of phosphorylated Smad-3 in the nucleus of control and 
RGMB, C knockdown cells, which was elevated by RGMB and RGMC knockdown and 
enhanced by BMP7 treatment.
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PC-3 control PC-3 ARGMB PC-3 ARGMC
Control
ID-1
BMP7 
treated
Figure 9.3.6 IFC staining o f  ID-1
IFC staining showed the ID-1 level was markedly increased in the nucleus (or 
nucleolus membrane) in the RGMB and RGMC knockdown cells under BMP7 
stimulation.
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9.3.3 The interaction of RGMs and BMP receptors
To further reveal which BMP receptor might be involved in the activation of 
Smad-dependent pathway regulated by RGMs knockdown, the expression and 
activation o f two BMP receptors (BMPRIA and BMPRII) were also investigated in 
the RGMs knockdown cells and their response to the BMP7 treatment.
As shown in Fig.9.3.7, RGMC (and RGMB) knockdown in PC-3 cell resulted 
in an subtle increase in BMPRIA and BMPRII expression compared to the control 
cells. However, this effect was not promoted by BMP7 treatment.
Furthermore, the activated forms o f these two BMP receptors were difficult to 
detect in these transfected cells using immunoprecipitation. Taken together, this 
indicated the BMPRIA and BMPRII might not be the main BMP receptors 
responsible for RGMs regulation on BMP signalling.
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Figure 9.3.7 BMPRI A and BMPRII levels in transfected PC-3 cells.
The phosphorylated BMPRIA and BMPRII were barely detected in these cells using 
immunoprecipitation (IP). The right panel shows the quantification of intensity of 
BMPRIA and BMPRII in the western blot (cell lysate).
1: PC -3 pEF
2: PC-3 ARGMA
3: PC-3 ARGMB
4: PC-3 ARGMC
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9.4 Discussion:
In PC-3 cells, RGMB and RGMC knockdown stimulated the Smad-3 signalling 
pathway which has been enhanced by BMP7, followed by increased ID-1 level. The 
loss o f RGMA did not cause such significant effect on the PC-3 cells. ID-1 is a direct 
downstream effector o f BMPs which has been reported to be induced by the BMP- 
Smad signalling pathway (Miyazono and Miyazawa, 2002; Valdimarsdottir et al., 
2002), promoting cell growth and inhibiting cell differentiation via regulation o f Raf- 
1/MAPK and JNK pathways in breast cancer and prostate cancer (Yap et al., 2008; 
Yap et al., 2010). In the current study, it has been shown that ID-1 expression in PC- 
3 can be regulated by BMP7 signalling pathway which is enhanced by RGM (B and 
C) knockdown (compared to RGMA, RGMB and RGMC might be more sensitive to 
the stimulation o f BMP). However, this effect may be largely through the Smad-3 
pathway, rather than the BM P-Smad-1/5/8 pathway as previously reported (Belletti et 
al., 2001; Lasorella et al., 2000; Ohtani et al., 2001; Ying et al., 2003). The main 
evidence to support this was the observation that the effect of BMP7 and RGMs on 
Smad-1 was minimal. Although there are other studies to claim that BMP7 has little 
direct effect on prostate cancer cell growth (Dai et al., 2005), the increase in ID-1 
expression in RGM knockdown cells was consistent with the promotion o f cell 
growth as mentioned in previous chapter, which was further support a positive role o f 
RGMs knockdown and ID1 in cancer. In fact, the function o f ID-1 also includes the 
promotion o f tumour cell invasion, angiogenesis which may also contribute to the 
metastasis o f prostate cancer. It is recognised that data presented here only decipher 
part o f the signalling events in RGM-BMP medicated cell functions, the study
indicated the interesting role of RGMs played in prostate cancer and a potential 
therapy target in the future.
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Chapter 10 
General discussion
RGMs have been shown to play role in axonal guidance during embryo 
development, neuronal cell adhesion, regulation of systemic iron metabolism (Doya 
et al., 2006; Hata et a l ,  2006). However, the role o f RGMs in cancer has not been 
elucidated, although they have been reported as co-receptor o f BMPs, a group of 
protein implicated in the development o f prostate cancer, particularly in bony 
metastasis.
Main findings
Firstly, I screened the expression o f RGMs. The expression o f RGMs was 
detected in a panel of cell lines from a variety o f tumour types and tissues using RT- 
PCR. The current study also has examined the staining pattern of RGMs in human 
prostate tissues and breast tissues. The transcript expression level of RGMs was 
determined in a panel o f breast cohort through Q-PCR, which is from the patients 
followed up to 120 months. All the three RGM isoforms were found expressed in the 
prostate cell lines including PC-3, while only RGMB was found in breast cancer cell 
line MDA-MB-231. However, during the tissue screening, almost all the RGMs were 
detected in the breast tissues with only RGMB absent in normal breast. Although 
there was no obvious difference o f RGMB protein staining between normal and 
tumour, the transcript level determined by Q-PCR showed RGMB had significantly 
higher expression in breast tumour tissues. All the RGMs except RGMA were 
detected in prostate tissues, while RGMB and RGMC expression were slightly higher 
in tumour according to the staining in tissues.
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The higher transcript level o f RGMA was associated with breast cancer patients 
with good prognosis, while RGMC has no obvious trend in the patients with 
progression o f breast cancer. The initial study o f RGMs expression and their 
association with clinical data suggests an intriguing role of RGMs in cancer. In the 
present study, to further investigate what the effect RGMs may have on cancer cells, 
the ribozyme method was employed to genetically reduce the expression o f RGMs in 
PC-3 and RGMB in MDA-M B-231, because of their strong and consistent expression 
and aggressiveness. The RGMA, RGMB and RGMC expression were reduced in the 
PC-3 both from mRNA and protein level. RGMB was also eliminated from MDA- 
MB-231 cells.
The loss o f RGMB in MDA-M B-231 resulted in a phenotype with faster rate of 
cell growth and aggressiveness compared with control cells: with an increase in 
proliferation, cell-matrix adhesion, motility and mobility in vitro. . This indicates that 
RGMB may play an inhibitory role in breast cancer, through inhibition on cancer cell 
growth and ability to migrate and attach to cell matrix. However, the in vitro 
inhibitory effect did not match with the increased expression o f RGMB in tumour 
tissues. The mechanism(s) o f the regulation on RGMB expression remain unknown.
Knock-down of RGMs in PC-3 also promoted the cells ability to grow, adhere 
and migrate. The effect in RGMB knockdown cells was most significant, compared 
to the two RGMs. All the RGM knockdown cells increased the cell-matrix adhesion. 
RGMB and RGMC knockdown cells have a significant effect on cell growth. Only 
RGMB knockdown cells showed its significant effect on motility after wounding. All 
the evidence suggests that RGMs (especially RGMB) also inhibited prostate cancer
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cell growth, cell-matrix adhesion, motility and mobility. Consistent with that 
observed in the breast cancer cells and tissues, the inhibitory role o f RGMs in PC-3 
cells was in contrast to the increased expression pattern in tumour tissues staining.
Potential mechansims underlying the action of RGM proteins
To investigate the mechanism(s) and cascade downstream of RGM, I proposed 
that the involvement o f RGMB in BMP signalling could be at three distinct but 
related steps, namely targeting BMP binding or the activation of BMP downstream 
signalling, the interaction o f phosphorylated Smads and BMP regulated genes.
RGMB knockdown facilitated the Smad-1 dependent pathway. This effect was 
linked to upregulated EMT regulators including Snail and adhesion molecules such 
as FAK and Paxillin. As a consequence o f these changes of intracellular regulator, 
cells lost their cell-cell contacts, acquired migration and cell-matrix adhesion ability 
(Fig. 10.1).
It was also strongly suggested that the RGMB knock-down inhibits apoptosis via 
reducing caspase-3 expression and activation. This suggestion was further supported 
by the weakening o f MAPK / JNK pathway, a known regulatory pathway of 
apoptosis. C-Myc is a proto-oncogene with profound influence on cell cycle but 
inducing apoptosis. However, this effect o f c-Myc on apoptosis can be inhibited by 
inactivation o f the JNK pathway (Noguchi et al., 2000). Additionally, the other 
reported role for c-Myc is to stimulate cell growth independently (Schuhmacher et al.,
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1999; Steiner et al., 1995). It was interesting to find expression of c-Myc was 
significantly increased in RGMB knockdown cells.
Therefore, it is anticipated that the biological effect of RGMB on MDA-MB-231 
is likely to be associated with reducing the BMP Smad dependent pathway (mainly 
Smad-1) and enhancing BMP non-Smad pathway (JNK pathway).
In PC-3 cells, RGMB and RGMC knock-down also promoted BMP/Smad-3 
dependent pathway. This is clearly correlated with the upregulation on ID-1, a 
transcription factor for cell growth and differentiation regulatory proteins. This was 
well reflected in the in vitro data here that RGMB and RGMC knockdown cells had 
an increased rate o f cellular growth. BMP7 has been shown in the past to be able to 
induce Smad-3 phosphorylation (Cassar et al., 2009). Here and for the first time, we 
presented evidence that BMP7 induced upregulation of ID-1 was enhanced by RGMs 
knockdown and that this might be via the Smad-3 pathway.
RGMs were reported as co-receptors o f BMPs and can enhance the BMP 
signalling pathways. However, the present study has shown that the co-receptor and 
co-regulation by RGM are probably more complicated. Here, we clearly demonstated 
that RGMs inhibit the BMP Smad-dependent pathway. This was seen for RGMB and 
RGMC in PC-3 cells and for RGMB in MDA-MB-231 cells. It is more interesting to 
note that RGMs not only inhibit the Smad-dependent pathway, they appear to 
skillfully switch the signal to Smad-independent MAPK pathway in MDA-MB-231 
(RGMB).
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It is concluded that RGM proteins influence the biological function of breast 
and prostate cancer cells. Collectively and as shown in Fig. 10.1, these effects are 
more likely to be mediated by the change o f the BMP receptor downstream signalling. 
The study has further shown that the change/switch of the pathways by RGM might 
be via the interference o f the interaction between BMP and the BMP receptors, thus 
at the upstream of Smads.
Future work
In the current study o f RGMB knockdown, increased Paxillin, FAK and Snail 
have been correlated with adhesion and motility of MDA-MB-231. Furthermore, this 
effect seems associated with the promotion on Smad-1 dependent pathway. However, 
the direct relationship o f the Smad-1 activation and these target genes expression has 
not been established due to the absence o f specific Smad-1 inhibitor. Smad-1 or 
Smad-4 could be double knocked down in RGMB knockdown cells to investigate 
whether this effect on these molecules or integrins will be reversed.
There might be a link between the JNK inhibition and apoptosis reduction. 
However, in order to confirm whether the inhibited JNK pathway was sufficient to 
cause anti-apoptotic effect o f RGMB knockdown, the JNK inhibitor could be used. 
The expression of c-Myc and caspase-3 could also be determined again to reveal the 
correlation with JNK.
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It’s also very interesting to further reveal the nature of RGMs binding to BMPs 
and BMP receptors, and the insight o f the Smad pathway switch, namely from Smad- 
dependent to Smad-independent.
Furthermore, the structure o f RGMs gene promoter or the regulation of RGMs 
expression remains unknown. The RGMB induced inhibitory effect on breast cancer 
whereas its expression was increased in the tumour tissues compared to the normal 
tissues, a pattern also seen in prostate cancer. The presence o f a possible feedback 
loop to upregualte the expression o f RGMB in vivo would be worthwhile to explore.
Above all, as potential tumour suppressor genes, further studies using in vivo 
tumour model are helpful to elucidate the implication of RGMs in prostate cancer and 
breast cancer and their metastasis. The role o f RGMs in vivo may indicate us a 
therapeutic target for prevention and treatment of prostate cancer and breast cancer.
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Figure 10.1 RGMs signalling pathway
RGMs knockdown facilitates BMP signalling through Smadl/5/8 pathway and part of 
Smad2/3 and inhibits the MAPK JNK pathway thereby to mediate the BMP downstream 
genes. FAK/Paxillin was induced by BMP through Smadl/5/8 and by TGF-B through 
Smad2/3 (Park et al.; Tamura et al., 2001) and also has interaction with ERK1/2 pathway 
(Bechara et al., 2008). Focal adhesion molecules expression was stimulated mainly by 
activation of Smadl/5/8 and partially by Smad2/3 with the absence of RGMB, which leaded 
to the increased cell adhesion. Snail can be regulated by TGF-B through Smad2/3 (Miyazono, 
2009). The regulation on Snail was also found to be associated with Smadl/5/8 activation 
after RGMB was knocked down in this study which induced EMT. ID-1 was up or down 
regulated by TGF-B via Smad2/3 depending on different phases (Liang et al., 2009; Song et 
al.) and it could also be activated by BMPs through Smadl/5/8 and PI3K/Akt pathway 
(Lopez-Rovira et al., 2002; Su et al.). After RGMs was knocked down in prostate cancer 
cells, ID-1 was mainly upregulated through Smad2/3 which might promote cell proliferation 
(Lo et al.), migration (Bhattacharya et al.) and adhesion (Su et al.). The knockdown of 
RGMB suppressed the expression and activation of caspsae-3 which executes the cell 
apoptosis and the reduced c-Myc expression might also be involved in the regulation on cell 
death.
The binding of RGMs with neogenin might trigger different pathways on to mediate neuronal 
growth and differentiation and iron metabolism (Conrad et al., 2007; Jiang et al., 2003; 
Schaffar et al., 2008; Zhou et al.).
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